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1 ABSTRACT 
The neuronal epidermal growth factor (EGF)-like growth factor NRG1 type III serves as 
a master regulator of myelination in the peripheral nervous system (PNS). It has been 
proposed that NRG1 type III is proteolytically cleaved to become fully active, but the 
identity of the protease(s) as well as the number and order of cleavage events have 
been elusive. Peripheral myelination is strongly impaired in BACE1 (-site amyloid 
precursor protein-cleaving enzyme 1) null mutants, very similar to NRG1 type III 
heterozygous mouse mutants, suggesting that BACE1-processing is required for the 
myelinating activity of NRG1 type III. However, a functional interaction between NRG1 
type III and BACE1 in vivo has not been demonstrated.  
In this study, we have used transgenic mouse lines that neuronally overexpress N-
terminally epitope-tagged full length NRG1 type III and a C-terminally shortened NRG1 
type III-variant that mimics BACE1 processing in the stalk region (‘GIEF’) to further 
explore NRG1 processing and a functional interaction between BACE1 and NRG1 type 
III in myelination in vivo. Neuronal overexpression of the ‘GIEF’-variant induces sciatic 
nerve hypermyelination, very similar to full length NRG1 type III. This demonstrates 
that the product of BACE1-mediated cleavage in the stalk region is myelination 
competent, whereas back signalling by the cytoplasmic tail of NRG1 type III is 
dispensable for myelination. Unexpectedly, overexpression of NRG1 type III retains the 
potential to promote myelination in BACE1 null mutants, albeit at reduced capacity. 
These findings identify a functional interaction of BACE1 and NRG1 in peripheral 
myelination in vivo, but also point to more complex processing mechanisms involving 
other proteases. 
We also took advantage of the in vivo-expression of epitope-tagged NRG1-variants to 
study the subcellular localization and transport of NRG1-variants in spinal cord motor 
neurons. Histological and biochemical analysis strongly suggest that subsequently to 
cleavage in the stalk region, N- and C-terminal NRG1 type III-fragments are sorted to 
distinct membrane domains and that vesicular transport of the N-terminal fragment 
(harboring the EGF-like domain) into the axonal compartment is rate-limiting. Finally, 
we observed an additional smaller-sized N-terminal product in sciatic nerve, compatible 
with EGF-like domain shedding from the axonal surface. Thus, our data strongly 
suggest an orderly array of proteolytic processing as a critical component of NRG1 
type III-mediated peripheral myelination. 
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2 INTRODUCTION  
2.1 Myelination in the peripheral nervous system  
2.1.1 Function of the myelin sheath  
Formation of a myelin sheath around axons enabled fast nerve impulse propagation 
and fulfilled one of the crucial conditions for the evolution of a complex nervous system 
in vertebrates. By insulating axons, the myelin sheath increases resistance and 
decreases the capacitance of the axonal membrane. Together with clustering of 
voltage gated sodium channels at the node of Ranvier, myelin creates fast saltatory 
conduction of action potentials. Myelination thereby improves the propagation speed of 
electrical pulses along axons by 10 fold, excluding the necessity for an enlargement of 
the axonal diameter to achieve the same goal (Garbay et al., 2000; Hartline and 
Colman, 2007). Fast conducting myelinated fibers of a few µm in diameter represent an 
evolutionary advantage if we consider the space constrains of the central nervous 
system (CNS) and the requirement for high speed information processing. Vertebrate 
body size would not be imaginable without fast propagation of nerve impulses. For 
instance, the magnitude of conduction velocity for sensory information and motor 
reactions along the correspondingly increased length of peripheral nervous system 
(PNS) axons would not satisfy functional criteria without the existence of myelin. 
Although myelin serves similar functions in the PNS and CNS, it is formed by two 
distinct types of glial cells and the myelination process is differentially regulated 
(Sherman and Brophy, 2005). In the PNS, the myelin sheath is formed by Schwann 
cells (Sc) that spirally elongate their membranes to wrap the axon and from one myelin 
segment surrounded by the basal lamina. In the CNS oligodendrocytes extend 
processes to form multiple myelin segments around multiple axons of variable 
diameter. The function of myelin forming glial cells extends beyond providing electrical 
isolation for axons. Sc and oligodendrocytes also have an important role in maintaining 
axonal integrity (Nave and Trapp, 2008). Secondary axonal loss occurs, for instance 
after demyelination in the CNS as a part of neuropathology of multiple sclerosis (Trapp 
and Nave, 2008). Type1 Charcot-Marie-Tooth (CMT) disease, an inherited peripheral 
neuropathy, is also characterized by primary demyelination followed by the loss of 
axonal integrity with a severe clinical outcome (Nave et al., 2007). It is not clear to 
which extent myelin formation per se contributes to this support. Mutations in 
oligodendrocyte proteins are found to affect axon integrity without change in the myelin 
compartment (Lappe-Siefke et al., 2003). Similarly, an experimental therapy in a rat 
animal model of CMT1 improved axonal function without a corresponding improvement 
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in myelination (Meyer zu Horste et al., 2007). The process of development and 
differentiation of myelinating glia has been extensively studied in efforts to understand 
the basis of their functional mechanisms and molecular players of myelin formation. 
(Jessen and Mirsky, 2005; Poliak and Peles, 2003; Sherman and Brophy, 2005). A 
detailed insight in to these mechanisms will hopefully contribute to the development of 
successful strategies to restore lost functions of glial cells in demyelinating diseases 
and peripheral neuropathies.  
2.1.2 Structure and composition of the peripheral nervous system 
myelin 
The myelin sheath represents a highly specialized cellular compartment of myelinating 
Sc which is formed by tightly packed Sc membranes.  The myelin membrane has a 
specific lipid-protein composition. It is enriched in lipids, which comprise 70-80% of the 
myelin membrane. Main lipid classes are cholesterol, phospholipids and 
glycosphingolipids, which assemble to form membrane lipid microdomains (Stoffel and 
Bosio, 1997). Proteins constitute 20-30% of the myelin dry mass. Myelin proteins are 
highly specific for the myelin membrane and unlike myelin lipids are normally not found 
as constituents of any other cell membrane. The majority of the proteins found in the 
myelin membrane are proteins of compacted myelin, such as myelin protein zero (PO), 
peripheral myelin protein 22 (PMP22) and myelin basic protein (MBP) (Arroyo and 
Scherer, 2000). Compacted myelin is a structure with characteristic radial periodicity 
resulting from tightly apposed membranes. Compaction is achieved by homophilic 
interactions of the extracellular domains of P0 tetramers on opposing membranes, that 
bring together extracellular sides of the membranes forming the intraperiod lines 
(Shapiro et al., 1996). Importance of the P0 protein in compaction, has been shown in 
P0 null mutants which fail to form compact myelin (Giese et al., 1992). The intracellular 
compartments in the myelin sheath with the cytoplasmic domain of P0 and MBP form 
the major dense lines. Compact myelin is interrupted by non-compacted regions of 
cytoplasm filled spiral channels, called Schmidt-Lantermann incisures, which are 
important for the transport of molecules through the myelin sheath (Balice-Gordon et 
al., 1998). Myelin associated protein (MAG), E-cadherin, and connexin32 (cx32) are 
proteins found within non-compacted myelin. Action potentials along myelinated fibers 
are formed at the node of Ranvier, a small patch of naked axonal membrane with 
highly concentrated voltage gated sodium channels. This local depolarization of the 
membrane is transmited along the myelin internode to the next node of Ranvier in a so 
called saltatory fashion (Poliak and Peles, 2003).  Myelin segments confer lateral 
polarity between two nodes of Ranvier, with structurally specialized domains to provide 
the functional conditions for saltatory conduction of nerve impulses. One can 
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distinguish nodal, paranodal, juxtaparanodal and internodal domain (Salzer et al., 
2008). Sc microvilli make contact with the nodal region. Paranodal regions are flanking 
the node of Ranvier on both sides where Sc membranes protrude to form uncompacted 
paranodal myelin loops, which are connected to the axon by septate junctions. Axo-
glial contacts at the paranode are established through the interaction between glial 
neurofascin 155 (Nf-155) and axonal contactin associated protein (Caspr) and 
contactin (Charles et al., 2002). It is believed that the paranode is the initial site of 
myelin attachment to the axon, that secures separation of the electrical activity in the 
axonal region from the internode. The juxtaparanode is a region where shaker like 
potassium channels are accumulated, and it is maintained through interaction between 
axonal transient axonal glycoprotein1 (Tag1)/Caspr2 heterodimer and juxtaparanodal 
glial Tag1 (Traka et al., 2003). Finally, the Internodal region is a region of compacted 
myelin in a close apposition to the axonal membrane. Recently, it has been shown that 
the contact between the internode and axonal membrane is maintained by the Necl 
protein family, specifically axonal Necl1 and glial Necl4, which are crucial for myelin 
formation (Maurel et al., 2007; Spiegel et al., 2007).  
2.1.3 Schwann cells: myelinating glia of the PNS 
Mature myelinating Sc (mSc) are generated in the course of regulated, gradual 
differentiation from pluripotent neural crest progenitor cells, which are the source of all 
components of the PNS (Le Douarin, 1986). Two cell types with distinct morphological 
characteristics and cell specific markers can be identified during embryonic 
development of the Sc lineage, before final differentiation into mature Sc (Jessen and 
Mirsky, 2005). Schwann cell precursors (SCP) develop first in the Sc lineage around 
embryonal day 12 (E12) from neural crest cells migrating into developing nerves. 
These cells associate with multiple axons, and undergo proliferation and differentiation, 
largely dependent on neighboring axonal signals (Salzer et al., 1980). Axon derived 
NRG1 growth factor has been found to be critical for SCP survival, proliferation and 
development (Birchmeier and Nave, 2008). Formation of immature proliferating Sc can 
be detected in the nerve at E14 and these cells remain the nerve resident Sc until the 
time of birth. These cells are characterized by the presence of a basal lamina and 
autocrine survival mechanisms which make them less dependent on axonal contact 
compared to SCP (Meier et al., 1999). In vitro, it was shown that autocrine survival 
factors include insulin-like growth factor 2 (IGF2), neurotrophin 3 (NT3), platelet derived 
growth factor-β (PDGFβ), leukemia inhibitory factor (LIF) and lysophosphatidic acid 
(LPA) (Dowsing et al., 1999; Meier et al., 1999; Weiner and Chun, 1999). This 
characteristic of immature Sc is the base for Sc plasticity observed after PNS injury 
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which is critical for axonal outgrowth and nerve regeneration (Chen et al., 2007) In the 
postnatal phase, immature Sc exit the cell cycle and adopt either a myelinating or a 
non myelinating phenotype. During the process of radial axon sorting each mSc 
segregates axon in a 1:1 ratio and extends myelin membrane to create a multilamellar 
compact myelin sheath of one myelin segment (Sherman and Brophy, 2005). Non 
myelinating Sc (nmSc) ensheath multiple small axons, thus forming Remak bundles in 
which individual small caliber axons are segregated into pockets by a nmSc  cytoplasm 
(Jessen and Mirsky, 1998). Axonal diameter appears to be critical for the Sc fate 
decision. Only axons larger than ~1 µm in diameter acquire a compact myelin sheath 
(Friede, 1972; Voyvodic, 1989). Additionally, the number of spiral myelin wraps formed 
around the axon is also regulated and proportional to axon diameter (Smith et al., 
1982). This ratio has a constant value and is expressed as the g-ratio (ratio between 
inner and outer axonal diameter). The development of Sc is directed and regulated to 
achieve adequate myelin formation, which ensures optimal functional properties of 
myelinated fibers. Sc numbers are adjusted to form appropriate number of myelin 
segments along the axons and the myelin sheath thickens is adjusted to the axon 
diameter.  
2.2 The Neuregulin1 family of growth factors  
2.2.1 Neuregulin1 isoforms  
Neuregulins (NRG) 1-4 are a family of growth and differentiation factors with multiple 
functions in the nervous system development (Falls, 2003). NRG1 is best 
characterized. It is encoded by one of the largest mammalian genes which results in 
multiple transcripts due to differential promoter usage and alternative splicing 
(Steinthorsdottir et al., 2004). NRG1 isoforms comprise a repertoire of more than 30 
different soluble and membrane-bound proteins, at least in humans (Mei and Xiong, 
2008). All isoforms contain an EGF like signalling domain, which alone is sufficient to 
induce ErbB receptor activation and downstream signalling. Based on their distinct N-
terminal structure NRG1 isoforms can be classified into six main groups (Mei and 
Xiong, 2008). As groups IV-VI have not been extensively characterized they will not be 
discussed further. The N-terminus of type I isoforms is characterized by an 
immunoglobulin (Ig) like domain (Fig. 1A). Members of this group were independently 
identified and named heregulin (Holmes et al., 1992), acetylcholine receptor-inducing 
activity ARIA (Falls et al., 1993) and neu-differentiation factor (Wen et al., 1992). The 
type II variants, also known as glial growth factor (GGF) (Marchionni et al., 1993) 
harbor a “kringle” domain N- terminal to the Ig-like domain (Fig. 1A). NRG1 type III 
isofoms, one of which is also known as sensory and motor neuron derived factor 
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(SMDF) (Ho et al., 1995), are lacking an Ig domain and harbor a cystein-rich domain 
(CRD).  The CRD-domain serves as a second transmembrane domain, thus type III 
variants are supposed to be tightly associated with the cell surface (Fig. 1A). An 
additional isoform variability is created by alternative splicing in the EGF-like domain (α 
versus β) with the β variant being more potent in signalling (Jones et al., 1999) (Fig. 
1A). Cytoplasmic tail is also a source of structural variability, as different variants (a, b, 
c) exist (Wen et al., 1994 485) (Fig. 1A). Most of the NRG1 isoforms are synthesized 
as a transmembrane proproteins. In vitro studies showed that proproteins are 
proteolyticaly processed by proteases of the ADAMs family (ADAMS17 and ADAMS19) 
(Horiuchi et al., 2005; Yokozeki et al., 2007) and BACE1 (Hu et al., 2008; Hu et al., 
2006; Willem et al., 2006). After processing, the extracellular parts of type I and type II 




Fig. 1 NRG1 protein isoforms 
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(A) According to their distinct N-terminal region sequences NRG1 isoforms are classified into three main 
groups. Isoform specific region in Type III isoforms contains cysteine rich domain (CRD) with an N-terminal 
transmembrane domain (TMn). Types I and II have an immunoglobulin (Ig)-like domain and can obtain 
additional variability by differentially spliced spacer (S) region. Epidermal growth factor (EGF)-like 
signalling domain is present in all isoforms with alternative α or β type. Variability is also generated by 
splicing in the stalk region (1-4) and splice variant 3 does not contain C-terminal transmembrane domain 
(TMc). Splicing in the cytoplasmic tail region produces a, b or c variant. (*)- STOP codon. 
(B) NRG1 isoforms are mainly produced as transmembrane proproteins with the EGF-like domain facing 
the extracellular space. Proproteins are processed by proteases BACE1 and/or ADAMs (lightning arrow) to 
generate mature signalling fragments. Mature Type I and Type II fragments are shed after processing for 
paracrine signalling. Mature Type III fragment is membrane bound due to presence of hydrophobic 
sequence in CRD domain. Potential second cut might occur (labeled with the question mark) to release 
EGF-like domain of Type III isform. (Adapted from Mei, 2008) 
 
The EGF-like domain of NRG1 type III even after processing in the stalk region stays 
attached to the cell membrane due to the presence of the CRD-domain to mediate 
juxtacrine signalling (Wang et al., 2001) (Fig. 1B). Recently, it has been speculated that 
further processing of NRG1 type III and a release of the EFG-like domain might occur 
(Birchmeier and Nave, 2008; Willem et al., 2009) (Fig. 1B). Studies with isoform-
specific null mutants revealed that the immense structural variability of NRG1 isoforms 
and pattern of expression indeed translates into differential functions (Meyer et al., 
1997; Wolpowitz et al., 2000). Ig-domain containing isoforms were found to be 
important for heart, cranial sensory neurons and sympathetic development. In contrast, 
CRD-domain containing isoforms were indispensable for normal development of SCP 
and the neuromuscular junction, but developed no heart abnormalities. Neuronal 
overexpression of different NRG1 isoforms in transgenic mice also revealed distinct 
phenotypes in the PNS (Gomez-Sanchez et al., 2009; Michailov et al., 2004). Only the 
type III-β1 isoform induced hypermyelination in the PNS, supporting isoform specific 
function. Distinct functions of NRG1-isoforms likely reside in structural differences and 
expression patterns. Paracrine signalling mediated by type I and type II and juxtacrine 
type III signalling specify distinct cell signalling paradigms. Even if the release of the 
type III isoform occurs different signalling microenvironments are plausible due to the 
distinct N-terminal structure compared to the NRG1 type I and type II. Soluble 
signalling fragments of the type I and type II isoforms contain Ig-like domain that 
interacts with the extracellular matrix heparin sulphate proteoglycans (Loeb and 
Fischbach, 1995) and can potentiate signalling by concentrating ligand at the site of 
action as shown for ARIA at the neuromuscular junction (Li and Loeb, 2001).  
2.2.2 ErbB receptor and signaling pathways 
NRG1 function is mediated by the EGF-like effector domain through activation of 
single-transmembrane receptor tyrosine kinases of the ErbB family (Mei and Xiong, 
2008).  The ErbB family comprises 4 members, ErbB 1-4 (Citri and Yarden, 2006). 
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NRG1 does not appear to be a ligand for the ErbB1 (epidermal growth factor receptor 
EGFR), but only binds to the extracellular domains of ErbB3 and ErbB4 receptors. 
ErbB2 has an impaired ligand binding domain and functions only as a coreceptor 
(Klapper et al., 1999). Upon binding, NRG1 induces conformational changes that allow 
receptor homo- or heterodimerization, which in turn activates the intracellular tyrosine 
kinase domain and auto-phosphorylation of tyrosine residues at the C-terminus. Auto-
phosphorylation of the cytoplasmic tail induces subsequent binding of adaptor proteins 
that stimulate downstream signalling cascades. To convey signals the ErbB3 receptor 
is compelled to form heterodimers as it is devoid of an active kinase domain (Guy et 
al., 1994). As ErbB2 is impaired in ligand binding, only the ErbB4 receptor can form 
functional homodimers. Nevertheless, the ErbB2 receptor serves as a preferential 
dimerization partner due to the structure of the extracellular domain that contains a 
constitutively exposed dimerization arm (Garrett et al., 2003). Analysis of ErbB 
expression and NRG1-induced receptor heterodimerization revealed that NRG1 signals 
in oligodendrocytes through ErbB2/ErbB4 and in Sc through ErbB2/ErbB3 receptor 
heterodimers (Deadwyler et al., 2000; Vartanian et al., 1997). Analysis of the ErbB-
specific mutants confirmed ErbB2/ErbB3 mediated NRG1 signalling in Sc development 
(Garratt et al., 2000b; Morris et al., 1999; Riethmacher et al., 1997). The mitogen-
activated protein (MAP) kinase (Raf-MEK-ERK) and phosphatidylinositol-3-kinase 
(PI3K-Akt) pathways are two major signalling pathways activated by NRG1-mediated 
stimulation of ErbB receptors in the cultured Sc (Li et al., 2001). The regulated and 
balanced activation of these two signalling pathways by NRG1 evokes differential 
responses in Schwann cells during development. Sc proliferation, survival and 
myelination are dependent on PI3K activation (Maurel and Salzer, 2000) whereas the 
MAPK pathway was shown to inhibit Sc differentiation (Harrisingh et al., 2004; Ogata et 
al., 2004). Besides forward signalling to ErbB receptors by the EGF domain, 
unconventional back signalling of the C-terminal domain (CTD) of NRG1 has been 
reported in neurons in vitro (Bao et al., 2003). Soluble ErbB dimers and depolarization 
induce γ-secretase mediated release of CTD from the membrane, which than 
translocates into the nucleus to promote transcription and neuronal survival. Another 
study showed that NRG1-CTD binds to zinc-finger transcription factor Eos to enhance 
transcriptional activity of PSD-95 promoter after stimulation of synaptic activity in 
mouse cohlea (Bao et al., 2004). NRG1 binding to the ErbB4 receptor can induce γ-
secretase mediated release of the receptor intracellular domain which also translocates 
to the nucleus to regulate transcription (Ni et al., 2001; Sardi et al., 2006). 
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2.2.3 Regulation of Sc development by NRG1 
Motor and sensory neurons of the PNS predominantly express type III isoforms of 
NRG1 (Bermingham-McDonogh et al., 1997; Ho et al., 1995; Meyer et al., 1997) (Fig. 
2; 2-5), Axonal NRG1 affects Sc development on many different levels (Garratt et al., 
2000a) (Fig. 2; 1-4). A critical role of NRG1-ErbB signalling in Sc development was 
demonstrated by studies using both ligand and receptor knock out mutants.  Mice 
deficient in Nrg1 type III display a substantial reduction of the Sc precursor pool 
(Wolpowitz et al., 2000). These mutants fail to form functional neuromuscular junctions 
and experience perinatal death due to the inability to breathe. Consequently, studies of 
postnatal differentiation and myelination are not possible in these mutants. 
Correspondingly, inactivation of ErbB2 and ErbB3 receptors leads to an even more 
severe Sc phenotype, namely having a complete lack of Sc precursors and Sc in 
peripheral nerves (Morris et al., 1999; Riethmacher et al., 1997; Wolpowitz et al., 
2000). Already on the level of neural crest cells, stimulation by NRG1 defines the glial 
fate of these multipotent progenitors and induces differentiation towards the Schwann 
cell lineage in vitro (Shah et al., 1994). Additional in vitro experiments with cultured Sc 
from embryonic and postnatal nerves showed that NRG1 promoted proliferation, 
survival and differentiation of Sc precursors and immature Sc (Dong et al., 1995; 
Morrissey et al., 1995). NRG1 also regulates apoptosis in the Sc lineage. Apoptotic 
death in the Sc lineage is a mechanism to match the number of Sc to the number of 
myelin segments formed along the axon. Apoptosis of immature Sc in culture could be 
blocked by NRG1 (Syroid et al., 1996). Furthermore developmental and axotomy 
induced apoptosis of immature Sc in vivo is prevented by the addition of NRG1 





Fig. 2 Regulation of Sc development by NRG1 
Sc are derived from proliferating neural crest progenitors (1) which migrate into developing nerves early in 
development. Under the influence of axonal signals they later develop into immature Sc (2). In the phase 
of final differentiation immature Sc associated with small caliber axons from Remak bundle (3). Sc 
associated with axons typically larger than 1 µm differentiate into mSc (4). All the phases of Sc 
development are controlled by NRG1 expressed on the axonal surface (5) (Adapted from Nave and 
Schwab, 2005) 
 
2.2.4 The role of NRG1 type III-β1 in myelination  
NRG1 type III-β1 has emerged as a master regulator of PNS myelination. The fate of 
immature Sc associated with multiple axons in the peripheral nerves is defined by the 
level of NRG1 on the axonal surface (Nave and Salzer, 2006). High levels of NRG1 on 
the axons larger than ~1 µm in diameter, will induce development of immature Sc into 
mSc resulting in formation of compact myelin sheath around single axons (Fig. 2; 2-4). 
Low levels of NRG1 on axons smaller than ~1 µm in diameter, will direct immature Sc 
towards a non myelinating phenotype. The nmSc ensheathe multiple small diameter 
axons in a Remak bundle (Fig. 2; 2-3). DRG neurons prepared from embryos of NRG1 
type III knock out mice are not myelinated in DRG-Sc co-cultures. Conversely, increase 
of NRG1 type III-β1 protein levels by viral overexpression is sufficient to induce 
myelination of normally unmyelinated sympathetic postganglionic fibers, when cultured 
in the presence of Sc (Taveggia et al., 2005).  Additionally, it was found that 
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overexpression of type III isoform in transgenic mice induces ectopic myelination of 
small diameter c-fibers normally found in Remak bundles (Humml and Schwab 
unpublished). These observations unquestionably show that Sc perceive levels of 
NRG1 as a biochemical measure of axon caliber and define the further course of 
differentiation (Taveggia et al., 2005).  Furthermore, levels of NRG1 type III-β1 control 
myelin sheath thickness, such that axons with a wide range of diameter, maintain a 
constant g-ratio values (Michailov et al., 2004). Overexpression of the NRG1 type III 
isoform in neurons induces formation of thicker myelin sheath when compared to wt 
animals. Haploinsuficiency of the same isoform correspondingly leads to the formation 
of thinner myelin sheath. Inactivation of ErbB signaling in myelinating Schwann cells 
leads to the same hypomyelinating phenotype (Garratt et al., 2000b). Specificity of the 
type III isoform of NRG1 in myelin thickness regulation was confirmed as no similar 
effect was achieved by neuronal overexpression of the NRG1 type I isoform (Michailov 
et al., 2004). This finding suggested the importance of a directional presentation of 
NRG1 and juxtacrine signalling for the function in myelination mediated only by the 
type III-β1 isoform. This is in line with the finding that incorrect presentation of NRG1 to 
the mSc in culture after addition of soluble NRG1 inhibited formation of myelin and 
even resulted in dedifferentiation of  myelin forming Sc and demyelination (Zanazzi et 
al., 2001). Surprisingly neuronal overexpression of the NRG1 type III-β3 failed to 
increase myelin thickness (Gomez-Sanchez et al., 2009). Thus, it seems that protein 
structure plays a major role in defining specific signalling patterns, which are beyond 
simple paracrine versus juxtacrine signalling mechanisms in order to induce proper 
myelin formation.  
2.3 Proteolytic processing and activation of NRG1 type III 
Proteolytic processing of membrane proteins is known to regulate signaling processes 
(Hooper et al., 1997). Both ligand and receptors can be activated or inactivated after 
ectodomain shedding. As previously mentioned, NRG1 type III is synthesized as a 
proprotein that is proteolytically cleaved to be engaged in signaling (Wang et al., 2001). 
In the following chapter proteases that have been reported to play a role in NRG1 
processing will be discussed in more details. 
2.3.1 Role of BACE1 in NRG1 processing and myelination 
β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is a β-secretase with 
aspartyl protease activity, which is well known for the release of amyloid-β-peptide 
(Aβ), the constituent of amyloid plaques in Alzheimer’s disease (AD) (Zacchetti et al., 
2007). BACE1 is highly expressed in neurons (Laird et al., 2005) where it mediates 
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cleavage and release of multiple substrates. Since its discovery 10 years ago (Vassar 
et al., 1999) numerous studies  revealed BACE1 substrates other than APP, such as 
low-density lipoprotein receptor related protein (LPR) (von Arnim et al., 2005), amyloid-
β precursor-like proteins (APLP1/2) (Li and Sudhof, 2004), sialyltransferase ST6Gal-I 
(Kitazume et al., 2001), β-subunit of the voltage gated sodium channel (Wong et al., 
2005) and P-selectin glycoprotein ligand1 (PSLG1) (Lichtenthaler et al., 2003). Until 
recently, the physiological role of BACE1 has been elusive as phenotype analysis of 
BACE1-/- mutants showed only moderate hyperactivity in behavioral assays 
(Dominguez et al., 2005). More detailed analysis revealed that BACE1 null mutants 
have impaired myelination in PNS and CNS suggesting a role of BACE1 in myelination 
(Hu et al., 2006; Willem et al., 2006). Sciatic nerve remyelination after nerve crush is 
also delayed in BACE1-/- mutants (Hu et al., 2008). Thus, side effects of AD treatment 
by blocking BACE1 activity require serious consideration. PNS axons of BACE1 null 
mutants exhibit significant hypomyelination similar to NRG1 type III heterozygous 
mutants (Hu et al., 2006; Michailov et al., 2004; Willem et al., 2006). Strong expression 
of BACE1 in CNS during active myelination and accumulation of unprocessed NRG1 in 
the BACE1-/- mutant brains strongly suggested NRG1 as a new physiological substrate 
of BACE1 and attributed the myelination phenotype of BACE1-/- mice to inefficient 
NRG1 processing. Even though processing of the NRG1 III-β1 by BACE1 in the stalk 
region has been shown in vitro and the BACE1 cleavage site in NRG1 protein 
sequence GIEF/MEAE has been identified (Hu et al., 2008; Willem et al., 2004) there is 
no evidence of NRG1 type III-β1 processing in PNS in vivo. Another open question is 
whether additional cleavage by BACE1 or other proteases occurs to release the EGF 
domain of NRG1 type III from the membrane. This proteolytic event repeatedly 
suggested in the literature remains to be proven (Birchmeier and Nave, 2008; Hu et al., 
2008; Wang et al., 2001; Willem et al., 2004; Willem et al., 2009)   
2.3.2 NRG1 processing by the metalloproteases of ADAMs family  
ADAMs (a disintegrin and metalloproteases) constitute a family of more than 30 
membrane anchored proteins with a role in protein ectodomain shedding mediated by 
the metalloprotease catalytic domain (Blobel, 2005). Not all ADAM proteins posses a 
catalytically active protease domain that classifies them as a subgroup of the matrix 
metalloproteases (MMP) family (Schlondorff and Blobel, 1999). Only about half of them 
are proteolytically active and the presence of the integrin binding (disintegrin) domain 
distinguishes them from other MMPs. The disintegrin domain by which ADAMs mediate 
cell-cell and cell-matrix interactions is specifically important for the cell adhesion 
function of proteolytic inactive ADAMs (White, 2003). Other ADAMs, especially 
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ADAM17 (TACE-tumor necrosis factor-α converting enzyme), are known to participate 
in cleavage dependent activation and release of various transmembrane protein 
ligands, such as tumor necrosis factor α (TNFα) (Black et al., 1997; Moss et al., 1997) 
and EGFR ligands (Sahin et al., 2004), thereby modulating signalling events. 
Therefore, the role of ADAMs processing of NRG1 has been addressed by numerous 
studies. Two members of the ADAMs family expressed in neurons (Yang et al., 2006) 
ADAM17 (TACE) and ADAM19 (meltrin β) have been identified to cleave NRG1 
proteins in various in vitro assays. Absence of ADAM17 in cells has been shown to 
abolish cleavage of the transfected NRG1 type I isoforms with EGF-α (Montero et al., 
2000) and EGF-β domains (Horiuchi et al., 2005). In vivo, the contribution of ADAM17 
processing to NRG1 function remains unknown due to the perinatal death of ADAM17 -
/- mice mutants induced by hart abnormalities (Jackson et al., 2003) and defects in 
epithelial structures such as skin, intestine, and lung (Peschon et al., 1998; Zhao et al., 
2001). Processing of NRG1 type I-β isoforms was not affected after transfection of 
ADAM19-deficient cells (Horiuchi et al., 2005; Zhou et al., 2004). Independent studies 
however revealed the role of ADAM19 in intracellular processing of NRG1 type I-β 
(Shirakabe et al., 2001; Yokozeki et al., 2007). Recently, the role of ADAM19 in Sc 
development and nerve regeneration has been addressed.(Wakatsuki et al., 2009). In 
this study the observed delay in remyelination in ADAM19 null mice, was explained by 
impaired intracellular processing activity by ADAM19, which normally inactivates NRG1 
type I to prevent MAPK pathway stimulation in Sc and enables activation of the 
promyelinating Akt pathway by axonal NRG1 type III.  Contribution of ADAM10 
(kuzbanian) to the NRG1 processing has been evaluated because of the known 
function in cleavage of APP substrate (Kojro et al., 2001; Lammich et al., 1999) and 
especially after BACE1 has been identified to process NRG1. However, NRG1 
processing was shown to be insensitive to ADAM10 both in cell culture and in vivo 
(Freese et al., 2009). In all studies of NRG1 processing by ADAM17 and 19, the NRG1 
type I-β isoform was used. Even though processing of NRG1 type III-β1 could be 
blocked by inhibition of ADAMs in cell culture (Hu et al., 2008) using broad spectrum 
ADAMs inhibitor, it is remains unclear if a functional interaction exists between ADAMs 
and the NRG1 type III-β1 isoform. Recently metalloendoprotease nardilysin 
(Nrd1/NRDc) has been found to play a role in myelination and indirectly in NRG1 
processing (Ohno et al., 2009). Nrd1-/- mice have hypomyelination in PNS. 
Correspondingly, neuron specific overexpression of Nrd1 promotes myelination 
showing that NRDc levels regulate myelin sheath thickness. Moreover, it was shown 
that NRDc indirectly enhances NRG1 shedding by activating BACE1 and TACE. 
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2.4 Aim of the study 
Previous studies have revealed a critical role of NRG1 type III-β1 in formation of 
peripheral myelin. Membrane bound NRG1 type III-β1 is an instructive myelination 
signal and its level determines myelin sheath thickness (Michailov et al., 2004; 
Taveggia et al., 2005). Recently, it has been shown that BACE1 inactivation leads to 
hypomyelination similar to haploinsufficiency of NRG1 type III-β1 (Willem et al., 2006). 
This finding suggested BACE1-mediated NRG1 type III-β1 activation for myelination, 
but a direct evidence for this interaction in PNS in vivo has not been presented. The 
goal of this study was to further explore BACE1 mediated activation of NRG1 for PNS 
myelination in vivo. For that purpose, we have generated a transgenic mouse line with 
neuronal overexpression of a tagged NRG1 type III-β1 variant “GIEF” mimicking 
BACE1 processing, and analyzed the effect on myelination. We also compared the 
“GIEF” line myelination phenotype with that of tagged full length NRG1 type III-β1 
“HANI”. Further, we wanted to address NRG1 processing in vivo and the structure of 
the active NRG1 type III-β1 fragment by biochemical analysis of transgenic full length 
and processed NRG1 type III-β1 in wt and BACE1 null background. Finally, we took 
advantage of transgenic mouse lines overexpressing tagged NRG1 variants to 
investigate trafficking and subcellular localization of NRG1 in neurons.  
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3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Kits Chemicals and protocol source 
The Chemicals used in experiments were purchased from Sigma-Aldrich and Merck 
unless stated otherwise. All molecular biology kits were purchased from Qiagen, 
Invitek, Promega, Stratagene, Sigma-Aldrich and Macherey-Nagel. General laboratory 
plastic ware was purchased from Gilson, Falcon and Eppendorf. 
 




http://mrw.interscience.wiley.com/emrw/9780471142720/home/   
Protein  
http://mrw.interscience.wiley.com/emrw/9780471140863/home/ 
3.1.2 Molecular biology buffers 
50x Trisacetate EDTA (TAE) buffer 
2 M   Trisacetate, pH 8.0 
50 mM  EDTA 
57.1 ml  glacial acetic acid 
Adjust to the 1000 ml volume with ddH2O 
 
1x Tris-EDTA (TE) buffer 
10 mM  Tris-HCl, pH 8.0 
1 mM   EDTA 
 
10x modified Gitschier buffer (MGB) 
6.7 ml   1M Tris-HCl, pH 8.8 
1.66 ml  1M (NH4)2SO4 
650 μl   1M MgCl2 
Add ddH2O the a final volume of 10ml  
 
1x MGB buffer (Working solution) 
1 ml   10x MGB 
500 μl   10% Triton X-100 
8.5 ml   ddH2O 
 
Injection buffer for transgene constructs 
5 mM Tris  pH 7.5 
0.1 mM  EDTA  
 
1% Ethidiumbromide in ddH2O (10 mg/ml) 
Final concentration in a gel 1 µg/ml 
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10x DNA sample buffer 
25 mg  Xilene cyanol 
25 mg  Bromophenol Blue 
1.25 ml 10% SDS 
12.5 ml 100% Glycerol 
10 ml  500 mM EDTA pH 8 
Add ddH2O to the final volume of 25 ml 
 
10mM dNTP (50x stock) 
2 mM each nucleotide (dATP, dCTP, dGTP, dTTP) (Boehringer) 
200 µM final concentration in a PCR reaction (50 µM each nucleotide) 
3.1.3 Protein biochemistry buffers 
10x Phosphate buffered saline (PBS) 
1.7 M   NaCl 
34 mM  KCl 
40 mM  Na2HPO4 x 2H2O 
18 mM  K2HPO4 
Adjust pH 7.2 with 1N NaOH. 
 
Modified RIPA buffer (protein lysis buffer) 
50 mM  Tris-HCl, pH 7.4 
150 mM NaCl 
1 mM   EDTA 
0.1%   SDS 
1.0%   sodium deoxycholate 
1.0%   TritonX-100 
 
Phosphatase inhibitors 
1 mM   sodium orthovanadate 
0.5 mM  zinc chloride 
4 mM   sodium pyrophosphate 
1 mM   sodium fluoride 
 
Complete Mini protease inhibitors (Roche) 1 tablet/10 ml of RIPA buffer 
 
Phosphatase and protease inhibitors are added freshly to the RIPA buffer before use. 
3.1.4 SDS PAGE and Western blotting solutions 
4x Tris-HCl (Separating gel buffer) 
1.5 M   Tris-HCl, pH 8.8 
 
4x Tris-HCl (Stacking gel buffer) 
1 M   Tris-HCl, pH 6.8 
 
8 % Polyacrylamide separating gel (4 gels of 0.75 mm thickness) 
9.3 ml   H2O 
5.3 ml   30% acrylamide/bis-acrylamide (29:1)  
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4.0 ml   4x Tris-HCl  
0.2 ml  10% SDS  
60 μl   10% APS 
12 μl   TEMED  
 
12% Polyacrylamide separating gel (4 gels of 0.75 mm thickness) 
6.6 ml   H2O 
8 ml   30% acrylamide/bis-acrylamide (29:1)  
5 ml   4x Tris-HCl  
0.2ml  10% SDS  
60 μl   10% APS  
8 μl   TEMED  
 
0.13% Polyacrylamide stacking gel (4 gels of 0.75 mm thickness) 
5.5 ml   H2O 
1.3 ml   30% acrylamide/bis-acrylamide (29:1)  
1 ml   4x Tris-HCl  
80 µl  10% SDS  
80 μl   10% APS 
8 μl   TEMED 
 
5x SDS sample buffer 
100 mM Tris, pH 6.8 
5% (w/v) SDS 
10% (v/v) 0.4% Bromphenolblue (in EtOH) 
50% (v/v) Glycerol 
 
5x Trisglycine electophoresis buffer 
125 mM Tris base 
1.25 M  Glycine 
0.5%  SDS 
pH ~ 6.8 no adjustment necessary 
 
10x Trisglycine transfer buffer 
250 mM Tris base 
1.92 M  Glycine 
 
1x Transfer buffer 
25 mM  Tris base 
192 mM  Glycine 
20%   Methanol 
 
Coomassie blue (Staining solution) 
2 g   Coomassie brilliant blue (R-250) 
1 L   Methanol 
200 ml  Acetic acid 
800 ml  ddH2O 
Stir overnight and filter through a Whatman paper.  
 
20x Tris buffered saline (TBS) 
1 M   Tris base 
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3 M   NaCl 
Adjust pH to 7.4 with fuming HCl. 
 
1x TBS with Tween-20 (TBST) 
50 mM  Tris-HCl (pH 7.4-7.6) 
150 mM  NaCl 
0.05%  Tween-20 
 
Western blot stripping buffer 
0.2 M   Glycine-HCl, pH 2.5 
0.1%   Tween-20 
 
Western blot blocking buffer 
5% non-fat dry Milk powder in 1x TBST 
 
Enhanced Chemiluminescence (ECL) Western-blot detection kit 
Western Lightning™ Plus-ECL, Enhanced luminol reagent plus (Perkin Elmer Life 
Sciences, Inc.). 
 
ECL-Hyperfilms (Amersham Biosciences) 
 
PVDF membrane -Hybond P pore size 0.45 μm (Amersham) 
3.1.5 DNA and protein markers 
DNA-marker Lambda/HindIII     Promega 
GeneRuler 1 kb DNA ladder      Fermentas 
GeneRuler 100 bp DNA ladder     Fermentas 
Precision Plus prestained protein standard    BioRad 
3.1.6 Immunocytochemystry buffers 
1x Phosphate buffered saline (PBS) 
117 mM  NaCl 
3.4 mM  KCl 
4 mM   Na2HPO4 x 2H20 
1.8 mM  KH2PO4 
Adjust to pH 7.2 with 1N NaOH 
 
4 % Paraformaldehyde in Phosphate buffer 
10 ml   0.2 M NaH2PO4 x H2O 
40 ml   0.2 M Na2HPO4 x 2H2O 
25 ml  16%  Formaldehyde  
25 ml   ddH2O 
  
Blocking Buffer 
2%  BSA (Fraction V)  
2%   Horse serum  
0.02%  Biotin  
0.1%   Porcine skin gelatine  
0.025%  Saponin  
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Dissolved in PBS 
 
Permealisation buffer 
0.1% Saponine in PBS 
 
Mounting Media  
Aqua polymount (Polysciences) 
3.1.7 Histology buffers and solutions 
Phosphate buffer (Stock Solutions) 
0.2 M   NaH2PO4 x H2O 
0.2 M   Na2HPO4 x 2H2O 
 
Phosphate buffer working solution (pH 7.4) 
20 ml  0.2M NaH2PO4  
80 ml   0.2M Na2HPO4  
100 ml  ddH2O 
 
Perfusion fixative for immunostainings: 
4% Paraformaldehyde in Phosphate buffer 
 
Karlsson-Schultz (fixative solution for electron microscopy)  
10 ml   0.2 M NaH2PO4 x H2O 
40 ml   0.2 M Na2HPO4 x 2H2O 
0.5 g   NaCl (0.5% final concentration) 
25 ml   16% PFA (4% final concentration)  
10 ml   25% Glutaraldehyde (2.5% final concentration)  
Add ddH2O to a final volume of 100 ml  
 
Citrate Buffer (stock solution)  
0.1 M   Citric acid  
0.1 M   Sodium citrate dihydrate  
Stored at 4°C  
 
Citrate Buffer (working solution, 0.01 M, pH 6.0) 
9 ml   0.1 M Citric acid   
41 ml   0.1 M Sodium citrate dihydrate  
450 ml  ddH2O  
Always freshly prepared  
 
Tris Buffer (stock solution) 
0.5 M   Tris base  
Adjust to pH 7.6 with HCl  
Stored at 4°C  
 
Tris Buffer (working solution) 
100 ml  0.5 M Tris base (pH 7.6)  
9 g   NaCl  
Add up to 1000 ml with ddH2O  
Always freshly prepared  
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Washing buffer (2% milk powder in Tris Buffer)  
20 g of non-fat milk powder  
Add Tris buffer up to 1000 ml  
 
Bovine Serum Albumin in PBS (PBS/BSA)  
20 ml   0.2 M NaH2PO4  
80 ml   0.2 M Na2HPO4  
1.8 g   NaCl  
1 g   BSA  
100 ml  ddH2O 
 
Blocking buffer 
20% Goat serum in PBS/BSA 
 
Ca+2/Mg+2- free HEPES buffered Earles balanced salt solution (E/H) 
120 mM NaCl 
10 mM  NaHCO3 
1 mM  NaH2PO4xH2O 
2.5 mM KCl 
20 mM  Glucose  
20 mM  HEPES 
0.3%  BSA 
0.0005% Phenol Red 
Adjust pH to 7.4 and filter through 0.22 µm pore size filters to sterilize. Store frozen or 
on 4 ºC in sterile bottles. 
 
Mounting media 
Eukit    (Kindler) 
Aqua polymount        (Polysciences) 
Shandon Cryomatrix  (Thermo Scientifics) 
3.1.8 Histology staining solutions and reagents 
Mayer’s Haematoxylin solution  
Dissolve 1 g Haematoxylin in 1000 ml dH2O  
Add 0.2 g sodium iodate and 50 g of potassium aluminium sulphate under constant 
shaking.  
Add 50 g chloralhydrate and 1 g citric acid  
Filter the solution before use.  
 
Eosin solution  
Stock solution (10x)  
10 g of Eosin were dissolved in 100 ml of ddH2O and left to mature.  
 
Eosin working solution  
Add 2.5 ml of stock solution to 250 ml ddH2O and finish by adding 12 drops of glacial 
acetic acid 
 
Scott’s solution  
2 g   KHCO3  
20 g   MgSO4  
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Add ddH20 to the final volume of 1l 
 
HCl-Alcohol  
1.25 ml  HCl  
350 ml  Ethanol  
150 ml  ddH2O  
 
Reagents for Gallyas silver impregnation of myelin 
 
Incubation solution 
1 g   Ammonium nitrate 
1 g   Silver nitrate 
Dissolve in 1000 ml ddH2O 
Add 3 ml 4% Sodium hydroxide (pH 7.4-7.6) 





5%   Sodium carbonate (dehydrated) in ddH2O 
 
Solution B 
2 g   Ammonium nitrate 
2 g   Silver nitrate 
10 g   Wolframosilicic acid (silicotungstic acid) 
Dissolve in 1000 ml ddH2O 
 
Solution C 
2 g   Ammonium nitrate 
2 g   Silver nitrate 
10 g   Wolframosilicic acid (silicotungstic acid) 
7 ml   Formalin (37% paraformaldehyde) 
Dissolve in 1000 ml ddH2O 
 
To make the physical developer, add gently first 70 ml of solution B and than 30 ml of 
solution C, gently with constant shaking to 100 ml of solution A. 
 
Fixing solution 
2% sodium thiosulphate 
 
Methylenblue Stock solution 
1 g  Na-tetraborat (Borax)  
1 g   Methylenblau 
Add H2O to the final volume of 100ml 
The solution is stable for a month 
 
Azur II stock solution 
1 g Azur II in 100 ml ddH2O 
The solution is stable for a month 
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Methylenblue-Azur II working solution 
Mix both staining solutions in a 1:1 ratio and filter through a syringe filter tip when 
applying to the sections. 
 
Chemicals for EM contrasting 
4% Uranyl acetate 
Reynolds lead citrate  
1M HCl 
3.1.9 Bacteria and bacterial culture media 
Bacterial strains 
Escherichia coli XL1-Blue   (Stratagene) 
 
TB jap 
10 mM PIPES 
15 mM  CaCl2 
250 mM KCl 
Adjust pH to 6.7 with KOH 
55mM     MnCl2x2H2O 
Sterilize by filtrating (0.22 µm filter pore size)   
 
LB medium (Luria and Bertani medium) 
1 %   Bacto-Pepton  
0.5 %   Yeast extract 
1 %   NaCl 
 Media pH was set to 7.5 with 10 N NaOH and autoclaved. 
 
Selective LB media was supplemented with following antibiotics: 
100 µg/ml  Ampicillin 
50 µg/ml  Kanamycin 
 
LB-Agar plates 
1 %   Bacto-Pepton  
0.5 %   Yeast extract 
1 %   NaCl 
1.2%   Bacto-agar 
Mix with adjusted pH7.5 is autoclaved and left to cool to 55°C when desired antibiotics 
are added. 
 
For blue-white selection LB-agar is further supplemented with 
35 μg/ml   X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside)  
15 μg/ml  IPTG (Isopropyl-β-D-thiogalactopyranosid)  
 
Plates are stored at 4°C. 
 
Bacterial glycerol stock (1ml) 
80%   fresh overnight bacterial culture in LB media with antibiotic 
20%   100% glycerol  
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3.1.10 Cell lines and cell culture media  
All the media and the cell culture chemicals were purchased from GIBCO or LONZA 
unless stated otherwise 
3.1.10.1 Mammalian cell lines and media  
PC12: Rat adrenal pheochromocytoma cell line (Greene and Tischler, 1976) 
Medium: 
DMEM  (1g/l glucose) 
10%    HS 
10%    FBS (heat inactivated) 
1%      Pen/Strep 
1%   L-Glutamin 
 
COS7: African green monkey kidney immortalized cell line (Jensen et al., 1964) 
Medium: 
DMEM  (1g/l Glucose) 
10%   FBS (heat inactivated) 
1%   Pen/Strep 
1%   L-Glutamin 
 
HEK293T: Human embryonic kidney immortalized cell line (Graham et al., 1977) 
Medium: 
DMEM  (4.5 g/L Glucose) 
10%   FBS (heat inactivated) 
1%   Pen/Strep  
1%   L-Glutamin 
 
2x Freezing medium for eukaryotic cell lines: 
40%  DMEM 
20%  DMSO 
40%  FBS 
3.1.10.2 Chemicals and media for primary cell culture 
DRG-Schwann cell co-culture general chemicals: 
 
Leibovitz’s L-15 medium  
Ascorbic acid  (Sigma) 
0.25%    Trypsin solution  
10 µg/ml stock  2,5S NGF in DMEM (Alomone lab)  
10 mM   GM6001 ADAMS protease inhibitor (Calbiochem) 
1mM stock   ßsecretase inhibiotor IV in DMSO (Calbiochem) 
 
Maintainance medium: 
MEM (Earles salts and L-Glut) 
10%  FBS  
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Myelinating media: 
MEM (Earles salts and L-Glut) (Gibco) 
10%  FBS (Gibco) 
1%   Pen/Strep (Lonza) 
50ng/ml NGF  
50µg/ml Ascorbic acid  
3.1.11 Oligonucleotides 
All oligonucleotides (primers) were synthesized at “Oligo Syntesys Lab” of the Max 
Planck Institute of Experimental Medicine. They are provided at 50pM concentration. In 
house identification numbers are displayed in brackets. 
3.1.11.1 Genotyping primers 
Nrg1 TypeIII transgenic  
Forward: 5'-GGCTTTCTCTGAGTGGCAAAGGACC -3'   (6467) 
Reverse: 5'-GTCCACAAATACCCACTTTAGGCCAGC -3'  (11980) 
Amplification product: 552bp 
 
BACE knock out 
Forward: 5'-CGGGAAATGGAAAGGCTACTCC -3'   (12889) 
Reverse WT: 5'-AGGCAGCTTTGTGGAGATGGTG -3'    (12888) 
Reverse KO: 5'-TGGATGTGGAATGTGTGCGAG -3'    (12890) 
Amplification products: WT 272bp band and mutant 157bp band 
 
BACE1 transgenic 
Forward: 5'-GGCTACAACATTCCACAGACA -3'    (11784) 
Reverse: 5'-GTTCTGAGATATTTGAAGGAC -3'    (11785) 
Amplification product: 300bp 
3.1.11.2 Quantitative real time PCR primers 
β-actin 
Forward: 5'-CTTCCTCCCTGGAGAAGAGC-3'    (9146) 
Reverse: 5'-ATGCCACAGGATTCCATACC-3'    (9147) 
 
Neuregulin1 type III 
Forward: 5'-TGAGAACACCCAAGTCAGGA -3'    (9156) 
Reverse: 5'-CCCAGTCGTGGATGTAGATGT-3'    (9157) 
3.1.11.3 RT-PCR primers  
Neuregulin1 type III transgene 
Forward: 5'-GGTGCAGCAACTGGAGGCGTTG -3'   (5648) 
Reverse: 5'-GTCCACAAATACCCACTTTAGGCCAGC -3'  (11980) 
Amplification product: 450bp from cDNA template 
 
β-actin 
Forward: 5'-GATATCGCTGCGCTGGTCGTC -3'   (4262) 
Reverse: 5'-CATGGCTGGGGTGTTGAAGGTC -3'   (4264) 
Amplification product: 300bp from cDNA template, 800bp from genomic DNA template 
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3.1.11.4 Cloning primers 
GIEF construct cloning: 
Forward: 5’-ATATGAATTCCTCGAGGCCACCATGTACCCATACGATGTTCCAG 
ATTACGCTCTTTACCCATACG-3’       (10948) 
Reverse: 5'-TACTCGAGGCTAAAATTCAATCCCAAGATGCT -3'  (10851) 
 
Cloning of GIEF into the pLenti6/V5-DEST 
Forward: 5’GGGGACAAGTTTGTACAAAAAAGCAGGCTCTACCATGTACCCATA 
CGATGTTCCAGATTAC -3'        (13578)  
Reverse:5’-GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAAAATTCAATCC 
CAAGATGCTTGTAGAAGC -3'        (13760) 
 
Cloning of HANI into the pLenti6/V5-DEST 
Forward: 5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTCTACCATGTACCCAT 
ACGATGTTCCAGATTAC -3'       (13578)  
Reverse: 5'-GGGGACCACTTTGTACAAGAAAGCTGGGTCTTATACAGCAATA 
GGGTCTTGGTTAGCG -3'        (13761) 
 
3.1.12 Plasmids 
Vector     Resistance  Source 
 
pGEM-T    Amp   Promega 
pCMV2-GIEF    Kan 
pCMV2-HANI    Kan 
pcDNA3.1-BACE1   Amp 
pEGFP-N1    Kan   Clontech 
pTSC-Thy1.2    Amp   (Caroni, 1997) 
pTSC-Thy1.2 GIEF   Amp 
pDONR207    Gent 
pLenti6/V5-DEST   Amp   Invitrogen 
3.1.13 Enzymes 
Restriction enzymes      New England Biolabs 
REDTaq DNA polymerase     Sigma-Aldrich 
HotStarTaq DNA polymerase    Qiagen 
GoTaq polymerase     Promega 
Easy-A HiFi PCR cloning enzyme    Stratagene 
Superscript III Reverese Transcriptase   Invitrogen 
CIP (alkaline phosphatase)      Roche 
T4 DNA ligase      Promega 
Gateway BP Clonase II    Invitrogen 
Gateway LR Clonase II Plus    Invitrogen 
CIP (Calf intestine alkaline phosphatase)    Roche 
Power SYBR Green PCR master mix   Applied Biosystems 
ProteinaseK       Roth  
DNase       Qiagen  





Antibody  Species Dilution Application Company 
 
GAPDH  Mouse  1:1000  IB  Stressgen 
GFAP    Rabbit   1:200   IHC   DAKO 
HA    Mouse  1:250  IHC    Covance 
HA    Rat   1:1000  IB   Roche 
Krox20   Rabbit  1:400   IHC  Dies Meijer 
Mac3    Rat   1:500   IHC   Pharmingen 
MBP    Rabbit  1:200    ICC   DAKO 
NF200   Rabbit  1:200   IHC   Sigma 
Necl1    Rabbit  1:000   ICH/IB  Elior Peles 
NRG1    Rabbit  1:100 /1:500  ICC/IB  Santa Cruz  
Oct6    Rabbit  1:200   IHC  Dies Meijer 
P0    Mouse   1:000   IHC   J.J Archelos 
pAkt (ser473)   Rabbit  1:1000  IB   Cell signalling 
Peripherin   Rabbit  1:500   IHC   Chemicon 
pMAPK   Rabbit  1:1000  IB   Cell signalling 
α-tubulin   Mouse  1:2000  IB   Sigma 
Tuj1    Mouse  1:250/1:500   IHC/ICC Covance 
rHIgM22  Human 10µg/ml IHC  Mayo clinic, MN 
sHigM42  Human 10µg/ml IHC  Mayo clinic, MN 
sHIgM39  Human 10µg/ml IHC  Mayo clinic, MN 
sHIgM79.08  Mouse  10µg/ml IHC  Mayo clinic, MN 





Antibody   Species Dilution Application Company 
 
α-rabbit-cy2    Goat   1:100   IHC   Dianova 
α-rabbit-cy3    Goat   1:1000  IHC   Dianova 
α-rabbit-Alexa488   Goat   1:400   ICC   Dianova 
α-rabbit-HRP    Goat   1:5000  IB   Dianova 
α-mouse-cy2    Goat   1:100   IHC   Dianova 
α-mouse-cy3    Goat   1:1000  IHC   Dianova 
α-mouse-HRP   Goat   1:5000  IB   Dianova 
α-Rat-HRP    Goat   1:5000  IB  Dianova 
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3.1.15  Mouse lines 
HANI  NRG1 typeIII HA tagged on the N terminus  (Gummert unpublished) 
 
GIEF.  BACE1 processed NRG1typeIII HA tagged on the N terminus 
 
BACE1 knock out  (Cai et al., 2001) 
 
BACE1 transgenic (Willem et al., 2004) 
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3.2 Methods 
3.2.1 Molecular cloning  
3.2.1.1 Generation of chemical competent E. coli (XL-1 blue) 
E. coli XL-1 blue culture was grown in 4 ml LB-tetracycline (10 μg/ml) medium ON at 
37ºC with gentle shaking. On a next day bacterial culture was inoculated into 200 ml 
LB-tetracycline media and left to grow at 37ºC with gentle shaking until OD600 ~0.5. 
The culture was then centrifuged on 4ºC at 5000g for 10 min. After careful removal of 
the supernatant, bacterial pellet was washed with 80 ml “TB jap” containing 2% DMSO. 
After another centrifugation for 10 min at 5000g on 4ºC pellet was resuspended in 18 
ml of “TB jap” containing 7% DMSO and incubated on ice for 10 min. Bacterial cells in 
100µl aliquots were snap frozen and stored at -80ºC. The competence of the cells was 
(4x107 – 1x108 /μg pUC18 DNA), 
3.2.1.2 Transformation of XL1 blue 
Chemical competent E.coli (100 µl) where thawed on ice and transferred into pre 
cooled 2 ml safe lock tubes. 50-150 ng of plasmid DNA or typically half of the ligation 
mix was added without mixing in to the bacterial suspension and left on ice for 30 min.  
Bacteria where heat shocked for 40 sec on 42ºC and than incubated on ice for 2 min.  
800µl of LB medium was added to the bacteria and they where left to shake for 45 min 
in the 37ºC incubator in order to develop enough antibiotic resistance. 200 µl of the 
bacterial suspension was plated onto the LB plates supplemented with appropriate 
antibiotic. Plates were incubated ON at 37ºC to grow colonies. Propagation of single 
bacterial clones was carried out by inoculation into 4 ml of LB medium and ON 
incubation at 37°C with gentle shaking. 
3.2.1.3 Storage and revival of glycerol stocks 
Genetically modified E. coli were stored as glycerol stocks (20 % glycerol (v/v)) at -
80°C. For revival of the culture, 4-5 ml of LB medium with appropriate antibiotic was 
inoculated by bacteria from a glycerol stock picked with an autoclaved toothpick. The 
inoculated LB medium was incubated ON at 37°C with gentle shaking. 
3.2.2 DNA isolation and purification 
3.2.2.1 Small scale DNA purification “mini prep” 
The small scale amounts of plasmid DNA were purified using Qiagen’s “QIAprep 8 
Miniprep kit” or Macherey-Nagel’s “NucleoSpin Plasmid QuickPure kit”. The DNA 
preparation is carried out by a modified 'alkaline lysis' protocol (Birnboim and Doly, 
1979) followed by binding of the DNA to an anion-exchange resin under the 
appropriate pH and low-salt conditions and subsequent wash and elution steps. 
Briefly, ON cultures in 4 ml of LB media with antibiotics were transferred into the 2 ml 
safe lock tubes and bacteria were pelleted by centrifugation at 8200 rpm for 5 min at 
RT. Plasmids were isolated from this bacterial pellet following the manufacturer’s 
protocol. The bound plasmid DNA was eluted from the columns with 50 µl of 
prewarmed (50°C) ddH20. 
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3.2.2.2 Large scale DNA purification “maxi/midi prep” 
Large scale amounts of plasmid DNA were purified using Qiagen’s 'Plasmid midi kit' or 
Macherey-Nagel’s “NucleoBond PC500 EF Maxi kit” that are based on an 'alkaline 
lysis' procedure (Birnboim and Doly, 1979) coupled to an anion exchange resin 
purification under appropriate low-salt and pH conditions. The contaminating RNAs and 
low-molecular weight impurities are removed by medium salt washes. The plasmid 
DNA is then eluted from the resin by a high-salt buffer and precipitated with 
isopropanol followed by several washes to remove residual salt from the elution buffer.  
Briefly, 1 ml of fresh ON 4 ml Bacterial culture was used to inoculate 200 ml of LB 
medium (with antibiotic) which was than incubated at 37°C with gentle shaking ON. 
Bacteria were pelleted by centrifugation at 6,000g for 20 min at 4°C (SLA-1500 rotor). 
Plasmids were isolated from the bacterial pellet following the manufacturer’s protocol. 
Finally, the plasmid pellet was resuspended in ~500 µl endotoxin free ddH2O.  
3.2.2.3 Preparation of mouse genomic DNA  
Standard method 
 
Mouse genomic DNA for genotyping was prepared from 5mm pieces of tail biopsy. For 
lysis each tail was placed in tightly closed tube with 200 µl of lysis buffer containing 180 
μl of 1X MGB and 20 μl of proteinase K (10 mg/ml).  Lysis was carried out ON at 52ºC 
with vigorous shaking. Digested tails where centrifuged 5 min at 5000 rpm and 
proteinase K was heat inactivated by 10 min incubation at 95ºC. Lysate was then 
centrifuged at 5000 rpm for 10 min. 1 µl of the supernatant was used in genotyping 
PCR reactions. Alternatively surface phase of the supernatant was diluted with ddH20 
(1:5) and 1.5-2 μl of this diluted DNA was used in the genotyping PCR reaction. 
 
Preparation of a highly clean mouse genomic DNA 
 
To obtain higher purity of the genomic DNA, preparation was done with Invitek’s 
“Invisorb Spin Tissue Mini Kit”, combining cell lysis with column purification. Briefly, 
mouse tail or brain tissue was digested with proteinase K in lysis buffer G ON at 52ºC. 
DNA was then purified following the manufacturer’s protocol. After purification genomic 
DNA was eluted from the column with 100 µl pre-warmed elution buffer. 
3.2.2.4 DNA extraction from agarose gels  
DNA extraction from agarose gels was performed using Qiagen’s"QIAquick Gel 
Extraction kit" or Macherey-Nagel’s “NucleoSpin Extract II kit”. The principle of the gel 
extraction kit is based on the ability of DNA fragments to bind to silica-membranes 
under high-salt conditions at pH 7.5. Briefly, the desired DNA fragment visualized by 
UV light was cut out of the agarose gel and placed into a safe lock tube. DNA 
fragments were isolated from agarose by following the manufacturer’s protocol. Finally, 
the DNA was eluted in 50 µl of prewarmed (50 °C) ddH2O. 
3.2.2.5 DNA precipitation 
To concentrate and purify the DNA sample in solution a precipitation was performed. 
3M sodium acetate pH 5.2 (1/10 of the final volume) was first added to a DNA sample. 
After extensive mixing 2.5-3 volumes of 100% ethanol were added and the solution 
was mixed well once again. After incubation of 1 hour at -20 ºC precipitate was pelleted 
by 10 min centrifugation step at maximum speed. Pellet was washed once with 70% 
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ethanol and after 2 min centrifugation at maximum speed, the supernatant was 
removed and the pellet was left to air dry to remove any residual ethanol. Dry pellet 
was then resuspended in an adequate volume of ddH2O. For precipitation of small 
amounts of DNA a carrier substance (glycogen) was added to the DNA sample at the 
beginning to increase the efficiency and enable the visualization of the pellet. 
3.2.2.6 Transgene DNA purification for microinjection 
70 µg of pTSC vector containing the Thy1 cassette with GIEF were digested with PvuI 
and NotI ezymes in the appropriate NEB buffer 3 to remove the vector backbone.  A 
small aliquot of the restriction reaction was analyzed by gel electophoresis to verify the 
fragment size and efficiency of the digestion. The digested transgene vector was than 
loaded onto a gel without ethidium bromide for elecrophoresis. After separation the 
transgene containing DNA fragment was cut out and extracted from the agarose gel 
using Qiagen’s"QIAquick Gel Extraction kit". DNA was eluted of the gel extraction 
column with Tris- EDTA injection buffer. For further purification DNA for the injection 
was ethanol precipitated. After precipitation the DNA pellet was resuspended in the 
Tris- EDTA injection buffer to the final concentration of 30 ng/μl. 200 µl of the DNA 
sample together with a gel photo proof of the 40 ng of DNA fragment next to the 
Lambda/HindIII DNA-marker were submitted to the transgenic facility for pronuclear 
microinjection. 
3.2.3 DNA modification and analysis 
3.2.3.1 DNA amplification in vitro by polymerase chain reaction (PCR) 
The polymerase chain reaction PCR (Mullis et al., 1986) is a method that enables in 
vitro enzymatic amplification of selected DNA sequence. The reaction is catalyzed by 
the DNA polymerase from the termophilic bacterium Thermus aquaticus (Taq 
Polymerase) which is stable at the melting temperature of the double stranded DNA 
and has an optimal activity at 72 ºC. Template sequence for amplification is defined 
with primers, single stranded oligonucleotides that complementary bind to the sense 
and antisense strand on the opposite ends of the template. A PCR amplification is 
performed in a thermocycler (Thermocycler T3, Biometra) through multiple repetitions 
of the three step PCR cycle. In the first phase of PCR double stranded DNA template is 
denatured at 95ºC. In the second step (variable temperature) primers anneal to the 
complementary sequences of the template DNA.  Finally each strand of the template is 
replicated by elongation of the primer sequence by the Taq Polymarse which adds 
nucleotides complemetary to the template.  
 
Standard PCR reaction mix for the RedTaq polymerase (Sigma): 
1 µl   DNA (100 pg-100 ng) 
1 µ  sense primer (10 pM) 
1 µl  antisense primer (10 pM) 
2 µl   dNTP mix (2 mM) 
2 µl  10x RedTaq buffer 
1 µl  RedTaq polymerase (1 U/µl) 
1 2µl  ddH2O 
 
Taq Polymerase introduces about 0.8 mismatches per 1 kb per amplification cycle. To 
avoid a PCR induced mutagenesis, genetic constructs were amplified with the DNA 
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proofreading EasyA high fidelity polymerase with 3’-5’ exonuclease activity. Additionally 
number of cycles in PCR reaction was lowered.  
3.2.3.2 DNA restriction  
Restriction digest of DNA is carried out by the restriction endonucleases. These 
enzymes recognize specific, mostly palindromic sequences of dsDNA, 4-8 bp long and 
cut dsDNA leaving sticky or blunt ends. The dsDNA with 5’ and 3’ sticky ends can be 
ligated to another DNA fragment cut by the same or compatible restriction enzymes. 
This feature makes them a powerful cloning tool. Moreover, DNA sequence identity can 
be determined by the specific pattern of endonuclease fragmentation.  For analytical 
digests, in typically 20 µl digestion reaction, ~500ng of DNA was incubated at 3 ºC with 
1-10 units of an enzyme in optimal buffer condition and addition of BSA. Preparative 
digests for cloning were scaled up proportionally. Restriction enzymes can be 
inactivated by incubation at 65°C for 20 min. Gel extraction of the digested fragments 
normally removes enzymes from the final DNA sample. 
3.2.3.3 Dephosphorilation of the restriction digested plasmid DNA 
To prevent the re-ligation of restriction digested vector DNA prepared for cloning, 5’-
phosphoryl groups where removed by calf intestinal alkaline phosphatase (CIP). To 
remove phosphoryl groups 1-2 U of CIP were added to a restriction digested DNA and 
the reaction volume was adjusted to obtain a 1 time concentration of dephosphorilation 
buffer (provided as 10x concentrate). Reaction mix was incubated at 37ºC for 30min. 
CIP was eliminated from the sample by subsequent gel extraction.  
3.2.3.4 DNA ligation 
The bacteriophage T4 ‘DNA ligase' was used to catalyze the formation of 
phosphodiester bonds between 3’-hydroxyl and 5’-phosphoryl groups of the two 
restriction digested DNA fragments. Ligation reaction was set in the final volume of 10-
15 µl and it contained 3U of T4 ligase, optimal buffer conditions and vector-insert DNA 
in a 1 to 3 ratio. The ligation is carried out ON at 4°C and typically half of the ligation 
reaction volume was used for transformation. 
3.2.3.5 Gateway cloning 
Gateway® Cloning Technology (Invitrogen) is based on site-specific recombination 
between chromosomes of Bacteriophage λ and E. coli catalyzed by Int (integrase) and 
IHF (Integration Host Factor). Detailed description of the system can be found online in 
the Invitrogen’s product manual book. Tagged NRG1 constructs were efficiently cloned 
into the vector for Lentiviral expression using this method. PCR amplified NRG1 
constructs flanked by attB1 and attB2 sites were cloned into the pDONR vector 
carrying attP1 and attP2 sites in a so called “BP reaction” as follows: 
3 μl   attB-PCR product (PEG precipitated 10-100 ng) 
1 μl   pDONR207 (100 ng) 
1 μl  BP clonase II  
After 2 hours of incubation on RT 5 µl of the reaction were used to transform XL1 blue 
competent cells.  
Selected pDONR207 clones with integrated NRG1 constructs now flanked by attL sites 
were sequenced and used as an “entry clones” (pENTR) to integrate NRG1 constructs 
in to the final Lentiviral expression vector containing attR sites in so called “LR 
reaction”: 
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1 μl pENTR    (~100 ng/μl) 1 μl 
1 μl pLenti6.2/V5DEST  (60ng/μl) 1 μl 
0.5 μl     LR clonase II  
The reaction was incubated ON at RT and on the next day enzymes were inactivated 
with 1 µl Proteinase K 10 min at 37ºC followed by 5 min inactivation at 95ºC. 
2.5 µl reaction were used for transformation and positive clones were inoculated into 
the LB medium with ampicillin for ON cultures. 
3.2.3.6 Agarose gel electorphoresis for the size separation of DNA fragments 
For the separation of DNA fragments 1% to 2% agarose gels with ethidiumbromide 
were used. Gels were placed into the electrophoresis chambers filled with 1xTAE 
buffer so that the gel surface was covered by buffer and wells were filled. Standard 
DNA marker (100bp or 1kb ladder) and DNA samples in sample buffer were loaded 
into the wells. After loading, the chamber was connected to a power supply and gel 
was run until the desired fragment separation was achieved. For documentation, 
snapshots of UV-trans-illuminated gels were taken. 
3.2.3.7 Measurement of the DNA concentration and purity 
DNA concentration and purity was determined with UV spectrophotometer 
(Biophotometer, Ependorf). Concentration of a substance in aqueous solution is 
proportional to its absorption according to the Lambert-Beer law. Concentration of DNA 
in a solution can be determined by absorbance at 260 nm and 320 nm. DNA has 
absorption maximum at 260nm so the absorbance at 260 nm (A260) corresponds to the 
amount of DNA in the solution. Absorbance measurement at 320 nm (A320) provides a 
general measurement of the turbidity of the sample and is normally substracted from 
the A260 value as a background reading for the calculation of DNA concentration. To 
determine a protein contamination of the sample absorbance is measured at 280 nm 
(A280). Phenol and guanidium salts contaminations are detected by absorbance 
measurement at 230 nm (A230). 
To determine the concentration of the DNA in the solution, DNA was diluted 1:50 in 100 
µl final volume and the absorbance was measured at 230 nm, 260 nm, 280 nm and 
320 nm. DNA concentration was calculated from the formula 
 
(µg/ml) = (A260 - A320) × F x V 
 
F- multiplication factor (50 for DNA) 
V- dilution factor  
Purity of a sample was estimated from a ratios A260/A280 and A260/A230. A good quality 
DNA sample should have an A260/A280 ratio of 1.7–2.0 and an A260/A230 ratio of greater 
than 1.5. For an accurate measurement, the A260 value must lie between 0.1 and 1. 
3.2.3.8 DNA sequencing 
DNA samples were sequenced at the sequencing facility of the Max Planck Institute of 
Experimental Medicine. 16 μl of DNA samples (100 ng/μl) diluted in ddH2O and 
sequencing primer information were submitted for sequencing and obtained 
sequencing data was analyzed using DNAStar (Edit Seq) software package and 
BLAST at 'National Centre for Biotechnology Information' (NCBI) 
(http://www.ncbi.nlm.nih.gov/blast/Blast.cgi). Sequences were also verified on public 
domain databases such as ENSEMBL (http://www.ensembl.org). 
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3.2.3.9 Primer design 
All primers are designed manually based on the template sequence information using 
the DNAStar (EditSeq) software, pDRAW 32 software, BLAST at NCBI, and 
oligocalculator (http://www.pitt.edu/~rsup/OligoCalc.html ). They where designed to 
have at least 20 bp overlap with the template sequence, and the melting temperature 
~60ºC. 
3.2.4 RNA isolation and analysis  
3.2.4.1 RNA isolation (‘RNeasy mini prep’)   
Small scale RNA isolation from animal tissue was performed using “Qiagen’s RNeasy 
Mini Prep” kit. The kit is based on a selective binding of RNAs bigger than 200 bases to 
a silica-gel based membrane under high-salt conditions, which excludes binding of 5S, 
5.8S and tRNAs. RNA isolation and purification was carried out following the 
manufacturer’s instructions. 
Briefly, frozen (-80ºC) spinal cord or brain tissue was transferred into the RLT buffer 
and immediately homogenized with a Ultra-Turrax T8 for 30 sec. After addition of 
ethanol for optimal binding, the homogenate was applied to the RNeasy mini column 
where the RNA sample was treated with DNase, washed from the contaminants and 
finally eluted with 2 times 50 µl RNase free ddH2O. 
3.2.4.2 RNA precipitation 
To concentrate RNA sample a precipitation was performed. 1 µl of glycogen carrier 
was added to the RNA sample and mixed. In the following step 3 M sodium acetate pH 
5.2 (1/10 of the final volume) was added to the sample. After mixing by pipeting, 3 
volumes of 100% ethanol were added and the solution was mixed well once again. 
After incubation of 1 hour at -20ºC precipitate was pelleted by 10 min centrifugation 
step at maximum speed. The pellet was washed once with 200 µl of 80% ethanol and 
after 2 min centrifugation at maximum speed, the supernatant was removed and the 
pellet was left to air dry to remove any residual ethanol. A dry pellet was then 
resuspended in an adequate volume of RNase free ddH2O. 
3.2.4.3 cDNA synthesis 
In order to analyze specific RNA expression profile, the RNA repertoire isolated from 
mouse tissue was converted into the more stable complementary single stranded DNA 
(cDNA) library. First-strand cDNA is synthesized in a reverse transcription reaction 
catalyzed by RNA dependent DNA polymerase SuperScript III at 55ºC.  
cDNA synthesis protocol: 
X µl   RNA (500ng total) 
4 µl  primers (random nonamers 25pmol/µl) 
Add RNAse free ddH2O to a final volume of 13µl 
To co-precipitate RNA and primers, the mixture was incubated for 10 min at 70ºC and 
2 min on ice.  
Afterwards the following premix was added to the reaction: 
4 µl  5x first strand buffer 
1 µl  dNTP’s (10 mM) 
1 µl  DDT (100 mM) 
1 µl  SuperScript III reverse transcriptase (200 U/µl) 
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The final 20µl reaction mixture was incubated in a thermocycler under following 
settings: 
25 ºC  10 min 
50 ºC  30 min 
55 ºC  30 min 
70 ºC  15 min 
4 ºC  1 min 
 
Synthesized cDNA was diluted 5 times with ddH2O. 
3.2.4.4 Quantitative real time PCR (qRT-PCR) 
QRT-PCR was performed using Light Cycler 480 (Roche) and SYBR Green Master Mix 
according to the Manufacturer (Applied Biosystems). Assay for the gene expression 
analysis contained 5 µl of SYBR Green Master Mix, 2 ng of cDNA, 1 pM of primer pairs 
and ddH20 to the final volume of 10.2 µl. All reactions were performed in 
quadruplicates. PCR reaction was carried out under following temperature conditions 
60 for 1 min, 95 for 15 sec [45 cycles].  Analysis of the measurements was done with 
LC480 software. Results were displayed as histograms of relative gene expression with 
respect to the β-actin housekeeping gene. 
3.2.5 Protein biochemistry methods  
3.2.5.1 Preparation of protein lysates from cell cultures 
To acquire protein material for the subsequent WB analysis DRG-Schwann cells co-
cultures were lysed in RIPA buffer. Briefly, 12-well plates with cultures were transferred 
onto ice. Coverslips with cells were washed 2 times with PBS, 50 µl of RIPA buffer was 
applied and cells were scraped from the coverslips with the pipette tip. Scraped cells 
from 6-8 coverslips were pooled into a safe lock tube and homogenized for 1 min with 
the Ultra-Turrax T8. The homogenized material was left on ice for 15 min to lyse. To 
pellet the undigested material, cell lysates were centrifuged for 20 min on 4ºC at 
maximum speed. The supernatant containing the soluble proteins was transferred into 
a new tube and kept at –20ºC until use. The pellet containing the cell debris and 
unsolubilised material was also kept and stored at –20ºC. 
 
Protein lysates from transfected cells were prepared from 90% confluent 6 cm plates 
24 hours post transfection. Briefly, cells were washed on ice 2 times with PBS, 150 to 
250 µl of RIPA buffer was added and the cells were scraped with a rubber cell scraper. 
After transfer into a safe lock tube cells were left to lyse on ice for 15 min. Following 
this step protocol does not differ from the DRG culture protein lysates preparation. 
3.2.5.2 Preparation of protein lysates from animal tissue  
To prepare proteins out of frozen mouse nervous system tissue (-80ºC) spinal cords 
and sciatic nerves were homogenized in 600 µl and 200 µl RIPA buffer, respectively. 
Homogenization was carried on for 1 min with the Ultra-Turrax T8 or with the Precylis 
homogenizer (5000rpm 1x10sec). The homogenized material was than lysed on ice for 
20 min. Lysed tissue was then centrifuged at 4ºC for 30 min at maximum speed.  The 
supernatant containing the soluble proteins was transferred into a new tube and kept at 
–20ºC until use. Pellets were also kept and stored at –20ºC. 
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3.2.5.3 Protein concentration measurement by the Lowry assay 
The protein concentration was measured using the Bio-Rad DC Protein Assay kit. The 
assay was performed in a 96-well plate (flat bottom) according to the manufacturer’s 
“micro plate” assay protocol and absorbance was measured at 650 nm with a microtitre 
plate reader. The working principal of the kit is similar to the Lowry assay (Lowry et al., 
1951). The two step assay is based on the reaction between protein and copper in an 
alkaline medium, followed by the reduction of the Folin reagent that produces several 
reduced species of a characteristic blue color with a maximum absorbance at 750 nm. 
The color development is primarily due to the oxidation of the amino acids tyrosine and 
tryptophan, and to a lesser extent, cystine, cysteine, and histidine.  
3.2.5.4 Preparation of the protein samples for SDS electrophoresis  
For the separation by SDS polyacrilamide electrophoresis protein samples were 
denatured. Portions of the protein lysates containing 15-40 µg of protein were mixed 
with 5x sample buffer and 1% ß-mercaptoethanol in a 1.5 ml safe lock tube. Volumes 
of the samples were equalized with RIPA buffer and samples were than incubated at 
95ºC for 10 min.  
3.2.5.5 Discontinuous SDS polyacrilamide electrophoresis 
The size separation of the proteins from a sample was performed using the 
discontinuous SDS polyacrylamide gel electrophoresis (SDS-PAGE) described by 
Laemmli (Laemmli, 1970). The glass plates and the 0.75 mm or 1.75 mm spacer plates 
were assembled according to the Bio-Rad instructions. The separating acrylamid gel 
solution of the desired percentage was poured between the glass plates and separated 
from the air by a layer of ddH20 saturated with isobutyl alcohol. The gel was left to 
polymerize for 30 min at room temperature. After rinsing the isobutyl alcohol twice with 
ddH2O, the stacking gel solution was added. A Teflon comb (10 or 15 teeth) was 
immediately inserted into the stacking gel solution and the gel was left to polymerize for 
45 min. Polymerized gels were kept up to a week at 4ºC. The chamber for 
electrophoresis (mini protean 3) was assembled according to the the Bio-Rad 
directions and filled with the electrophoresis buffer. The comb was carefully removed 
and the wells were washed with electrophoresis buffer. 10-40 µg of denatured protein 
samples and 10 µl of prestained protein marker were loaded onto the gel. The chamber 
was connected to a power supply and the gel was run under a constant current 
protocol (10 mA/0.75 mm gel) until the tracking dye reached the end of the gel. The gel 
was than carefully removed and it was proceeded with Coomasie staining or Western 
Blotting. 
3.2.5.6 Coomassie staining 
To verify the protein transfer, the SDS-PAGE gels were stained with Comassie 
solution. Briefly, the gel covered with Coomassie solution was coocked in a microwave 
for 30 sec. Than the gel was washed with ddH2O at room temperature with gentle 
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3.2.5.7 Western Blotting  
Electrophoretic transfer  
 
For the immunodetection proteins resolved by size on SDS-gel were transferred onto a 
PVDF membrane by electrophoresis, as originally described with modification (Towbin 
et al., 1979). PVDF membranes were activated for 15 sec in 100% methanol and 
placed into transfer buffer. Blotting pads, and the Whatman paper were pre-soaked in 




The protein transfer was performed using Invitrogen’s chamber system(Western Blot 
chamber XCell II, Invitrogen) under a constant voltage of 38 V and a maximum current 
of 275 mA for a 1.5 mm gel and for 70 min at 4ºC. 
 
Immunological detection of proteins on PVDF membranes  
 
Membranes were first blocked for 30 min at room temperature in blocking buffer and 
than placed into a 50 ml falcon with 3 ml of the primary antibody diluted in blocking 
buffer. Incubation was carried out ON at 4ºC with constant rotation. After four 10 min 
washes in TBST, the membrane was incubated with the HRP-conjugated secondary 
antibody diluted in blocking buffer for 1 hr at RT. The membrane was again washed 
with TBST four times 10 min, followed by 1 min incubation with the Enhanced 
Chemiluminescence Detection (ECL) solution. The membrane was than placed into a 
plastic transparent foil brief and the ECL photographic film was exposed to the 
membrane to visualize the labeled proteins. The exposure time varied between 5 sec 
and 10 min depending on the signal intensity. The films were then developed in a 
KODAK X-OMAT developer. 
To reprobe the same membrane with a different antibody, the membrane was 
incubated in a stripping buffer for 1 hr at 60°C with vigorous shaking. After washing in 
TBST and blocking, the membrane was ready for the antibody incubation. 
3.2.6 Cell cultures 
Handling of the cell culture material and preparation of the media and solutions were 
performed under sterile conditions in the laminar flow tissue culture hood. 
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3.2.6.1  Maintenance of the cell lines  
All eukaryotic cell lines were grown on 10 -15 cm cell culture dishes with an appropriate 
medium in a humidified incubator (Hera Cell 150, Thermo Scientific) at 37°C and 5% 
CO2.  
 
Poly-L-Lysin (PLL) coating of cell culture dishes 
 
Cell lines adhere better when grown on Poly-L-Lysin (Invitrogen) substrate. The 
surface of the cell culture dish was covered with a thin layer of PLL in ddH2O (0.02 
mg/ml) and left for 20 min at room temperature. Dishes were washed twice with the 
sterile ddH2O and left to dry. Dry PLL coated dishes were kept at 4ºC up to one month. 
PC12 cells were always plated onto PLL coated dishes. HEK 293T cells were plated on 
PLL for the transfection assays. 
 
Passaging of the cell lines 
 
After reaching 90% of confluence cells were trypsinized and transferred onto the new 
culture dish. Briefly, confluent cells were washed with sterile PBS and 1 ml of 0.25% 
Trypsin-EDTA was applied to detach the cells. After 1-2 min incubation, the trypsin was 
inactivated by the addition of 10 ml of full cell culture medium. Trypsinized cells were 
washed off the dish surface by pipetting and transferred than into a 50 ml falcon tube. 
Cells were pelleted by a 5 min centrifugation at 800g and the supernatant was 
discarded. The cell pellet was than resuspended in 5 ml of medium and triturated with a 
1 ml pipette to achieve a better single cell separation. Variable amounts of cell 
suspension were than plated onto the new dish with medium.  
 
Determination of the cell number in a cell suspension 
 
To determine cell number in a cell suspension 10 µl of the cell suspension was pipetted 
on to a Neubauer counting chamber. Cells from the one quadrant of 4 different fields 
were counted. Number of cells was determined according to the formula: cells/ml = 
cells counted in 4 quadrants x 4 x 10000 
 
Generation of frozen eukaryotic cell lines stocks 
 
Cells were grown until a 90% confluence on a 15 cm dish (approximately 20x106 cells). 
After trypsinization cells were resuspended in 5 ml of ice cold growth medium. Than 
500 µl of cell suspension were transferred into a previously prepared and labeled 
cryovial with 500 µl of 2x ice cold freezing media. To mix the cells, the cryovial was 
gently inverted a couple of times. Cells were frozen on –20ºC for two hours. They were 
kept at –80ºC for 6 to 12 hours before placing into liquid nitrogen for long term storage. 
Typically cells before passage 10 were used to make frozen stocks. 
 
Revival of frozen eukaryotic cell lines stocks 
 
A cell culture dish (10 cm) with warm growth medium was prepared. The frozen stock 
of cells was taken out of the liquid nitrogen and placed onto dry ice. The cryovial with 
cells was placed into a 37ºC water bath to heat and loosen the frozen stock from the 
cryovial walls. Still frozen cells were quickly released from the cryovial into the 
previously prepared plate. After two passages the cell were ready for experiments. 
MATERIALS AND METHODS  
 38
3.2.6.2 Cell lines transfections 
Transfection by lipofection method was used to introduce plasmid DNA in to the 
mammalian cells. For the transfections cells were plated in a chosen setting depending 
on the experimental purpose: 
 
Cell line   ICC/24 well plate  WB/6 cm culture dish  
 
PC12     250 000   800 000 
HEK 293T   100 000   500 000  
COS7     250 000   600 000 
 
Cells were left to grow until a 50-70% confluence and transfected using Lipofectamine 
2000 Transfection Reagent (Invitrogen) according to the adjusted manufacturer 
recommendations.  For the 24 well plate 50 µl of OptiMEM medium were mixed with 
500 ng of plasmid DNA. 1 µl of Lipofectamine was mixed with another 50 µl of 
OptiMEM. The OptiMEM with diluted DNA and Lipofectamine were than mixed and left 
for 20 min to form complexes. Growth medium on cells was replaced with 400 µl fresh 
medium and 100 µl of OptiMEM with formed DNA- Lipofectamine complexes were 
added. For 6 cm dishes volumes were scaled up to 500 µl OptiMEM, 2 µg DNA and 4 
µl of Lipofectamine. 1 ml of OptiMEM with formed DNA-Lipofectamin complexes was -
in this case- added to the cells with 1 ml of freshly changed full growth medium.  
3.2.6.3 Split Tev assay  
Two cell Split Tev assay was performed as described in (Wehr et al., 2006; Wehr et al., 
2008). Briefly, NRG1 constructs were transfected into PC12 cells. This transfected cell 
population was mixed with the PC12 cell population expressing ErbB2 receptor and PI3 
kinase proteins coupled to the components of the Split Tev system. NRG1 mediated 
ErbB receptor dimerization and recruitment of PI3 kinase was detected by 
measurement of the luciferease reporter gene activation. The results were displayed in 
relative luminescence units (RLUs). 
3.2.6.4 Dorsal Root Ganglion (DRG) neuron-Schwann cell co-culture 
Dorsal Root Ganglion (DRG) neurons-Schwann cells co-culture was used to study 
myelination in vitro. 
3.2.6.4.1 Preparation of the culture 
DRG neurons-Schwann cells co-culture is prepared from dissected E13 mouse 
embryos DRG’s. Thirteen days pregnant mouse (the plug day is counted as E0) is 
sacrificed and the uterus with embryos was carefully removed from the abdomen and 
put into a 10 cm dish with L15 medium. Embryos were taken out of the uterus and 
transferred into the new 10 cm dish with cold L15. Embryos were kept on ice until the 
end of the preparation. One by one, embryos were dissected under the binocular in a 6 
cm dish using sterilized #5 Dumont medical biology forceps. After decapitation and 
removal of the abdominal organs, the ventral side of the spinal column was exposed.  
DRG’s were extracted attached to the spinal cord by carefully pulling the spinal cord 
out of the ventrally open spinal column. All the spinal cords with attached DRG’s were 
collected into a 6 cm dish with L15 medium and kept on ice. DRG’s were than plucked 
of the spinal cord and spinal cords were discarded. Extracted DRG’s in L15 medium 
were transferred into a 15 ml Falcon tube with a disposable plastic pipette. DRG’s were 
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pelleted by a 5 min centrifugation at 700 g and the medium was discarded. After 
addition of 1 ml of 0.25% trypsin, DRG’s were placed in a water bath at 37ºC and 
digested for 45 min. Trypsinization was stopped by adding 1.5 ml FBS and 3 ml L15 
medium. To obtain a single cell suspension, DRG’s were triturated with a 5 ml pipette 
and subsequently with a glass Pasteur pipette (tip reduced by flame polishing). The 
single cell suspension was centrifuged for 10 min at 800 g, the supernatant removed 
and cells resuspended in ~ 1 ml of growth medium. Cells number was determined by 
pipetting 10 µl of the cell suspension into a Neubauer counting chamber, and 75000 
cells in 50 µl medium were gently placed in the middle of collagen coated coverslip (18 
mm) in a 12 well plate. In this way a small cell culture island containing neurons, 
Schwann cells and fibroblast is formed on each coverslip. Cultures were placed into the 
incubator over night to settle. On the next day, after cells had attached, wells were 
carefully filled with 1 ml of DRG growth medium. Cultures were kept in the incubator 
without changing the medium for a week. During this week period DRG neurons 
processes extend to form a network. Proliferated Schwann cells aligning the processes 
are visible and ready to myelinate once permissive conditions are provided. 
3.2.6.4.2 Myelination induction of the culture 
Myelination of the DRG neurons by Schwann cells was achieved by addition of 
ascorbic acid (50 ng/ml final concentration) to the full growth medium. Under these 
conditions, Schwann cells can form a basal lamina and myelin segments around 
extended axons of DRG neurons. Ascorbic acid powder is diluted in ddH2O to a 1000x 
(5 mg/ml) stock.  Aliquots of ascorbic acid stocks were frozen and freshly added to the 
growth medium that is now changed every second day. The extent of in vitro 
myelination was analyzed 7 or 14 days post myelination. 
3.2.6.4.3 Treatment of the culture with proteases inhibitors 
DRG cultures were treated with 0.5-2 µM ß secretase inhibitor IV and 1 µM ADAM’s 
protease inhibitor GM6001. Proteases inhibitors treatment started on the day 5 post 
preparation. The inhibitors were added freshly, every time myelinating media has been 
changed. Effects of the inhibitors on mmyelination were analyzed 7 or 14 days post 
myelination induction. 
3.2.6.4.4 Viral infection of the DRG neurons 
DRG neurons were prepared from E14 mouse embryos as described previously and 
selected by cycles of  treatment with FUDR as described previously (Taveggia et al., 
2005). Lentivirus expressing HANI and GIEF NRG1 variants was generated using 
ViraPower Lentiviral Expression System (Invitrogen) according to manufacturer’s 
protocol. For infection DRG neurons cultures were incubated with viral supernatants in 
DRG culture media for 16 hours. Infection was confirmed by HA staining 11 days post-
infection. Rat Sc were prepared as described (Taveggia et al., 2005) and added to the 
established DRG neuron culture. Myelination was initiated by addition of ascorbic acid 
to the media. 
3.2.6.4.5 CNS neurons-oligodendrocytes co-culture 
Primary cultures of rat oligodendrocytes were prepared as described previously 
(Simons et al., 2000). After shaking, cells were plated in DMEM containing B27 
supplement, 1% horse serum, L-thyroxine, tri-iodothyronine, glutamine, pen/strep, 
pyruvate, and bicarbonate. For neuronal culture, the mixed brain cultures were 
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prepared from E16 mice and cultivated for 2 weeks at a density of 50000 cells/cm2 on 
poly-L-lysine–coated glass coverslips. Co-cultures of neurons and oligodendrocytes 
were prepared by adding primary oligodendrocytes to already 2 week cultivated mixed 
brain cultures. After 5 days, the cocultures were fixed and stained to monitor the 
myelination process.  
3.2.7 Immunocytochemistry  
3.2.7.1 Immunostaining of transfected cell lines 
Before fixing the cells for immunostaining, the medium was removed and cells were 
washed once with PBS. For fixation, cells were incubated with 4% PFA for 10 min at 
room temperature. Cells were than washed 3x with PBS and permeablized for 1 min in 
permeabilization buffer followed by a incubation with blocking buffer for 1 hour at RT. 
Coverslips were than transferred in to a box with parafilm and 100 µl of primary 
antibody dilution in blocking buffer was applied onto a coverslip. The incubation was 
carried on in a humidified chamber at 4ºC ON. On the next day, coverslips were 
washed three times with PBS, and 100 µl of the fluorescent secondary antibody in 
blocking buffer were applied. After an incubation period of 1 hour at RT, the coverslips 
were washed three times with PBS and the nuclear dye DAPI diluted in PBS was 
applied for 10 min. Coverslips were washed again 2x with PBS, dipped shortly into 
ddH2O and mounted with AquaPolymount. 
 
To stain the extracellular surface epitopes and prevent the antibody from entering 
intracellular spaces a “Live staining” protocol was applied. The plate with cells was 
placed on ice, medium was removed and ice cold DMEM was added for 3 min to 
further cool the cells. Primary antibody dissolved in cold 3% HS in DMEM was gently 
added and incubated for 15 min on ice. Cells were extremely carefully washed once 
with PBS and finally fixed with 4% PFA for 10 min. Coverslips were washed 3x with 
PBS and fluorescent secondary antibody diluted in PBS was applied for 45 min on RT.  
After 3x washing with PBS, DAPI nuclear dye diluted in PBS was applied for 10 min. 
Coverslips were washed again 2x with PBS dipped shortly into ddH2O and mounted 
with AquaPolymount 
3.2.7.2 Immunostaining of DRG neurons-Schwann cells co-culture 
To fix the cells for immunostaining, medium was removed, wells were washed once 
with PBS and the cells were incubated with 4% PFA for 10 min at RT. Cells were 
washed 3x with PBS and permeablized for 5 min at -20ºC with precooled methanol. 
Cells were washed 3x with PBS and blocked in 3% BSA in PBS for 1 hour at RT. 
Coverslips were than transferred into a box with parafilm and 150 µl of primary 
antibody in blocking buffer were applied onto the coverslip. The incubation was carried 
on in a humidified chamber ON at RT. Following steps do not differ from the protocol 
for immunostaining of the cell lines.  
3.2.8 Histology and immunohistochemistry 
3.2.8.1 Perfusion fixation of mouse tissue for histology 
To anesthetize mice 2.5% Avertine with a dose of 0.2 ml per 10 g of body weight were 
injected intraperitonealy. Once the mouse was anestesized it was fixed onto a 
Styrofoam board ventral side up and a piece of the tail was taken for the confirmation 
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of the genotype. The abdomen was opened and the cuts were made through the 
diaphragm and laterally of the rib cage to expose the heart. A 27 gauge needle butterfly 
connected to a peristaltic pump was inserted into the left ventricle and the right atrium 
was open by a small cut to ensure the perfusion flow. With help of the peristaltic pump, 
the mouse was first perfused with warm HBSS to clear the blood out of the circulatory 
system. The mouse was than perfused with 20-40 ml of the appropriate cold fixative, 
depending on the type of subsequent histological analysis (see histology fixatives in the 
material section). After the perfusion, fixed spinal cord, dorsal root ganglia and sciatic 
nerves were dissected and placed in cold perfusion fixative for post fixation. Tissue 
was kept in fixative at 4ºC until embedding. Tissue for paraffin embedding was further 
processed after the ON postfixation. Tissue intended for epon embedding and EM 
analysis can be kept longer in perfusion fixative but for very long storage should be 
transferred into 1% PFA. Tissue for immuno-EM should be transferred from the 
perfusion fixative into 1% PFA after no longer than 4 hours for ON postfixation. 
3.2.8.2 Procedures for tissue embedding  
Paraffin embedding  
 
Before the embedding process, the tissue was washed with PBS. Spinal cords were 
cut into 5 - 6 pieces and put into the plastic perforated chambers. Sciatic nerves and 
DRG’s were embedded in 2% agar blocks and also placed in plastic perforated 
chambers. Chambers with tissue were properly labeled and placed into the automated 
system (HMP 110, MICROM) for dehydration and paraplast impregnation.  
The tissue was dehydrated by an incubation in an ascending row of ethanol dilutions at 
room temperature: 
50% Ethanol   1 hour 
70% Ethanol  2x 1 hour  
96% Ethanol   2x 1 hour  
100% Ethanol  2x 1 hour 
Isopropanol   1 hour  
Xylene   2x 2 hours  
After dehydration, the tissue was impregnated with paraffin by a 2x 2 hours incubation 
at 60ºC. The tissue was than placed in the molds with hot paraffin and filled molds 





Perfusion fixed tissue was placed into a block  of Shandon cryomatrix embedding 
medium and immediately frozen on dry ice until the block turned white. Frozen blocks 




Fresh spinal cord tissue was embedded in 3% low melting point agarose on the surface 
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Epon embedding   
 
Tissue for subsequent EM imaging was embedded using an automated system (EM-
TP, Leica) in a multi step process involving osmification, dehydration and epon 
impregnation. 
Epon mix was prepared 30 min before embedding in the following way: 
 
171.3 g Glycidether 100 
115 g  DDSA (Dodecenyl succinic anhydride) 
89 g  MNA (Methyl nadic anhydride) 
Mix using magnet stirrer for 10 min and than add 
6.5 ml  DMP-30 
Mix using magnet stirrer for 20 min 
 
Before the embedding, tissue was washed from the fixative with 0.1 M phosphate 
buffer and placed into the plastic chambers. Chambers were than placed into the 
machine for embedding and tissue was processed using following set up: 
 
Solution   Incubation time   Temperature 
 
Phosphate buffer  3 times 10 min  4ºC 
2% OsO4   4 hours   4ºC 
ddH20    3 times 10 min  4ºC 
30% Ethanol   20 min    4ºC 
50% Ethanol   20 min    4ºC 
70% Ethanol   20 min    4ºC 
90% Ethanol   20 min    4ºC 
100% Ethanol   4 times 10 min  4ºC 
Propylenoxid   3 times10 min   RT 
Propylenoxid/Epon 2:1 2 hours   RT 
Propylenoxid/Epon 1:1 2 hours   RT 
Propylenoxid/Epon 1:2 4 hours   RT 
Epon    4 hours   RT 
 
Tissue was than placed into the labeled Epon filled molds and left ON at 60ºC for Epon 
polymerization. 
3.2.8.3 Tissue sectioning 
Paraffin embedded tissue was cut using a microtome (HM 400, MICROM). A cooled 
paraffin block was cut into 5 µm thick sections. Sections were placed into the 42ºC 
water bath to flatten the tissue. Floating sections were picked with positively charged 
glass slides and left to dry over night at 37ºC.  
 
Epon embedded tissue was cut using a microtome (Ultracut S, Leica). Semi-thin 
sections 0.5 µm were cut with a diamante knife (Diatome Histo 45º) and ultra-thin 
sections of 50 nm for electron microscopy with (Diatome Ultra 45º). Each cut sections 
was released from the block into a water filled pool on a knife holder. For light 
microscopy, floating 0.5 µm sections were picked with a glass stick, into the water 
puddle on a glass slide, dried on a hot plate at 60ºC and stained. For electron 
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microscopy 50 nm sections were placed on a double sized slot grid (2mm-1mm, 
AGAR) coated with Formvar polyvinyl and contrasted.  
 
Cryo sections were made using a cryostat (Leica). Shandon Cryomatrix embedded 
tissue was transferred from – 80ºC in to the cryostat (-18ºC to -20ºC) and after 5 min of 
temperature equilibration cut into 10-15 µm sections. Sections were put on super frost 
glass slides and allowed to dry on RT for at least 30 min. Sections were stored at – 
80ºC until use.  
 
For floating tissue slices staining 225 µm thick cross or sagital sections were cut out of 
the agarose embedded spinal cord using the McIlwain tissue chopper. Individual tissue 
slices were separated immediately under the binocular and transferred into a 24 well 
plate containing cold E/H for staining. 
3.2.8.4 Hematoxylin- Eosin (HE) staining 
Hematoxylin-Eosin (HE) staining is a widely used histological staining method that 
gives information of the overall tissue structure. Cells are easily differentiated with this 
type of staining as hematoxylin stains basophilic nuclei in dark purple and eosin stains 
eosinophilic cytoplasm pink. For HE staining, paraffin sections were first deparaffinised 
by incubation of the slides two times for 10 min in Xylol and 1x 10 min in 
Xylol/Isopropanol (1:1),  followed by a rehydratation with 5 min incubation steps in the 
descending ethanol dilutions (100%, 90%, 70%, and 50%). After 5 min wash in ddH2O, 
sections were stained with 0.1% Haematoxylin for 5 min and washed with ddH2O.The 
dark purple color was differentiated by a quick dipp in HCl-Alcohol solution. To stop the 
differentiation process and properly develop the color, sections were incubated for 5 
min in Scott’s solution. After a short rinse in ddH2O they were counterstained with 
0.1% Eosin for 3-5 min. The excess dye was washed of with ddH2O. Sections were 
dehydrated in the ascending row of ethanol dilution (50%, 70%, 90%, and 100%) by 
short incubations (10-30 sec) depending on the stability of the Eosin stain. Sections 
were then incubated for 10 min in Xylol/Isopropanol (1:1) and 2x 10 min in Xylol. 
Sections were mounted with the Xylol based mounting medium Eukitt. 
3.2.8.5 Gallyas staining of myelin on paraffin sections 
This myelin staining technique developed by Gallyas (Gallyas, 1979) is based on the 
binding of colloidal silver to myelin that can be than visualized by light microscopy after 
a particular process of physical development. Paraffin sections were deparaffinised and 
rehydrated as for HE stainig. After 5 min incubation in ddH2O sections were incubated 
with 2:1 mixture of pyridine (200 ml) and acetic acid anhydride (100 ml) for 30 min. 
Sections were washed three times for 10 min in ddH2O and incubated for 10 min at 
room temperature in the preheated (1 min in microwave at 150 W) incubation solution. 
Afterwards they were washed three times for 5 min in 0.5% acetic acid. Sections were 
then developed by incubation in a developer solution for 3-15 min and the extent of 
developed color was controlled under the microscope. Color development was stopped 
with 1% acetic acid with three incubation steps of 5 min. Finally, slides were washed 
properly in ddH2O. To stabilize the silver staining, slides were incubated in 2% sodium 
thiosulfate solution for 5 min. After two 5 min washings in ddH2O sections were 
dehydrated in as for HE staining (alchohol row incubations for 5 min) and mounted with 
Eukitt. 
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3.2.8.6 DAB immunostaining of the paraffin sections  
DAB immunostaining is based on the enzymatic reaction of Horseradish Peroxidase 
(HRP) attached to a secondary antibody and the DAB substrate, which forms a stable 
brown precipitate that can be visualized with light microscope (Harlow and Lane, 1988). 
Paraffin sections with 5 µm of thickness were incubated at 60ºC for 10 min and than 
deparaffinized and dehydrated as for the HE staining. Sections were than incubated for 
5 min in ddH2O and citrate buffer. For antigen retrieval sections were cooked for 10 
min in boiling citrate buffer at 650 W in a microwave oven. During the cooking process, 
evaporated H2O was replenished to maintain the buffer molarity. After cooking, 
sections in citrate buffer were left on RT for 20 min or longer to cool down, followed by 
a 5 min washing step in Tris buffer with 2% milk powder. Slides with sections were 
mounted with plastic cover-plates for following steps of the protocol. They were first 
washed with Tris buffer with 2% milk powder to test if the slides were mounted properly 
and the pace of the flow is optimal. Endogenous peroxidases were inactivated by 
incubation with 100 μl of 3% hydrogen peroxide for 5 min followed by a blocking step 
for 20 min at RT with 100 μl of blocking buffer. Then 100 μl of the primary antibody in 
PBS/BSA were applied onto a slide and incubated ON at 4°C. Sections were then 
washed with 2% milk-powder in Tris buffer followed by an incubation with 100 μl of the 
biotinylated secondary antibody (Dako LSAB2, yellow bottle solution A) for 10 min at 
RT. After washing with 2% milk-powder in Tris buffer, 100 μl of Steptavidine conjugated 
to Horseradish Peroxidase (Dako LSAB2, red bottle solution B) were added and the 
sections were incubated for 10 min at RT. Finally sections were washed with Tris 
buffer. Slides were than mounted of the plastic cover slides and placed into a box for 
staining by 10 min incubation with 100 μl of DAB substrate solution (1ml Dako 
Substrate buffer with two drops of DAB). Sections were then washed with ddH2O twice 
for 5 min. Sections were counterstained with Haematoxylin for 30 sec and after 
washing once in ddH2O for 5 min, the sections were rehydrated and mounted as for 
the HE staining. 
3.2.8.7 Fluorescent immunostaining of paraffin sections  
The protocol for fluorescent immunostainig of paraffin sections does not differ from the 
DAB staining protocol until the steps after the antigen retrieval. After cooling down, the 
sections were washed 3x for 5 min with 2% milk-powder in Tris buffer. Slides were than 
placed into a humidified box and blocked with 150 µl of blocking buffer for 20 min at 
RT. After the blocking buffer was applied onto a section, the slide was covered with a 
piece of parafilm to equally distribute the blocking solution over the slide surface. This 
procedure allows application of low (as low as 100 µl) volumes of the solutions onto a 
slide. 100 -120 µl of primary antibody were applied after blocking, slides were covered 
with paraffin and incubated ON at 4°C in a humidified chamber. On the next day slides 
were washed with 3x for 5 min with 2% milk-powder in Tris buffer and 120 µl of the 
fluorescent secondary antibody and DAPI in PBS/BSA were applied. After parafilm was 
placed onto a slide, the incubation took place at RT for 1 hour. Sections were then 
washed 3 times for 5 min in Tris buffer and mounted with AquaPolymount. 
3.2.8.8 Fluorescent staining of cryo sections  
Slides were taken from – 80ºC and a ring with an immupen was marked around the 
tissue slice to allow the solution to form a puddle. Slices were than rehydrated with 
PBS for 5 min and permeabilised for 10 min with 0.05% saponine in PBS. Tissue was 
blocked with 10% GS in PBS for 20 min followed by an incubation with the primary 
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antibody diluted in 5% GS in PBS for 2 hours on RT. After 3x for 5 min washing with 
PBS, the fluorescent secondary antibody diluted in 5% GS in PBS was applied and 
incubated for 1 hour at RT in darkness. Slices were than washed 3x for 5 min with PBS 
and mounted with Vectashield containing DAPI. 
3.2.8.9 Fluorescent staining of tissue slices  
All incubation steps were done at 4ºC with gentle rocking to minimize the volumes 
required. Tissue slices were placed in a 24-well plate filled with E/H solution on ice. 
The tissue was incubated in 4% BSA in E/H for 30 min to 1 hour. Primary antibody 
diluted in 1% BSA in E/H was incubated over night. Slices were than washed with large 
volumes of E/H three times for 5 min. Afterwards slices were fixed with 4% PFA for 30 
min and washed with PBS twice. Fluorescent secondary antibody diluted in 1% BSA in 
E/H was applied and incubated for 1 hour in darkness. After three washes of 5 min in 
PBS, slides were mounted with Vectashield containing DAPI to visualize the nuclei. 
Slides were imaged immediately for the best results and stored at 4ºC for several 
weeks. 
3.2.8.10 Methylenblue-Azur II staining of semithin sections 
To stain myelin on semi-sections, freshly prepared Methylenblue-Azur II working 
solution was applied through the syringe filter tip onto the dry slides with semi-sections 
on a hot plate at 60ºC. After 1 min of incubation, the Methylenblue-Azur II was washed 
with ddH2O and slides were left to dry. Dry slides were finally mounted with Eukit. 
3.2.8.11 Tissue contrasting for electron microscopy  
Grids were placed with the shiny side up on the drops and incubated in a following way 
30 min  Uranyl acetate (light sensitive) 
3x 1 min ddH2O 
6 min  Reynolds lead citrate  
4x 1 min  ddH2O 
Grids were carefully dried with a stripe of filter paper 
3.2.9 Imaging  
To image the processed tissue and cell culture material following microscopy 
equipment was utilized: 
 
Epifluorescence upright microscope: DMRXA (Leica) with Kappa DX20 H-FW digital 
camera 
 
Confocal microscope: SP2-AOBS Leica 
 
Electon microscope: LEO EM912 Omega (Zeiss) with on-axis 2048x2048-CCD camera 
(Proscan) 
3.2.10 Animal maintenance and handling 
All mouse mutants used in this study were maintained and bred in the animal facility of 
the Max-Planck-Institute of Experimental Medicine. Animals were kept and handled in 
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compliance with animal policies of the Max-Planck-Institute of Experimental Medicine 
and approved by the German Federal State of Lower Saxony.  
3.2.10.1 Generation of transgenic GIEF mouse 
To generate GIEF transgenic mouse mutant, transgene DNA was purified as described 
in the methods section 3.2.2.6. DNA microinjection into mouse pronuclei (C57/Bl6N) 
and embryo transfer were performed at the transgenic facility of the Max -Planck-
Institute of Experimental Medicine. Born animals were ear marked and tail biopsy for 
DNA preparation and genotyping of potential founders were taken at the age of 3-4 
weeks.   
3.2.10.2 Breeding of the mouse mutants  
All mice mutants were bred at 8 weeks of age. To maintain and expand the mutant 
lines, mutant mice were bred to wt mice of the C57/Bl6N strain. 
3.2.10.3 Genotyping of the mouse mutants  
At the 3 weeks of age mice tail biopsy was taken. DNA for genotyping was prepared 
with the standard procedure. DNA of potential founders was prepared with the “Invisorb 
Spin Tissue Mini Kit” kit. Genotype was determined by performing genotyping PCRs 
with mutant specific genotyping primers described in material section 3.1.11.1. 
 
20 µl genotyping PCR reaction: 
1 µl   tail DNA  
1 µ  genotyping forward primer (10 pM) 
1 µl  genotyping reverse primer (10 pM) 
2 µl   dNTP mix (2mM) 
2 µl  10x RedTaq buffer 
1 µl  RedTaq polymerase (1U/µl) 





1. 95ºC   3 min 
2. 95ºC 45 sec   
3. 58ºC 30 sec 
4. 72ºC 1 min 
2 to 4   35 cycles  
5. 72ºC 10 min 
6. 4ºC pause  
 
BACE ko 
1. 95ºC   3 min 
2. 95ºC 45 sec  
3. 58ºC 1 min  
4. 72ºC 1 min 
2 to 4   35 cycles  
5. 72ºC 10 min 
6. 4ºC pause 
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BACE1 tg 
1. 95ºC   3 min 
2. 95ºC 30 sec 
3. 56ºC 30 sec 
4. 72ºC 1 min 
2 to 4   35 cycles  
5. 72ºC 10 min 
6. 4ºC pause 
3.2.10.4 Theiler’s murine encephalomyelitis virus (TMEV) mediated model of MS 
TMEV induced demyelinating disease is a relevant mouse model of MS because of 
pathological similarities including inflammation, demyelination and axonal loss 
(Rodriguez et al., 1987). After intracerebral injection of Daniel’s strain TMEV into the 
susceptible SJL/J strain, mice within two weeks develop acute encephalitis followed by 
a progressive chronic demyelinating disease and axonal loss in the spinal cord 
(McGavern et al., 2000). The TMEV induced demyelination model used in this study 
was generated at the Mayo Clinic (Rochester, MN) animal facility, in accordance with 
the guidelines for use of experimental animals by the Mayo Clinic and the National 
Institutes of Health. SJL/J mice were infected with 200000 plaque forming units of 
Daniel`s strain of TMEV by a 10 µl volume intracerebral injection. Animals were used 4 
months post infection. 
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4 RESULTS  
4.1 Generation of the HA tagged NRG1 variant mimicking the 
BACE1 processed NRG1 type III-β1 
NRG1 type III-β1 proprotein is being processed in stalk region in vitro by BACE1 and 
possibly other proteases to generate a mature membrane bound N-terminal signalling 
fragment containing EGF like domain (Falls, 2003; Wang et al., 2001). However 
detection of the N-terminal fragment of the NRG1 has been hampered due to the lack 
of available antibodies. The only commercial antibody (sc-348, Santa Cruise) that gives 
satisfactory and reliable results recognizes the cytoplasmic tail of NRG1 type III. Thus, 
after proteolytic cleavage of the NRG1 proproteins in the stalk region it is not possible 
to follow the localization and transport of N-terminal fragment. In order to perform 
comprehensive studies of the mature signalling fragments, detection of both fragments 
resulting after processing is required. In our study we have therefore used NRG1 type 
III-β1 termed “HANI” which is full length NRG1 modified by addition of 2 HA tags 
(IDYPYDVPDYASL) at the N-terminus (Fig. 3A). Introduced tag enables 
immunodetection of the N-terminus and creates the possibilities to study cellular 
localization of N-terminal NRG1 fragment as well as processing by WB. Recently 
BACE1 protease was implicated in processing and activation of NRG1 for the function 
in myelination (Willem et al., 2006). To further investigate the role of the BACE1 in 
activation of NRG1 we have generated the construct representing BACE1 processed 
NRG1 type III-β1 termed “GIEF”. This construct represents N-terminal fragment of 
NRG1 type III-β1 resulting after cleavage by BACE1. In order to detect GIEF protein for 
histological and biochemical analysis it was necessary to introduce a tag. Therefore, 
HA tagged BACE1 processed NRG1 type III-β1, flanked by XhoI sites was PCR 
amplified from HANI cDNA sequence. Resulting GIEF protein is a truncated HANI 
protein ending with EGF-like domain flanked by GIEF amino acid sequence at the C-





Fig. 3 In vitro expression and functional analysis of NRG1 variants 
(A) Schematic representation of the HANI and GIEF protein structures. Note that the ‘GIEF’ protein 
represents the proteolytic cleavage product of HANI by BACE1 (indicated with an arrow). Specific domains 
are indicated by color coded boxes: EGF-like domain (red); cystein rich domain (green); transmembrane 
domain (dark blue); a-type cytoplasmic tail (light blue); HA tag (yellow).  
(B) Anti HA tag WB on PC12 cell lysates. Cells were transfected with HANI, GIEF and EGFP expression 
plasmids. The upper 140kD band corresponds to the full length NRG1 variant HANI (arrow). The ~70kD 
band of full length GIEF protein corresponds in size to the BACE1-processed HANI protein (arrow). ~38kD 
band detected in GIEF lysates (arrow) represents potentially processed GIEF protein. Specific NRG1 
protein bands detected by anti HA antibody are absent from the EGFP control lysates. 
(C) Immunocytochemistry (ICC) on GIEF transfected PC12 cells. GIEF (red) is localized to the membrane 
detected by HA antibody after permeabilization. The intracellular HA tag is not detected by non (live) ICC 
without permeabilization. Scale bar 5 µm. 
(D) Assesment of biological activity of HANI and GIEF by split-Tev assay. PI3K recruitment was used as a 
surrogate marker for ErbB receptor dimerization in a 2-cell split-TEV assay. Induction of luciferase reporter 
expression was significantly increased by HANI (
***
p<0.001) and GIEF (
**
p<0.01) overexpression in PC12 
cells compared to MOCK transfected controls. Results are given as relative luminescence units (RLUs) 





4.2 In vitro expression analysis of full length and BACE1 
processed NRG1 type III-β1 
As modifications in the primary structure can affect protein folding and mature 
conformation of the native proteins, expression and function of the modified proteins 
were tested in vitro. For in vitro expression analysis HANI and GIEF constructs cloned 
into the pCMV2 expression vector were used. Western blot (WB) was performed on 
HANI and GIEF transfected PC12 cells lysates using an antibody directed against HA 
tag. Tagged full length NRG1 showed expected 140kD full length protein band and 
~70kD processed N-terminal protein fragment as previously reported (Wang et al., 
2001) (Fig. 3B; arrows, first lane ). Size of the GIEF protein corresponds to the ~70kD 
fragment after proteolytic cleavage of HANI (Fig. 3B; second lane). An additional band 
of ~38kD detected by HA antibody in GIEF transfected cell lysates, could result from an 
additional processing event by BACE1 or another protease which could lead to a 
release of the EGF signalling domain (Horiuchi et al., 2005). Protein bands detected by 
HA antibody were HANI and GIEF specific as no immunoreactivity was detected in 
EGFP transfected control cell lysate (Fig. 3B; third lane). Amino acid sequences that 
target the protein to specific cellular compartments are imprinted into the primary 
structure of the protein. Truncation of the NRG1 could lead to the loss of these signals 
in the GIEF protein sequence. Therefore we performed immunostaining on transfected 
PC12 cells. Immunodetection of the HA tag on GIEF transfected PC12 cells showed 
localization of GIEF protein in the membrane (Fig. 3C; left panel). Additionally we 
applied a live staining protocol that prevents antibodies from entering the intracellular 
space. With this approach we could show that once it reaches the membrane, GIEF 
protein is inserted with the N-terminus facing the intracellular space, as we could not 
detect the N-terminal tag extracellularly (Fig. 3C; right panel). NRG1 mediates 
numerous functions through the EGF-like signalling domain by activating ErbB receptor 
tyrosine kinases (Burden and Yarden, 1997; Falls, 2003; Yarden and Sliwkowski, 
2001). To determine the functionality of the modified NRG1 proteins, with help of Dr. 
Michael Wehr we assessed their potential to induce ErbB2/ErbB3 receptor dimerization 
and the recruitment of downstream PI3K in the two-cell Split-TEV assay (Wehr et al., 
2006; Wehr et al., 2008). Both HANI and GIEF proteins expressed on the surface of 
the PC12 cells were potent in inducing ErbB receptors heterodimerization on 
neighboring cells and downstream signalling detected by the activation of luciferase 
reporter. Measured luminescence intensity (RLUs) was significantly increased in 
assays containing HANI (161.74±45.16;***p<0.001) and GIEF (124.53±41.77;**p<0.01) 
transfected cells compared to MOCK transfected control assays (64.67±28.23) (Fig. 
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3D). This was another indirect proof of a correct membrane orientation of the tagged 
NRG1 variants with the EGF domain exposed to the extracellular environment. 
4.3 In vitro processing of NRG1 type III-β1 by BACE1 
BACE1 mediates processing of NRG1 in vitro (Hu et al., 2008; Willem et al., 2006). In 
vivo, BACE1 knock out mutants accumulate full length (140kD) NRG1 in the brain 
(Willem et al., 2006) suggesting that NRG1 processing is BACE1 mediated. Even 
though it is widely accepted that signalling of NRG1 type III is mediated in a paracrine 
manner it remains possible that the EGF like domain is released by an additional 
cleavage (Birchmeier and Nave, 2008; Wang et al., 2001; Willem et al., 2009). To 
confirm the processing of NRG1 by BACE1 in our system and to further analyze GIEF 
protein processing by BACE1 we have overexpressed in vitro HANI or GIEF in HEK 
293T cells with or without overexpressing BACE1 and performed WB on cell lysates 
using HA antibody. Overexpression of BACE1 in vitro induces a potent cleavage of the 
140 kD HANI band and a shift to the ~70 kD processed band which in size corresponds 
to the GIEF protein (Fig. 4A; lanes 3 and 5). The effect of BACE1 on HANI processing 
was specifically blocked by β secretase IV inhibitor treatment (2 µM) (Fig. 4A lane 4). 
Residual base line processing pattern of the HANI protein in HEK 293T cells remains 
even after the inhibition of BACE1 (Fig. 4A lanes 1 and 2) suggesting the existence of 
other proteases cleaving HANI in these cells. Since the ADAMs family of proteases is 
known to cleave NRG1 (Horiuchi et al., 2005) we also applied the general ADAMs 
inhibitor GM6001 to transfected cells. ADAMs inhibitor treatment (1µM and 5µM) did 
not abolish base line processing of the HANI protein in HEK 293T cells (Fig. 4B). The 
integrity of the ~70 kD and ~38 kD GIEF protein bands pattern were unaffected after 
overexpression of BACE1, excluding further cleavage of GIEF and the release of EGF 
like domain by BACE1 (Fig. 4A; lane 6). Similar to HANI baseline processing of the 
GIEF did not change after the cells were exposed to BACE1 and ADAMs proteases 
inhibitors (Fig. 4A; lane 5 and 6; Fig. 4B). This observation suggests the existence of 







Fig. 4 In vitro processing of NRG1 variants HANI and GIEF 
(A) WB of HEK293T cell lysates transfected with HANI, GIEF, BACE1 and EGFP expression plasmids 
using HA tag antibody. BACE1 activity in the selected assays was blocked by 2 µM β-secretase inhibitor 
(Bi). The 140kD band (arrowhead) of the full length NRG1 detected in all HANI lysates was lost after 
coexpression of BACE1 (HANI+B) and shifted to the ~70kD processed N-terminal band. The 140kD 
processed HANI band corresponds in size to a higher molecular weight band of GIEF protein (arrowhead). 
The BACE1 effect on HANI is blocked by the β-secretase inhibitor (HANI+B+Bi). GIEF ~70kD and ~38kD 
protein bands intensity is unaltered upon cotransfection of BACE1 (GIEF+B). Application of Bi does not 
affect base line processing of HANI and GIEF (HANI or GIEF+Bi).  
(B) Anti HA antibody WB. ADAMs activity in the HEK293T cells was blocked by broad spectrum ADAMs 
inhibitor GM6001 (1µM and 5µM). It should be noted that the HANI 140kD and ~70kD and GIEF ~70kD 
and ~38kD protein bands intensity remains unchanged following inhibitor treatment. 
 
4.4 Thy1 promoter driven neuronal overexpression of the GIEF in 
vivo 
Neuronal overexpression of NRG1 type III-β1 under control of the Thy1 promoter in 
mice promotes PNS myelination (Michailov et al., 2004). We have used the same 
approach to asses the function of BACE1 processed NRG1 in myelination in vivo. 
Accordingly, GIEF transgenic mice were generated using the Thy1.2 expression 
cassette (Caroni, 1997) which confines trasngene expression to neurons. The GIEF 
construct was cloned via XhoI site into the open reading frame of the Thy1 gene (Fig. 
5A).  Pronuclear microinjection of the linearized GIEF transgenic cassette resulted in 
two genetic founders as determined by genotyping PCR with transgene specific 
primers (Fig. 5B; asterisk). Only one of the two founders (#48) produced the transgenic 
offspring. To verify the quality of the genomic DNA samples primers amplifying a short 
sequence of the ErbB2 gene were included into the PCR reaction as a control. 
Presence of transgenic DNA in the mouse genome does not always ensure the 
functional expression of the transgene. Therefore, as a next step transgenic expression 
was analyzed. At two months of age, a transgenic GIEF mouse and a wt littermate from 
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the F1 generation were analyzed for the transgene expression on the RNA level. RT-
PCR performed on spinal cord cDNA using intron spanning transgene specific primers 
(Fig. 5A; black arrows) revealed the presence of a transgenic transcript in the GIEF 
cDNA sample but not in WT and negative controls (Fig. 5C). Transgenic mice 




Fig. 5 Transgenic overexpression of GIEF NRG1-variant 
(A) Schematic model of the Thy1-GIEF construct. The GIEF cDNA variant was PCR amplified from mouse 
NRG1 type III-β1 cDNA with two additional HA tags at its 5’ end. Gray arrows depict the position of 
genotyping primers. Black arrows represent RT-PCR primers. 
(B) Screening of GIEF genomic founders by transgene specific genotyping PCR. Two animals positive for 
GIEF transgenic sequences are labeled with asterisk. Lower PCR band represents amplified ErbB2 
fragment used to control for DNA quality. 
(C) Transgene specific RT-PCR on spinal cord cDNA derived from founder (#48) F1 offspring at 2 months. 
Transgene derived transcript is detected in transgenic offspring. β-actin specific RT-PCR was performed 
as a cDNA quality control. 
 
4.5 Analysis of the onset and the expression levels of the GIEF and 
HANI transgene. 
Myelination program in developing Schwann cells is triggered perinatally (Jessen and 
Mirsky, 2005). As we wanted to study effects of the HANI and GIEF overexpression on 
myelination we have next determined the onset of transgene expression. We have 
prepared cDNA from spinal cord of newly born mice at postnatal day 1 (P1). Transgene 
specific PCR confirmed the presence of both transgene transcripts in spinal cord 
neurons at the onset of myelination (Fig. 6A). The expression level of the transgene 
can vary depending on the number of integrated transgene copies and the level of 
transcription at the transgene integration site. Different transgenic lines even with the 
same expression cassette can therefore exhibit very different transgene expression 
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levels. Comparison of transgene expression levels between two different transgenic 
lines allows more accurate comparison and interpretation of the observed phenotypes. 
We therefore evaluated relative expression levels of the GIEF and HANI transgenes in 
the spinal cord at two months of age by quantitative RT-PCR using primers specific for 
the type III isoforms. To obtain a highly accurate estimation of the expression, 
experiment was carried out in the setting of 5 experimental replicates per genotype and 
4 technical replicates each. Expression was normalized to β actin. The mean relative 
expression of GIEF transgene was increased 9 fold (8.9±6.06; ***p<0.001) when 
compared to wt NRG1 type III (1±0.3), whereas HANI overexpressors had only 3 fold 




Fig. 6 Analysis of the expression profiles of HANI and GIEF transgenes 
(A) Transgene specific RT-PCR on spinal cord cDNA from P1 GIEF and HANI transgenics and wt 
littermate controls. GIEF and HANI transgenes are expressed at the onset of myelination. β-actin-specific 
RT-PCR was used as cDNA quality control. 
(B) CRD-NRG1 specific qRT-PCR performed on a spinal cord cDNA from wt, GIEF and HANI animals at 8 
weeks of age (5 animals/genotype; 4 technical replicates each). Expression levels are normalized to β-
actin. The average expression level values (± STDEV) are displayed (left panel). The HANI transgene 
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expression is 3 fold increased (*p< 0.05) and GIEF 9 fold (**p< 0.01) compared to wt. Individually plotted 
relative transgene expression levels depicting large variability in expression between the individual animals 
(right panel). 
(C) Spinal cord protein lysates with 40 µg of protein from HANI, GIEF and wt mice immunobloted with HA 
antibody. Stronger overexpression of GIEF transgenics compared to HANI on mRNA level translates into 
increased protein amounts.  
 
 
Three fold differences in the relative expression between GIEF and HANI lines were 
taken into consideration during the interpretation and comparisons of the phenotypes in 
GIEF and HANI transgenics  Both transgenic lines display large expression level 
variability between individual animals (Fig. 6B; right panel). This important information 
was taken carefully into account during analysis as we expected to observe 
corresponding phenotype variability. We finally wanted to see if the difference in an 
expression level translates in to the amount of the synthesized protein. We have 
performed the WB on a spinal cord lysates from HANI, GIEF and wt mice. Membrane 
was probed with the HA antibody and expected protein band patterns were observed 
for both transgenic proteins. It is obvious from the WB that the difference in gene 
expression translates into a difference in the transgenic proteins amounts. 40 µg of 
protein lysate contains higher amount of GIEF than HANI transgenic protein (Fig. 6C).   
4.6 Absence of pathology observed in mice upon early onset of the 
GIEF transgene overexpression 
We have next analyzed if the GIEF protein overload in transgenic mice has a toxic 
effect on neurons. Since the Thy1 cassette is expressed in spinal cord ventral horn 
motor neurons that project into the sciatic nerve, we decided to examine the spinal cord 
and sciatic nerve for the presence of pathology. By HE staining of the spinal cord cross 
sections, we did not observe obvious changes in number and overall neuronal 
morphology at 4 months time point, in GIEF transgenic mice compared to controls (Fig. 
7; arrowheads). Transgenic spinal cord tissue was also examined for the presence of 
astrogliosis or microglial activation which are the markers of inflammation, disturbed 
homeostasis and neuronal tissue pathology (Eng and Ghirnikar, 1994; Hanisch and 
Kettenmann, 2007). Immunostaining for astrocytic marker GFAP (glial fibrillary acidic 
protein) showed absence of astrocytes proliferation in GIEF mice when compared to 
the wt (Fig. 7; not quantified). Immunostaining for the MAC3 marker of the activated 
microglia revealed no inflammation induced by the GIEF overexpression (Fig. 7) 
Integrity of sciatic nerve axons was also unchanged in mutants when compared to WT 
littermates as shown by neurofilament and MBP myelin staining (Fig. 8A). Mutant mice 
also did not exhibit axon pathology and axonal loss in sciatic nerves as no difference in 
total number of axons between mutants and wt controls was observed when quantified 
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Fig. 7 Absence of pathological changes in the spinal cord of GIEF transgenic mice 
Paraffin-embedded 0.5 µm spinal cord cross sections of wt and GIEF mice (4 months) were stained for 
pathology markers. Ventral horns of spinal cords containing GIEF expressing motor neurons are depicted 
(arrowheads). HE histological staining reveals normal gross morphology in the spinal cord. Chromogenic 
GFAP IHC shows no sign of astrogliosis. Chromogenic immunostaining for MAC3 a marker for activated 












Fig. 8 Unaltered sciatic nerve morphology upon GIEF overexpression 
(A) 5µm thick cross sections were cut from paraffin embedded sciatic nerves of wt and GIEF transgenic 
animals. No apparent change in morphology was observed based on immunofluorescent assessment of 
NF (red) and P0 (green) expression. Scale bar 10µm.  
(B) Quantification and comparison of the number of myelinated fibers on sciatic nerve semithin sections 
(0.5µm) of wt and GIEF animals (n=3). The average total number of axons is displayed (average±STDEV) 
showing no significant difference (p=0.28). No axonal degeneration was detectable after overexpression of 
GIEF. 
 
4.7 GIEF overexpression induces hypermyelination of PNS axons 
Overexpression of full length NRG1 type III-β1 in vitro and in vivo induces 
hypermyelination of peripheral axons (Michailov et al., 2004; Taveggia et al., 2005). To 
study the effect of GIEF overexpression on myelination we analyzed sciatic nerve 
semi-thin sections stained with Methylenblue-Azur II. GIEF mutant nerves exhibit 
hypermyelination compared to the myelin of the wt control nerves (Fig. 9A). Further 
morphological analysis of the same nerves by electron microscopy (EM) showed no 
changes in myelin ultrastructure in the GIEF transgenics (Fig. 9B). Myelin sheet of 
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Fig. 9 Hypermyelination in the PNS of GIEF transgenic mice 
(A) Semithin cross sections (0.5µm) of sciatic nerves comparing wt control and GIEF overexpressing mice 
at 2 months of age. GIEF transgenic mice are hypermyelinated with thicker myelin sheaths. Scale bar 
10µm 
(B) Electron micrograph of ultrathin cross sections (50nm) of the sciatic nerves comparing individual axons 
of the same diameter in wt and GIEF mutants. Considerably thicker myelin sheath of the GIEF axon is 
apparent compared to wt. Scale bar 1µm. 
(C) Blow-up of aligned wt and GIEF myelin sheaths depicting unchanged myelin ultrastucture and radial 
periodicity upon increase in myelin thickness. Scale bar 200nm 
(D) Quantification of the myelin sheath thickness by g-ratio measurement comparing wt and GIEF mice. 
Average of at least 100 myelinated axons per animal is depicted (average±STDEV) (wt n=2; GIEF n=4). 
Average g-ratio in GIEF mice is significantly decreased (***p< 0.001).  
(E) Scatter plot depicting g-ratio as function of axon diameter. Smaller caliber axons are more strongly 
affected by hypermyelination. 
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Thus, increased thickness occurred as a consequence of the additional myelin 
membrane wrappings formed by the Sc, similar to previously observed with the full 
length NRG1 (Brinkmann et al., 2008; Michailov et al., 2004). To quantify myelin 
thickness we determined the ratio between axon and myelin diameter (g-ratio). Four 
GIEF mutants and two wt animals were analyzed and g-ratios of randomly selected 
myelinated axons (n=100/nerve) were measured. The average g-ratio value of axons 
determined for GIEF mice was significantly decreased when compared to wt controls 
(0.57±0.09 vs 0.63±0.06; ***p<0.001) (Fig. 9D). A scatter plot depicting g-ratio as a 
function of axon diameter shows more pronounced hypermyelination of smaller 
diameter axons (Fig. 9E). This is in line with the idea that larger axons require 
proportionally more “signal” to achieve the same level of hypermyelination. Not all 
axons were affected by hypermyelination, probably due to the mosaic expression of the 
Thy1 transgenic promoter (Caroni, 1997). This finding supports the hypothesis that the 
N-terminal fragment formed after BACE1 mediated cleavage is active and sufficient to 
perform the myelination promoting function of full length NRG1 type III-β1 in vivo. 
Additionally, it demonstrates that the C-terminal fragment of NRG1 is dispensable for 
myelination promoting function. 
4.8 GIEF mice are ectopically myelinated   
Multiple layers of myelin are formed by myelinating Sc around PNS axons typically 
larger than 1 µm in diameter (Friede, 1972). Smaller axons are grouped and ensheated 
by non myelinating Sc in so called Remak bundles without a formation of multilamellar 
myelin sheath. NRG1 is the factor on the axon that translates the axon diameter into 
the myelination status of the axon and determines one of the alternative phenotypes of 
the Sc at least in vitro (Taveggia et al., 2005). Upon overexpression of NRG1 type III in 
vivo and in vitro myelin sheath is formed around normally unmyelinated small diameter 
axons (Taveggia et al., 2005) (Humml, Unpublished). We have investigated on ultrathin 
cross section of sciatic nerve by EM how GIEF overexpression affects the myelination 
status of Remak axons. Overexpression of GIEF on the surface of small diameter 
axons induces ectopic myelination of these axons (Fig. 10A; EM micrograph). Axons 
smaller than 1 µm in diameter normally found in Remak bundles are being sorted out 
and myelinated in mutant mice (Fig. 10A; labeled with asterisk). Quantification of this 
observation on semithin cross sections of sciatic nerve, 3 animals per genotype, 
showed significant increase of the ectopically myelinated fibers (<1µm) in mutants 







Fig. 10 GIEF overexpression induces ectopic myelination of small caliber axons 
(A) Electron micrographs of sciatic nerves showing wt Remak bundle and an example of out sorted and 
ectopically myelinated small diameter axon in GIEF sciatic nerve. Asterisk labels the axon in the Remak 
bundle of the same diameter as an ectopically myelinated one. Number of ectopically myelinated axons 
quantified on sciatic nerve semithin cross sections (n=3) reveals a significant fourfold increase in mutant 
animals (average±SEM; *p< 0.05).  
(B) Ultrathin (50 nm) cross section of a sciatic nerve with an example of myelinated Remak bundle 
structure, which is never found in wt animals. The myelinated Remak bundle contains unsegregated axons 
and larger diameter axons typically not found within Remak bundles (asterisk). Quantification (n=3; 
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average±SEM) revealed low incidence of this structure in mutants (1.5 in average) without significant 
increase compared to wt (p=0.06). 
(C) The examples of Remak bundle structures in wt and GIEF sciatic nerves on ultra thin (50nm) cross 
sections. The majority of mutant Remak bundles show normal structure comparable to wt. Note in the blow 
up box that the spacing between axons (arrowheads) within Remak bundles of GIEF mutants is larger than 
in the wt (observation not quantified). 
 
 
Additionally in mutant Sciatic nerves we found the Remak bundles surrounded by a 
multilamellar myelin sheath without segregation of individual axons within the Remak 
bundle, as if the whole bundle of small axons was perceived as one axon of the large 
diameter (Fig. 10B; left panel). “Myelinated” Remak bundles also contained axons 
larger than 1 µm in diameter (Fig. 10B; asterisk). In mutants, the incidence of this 
Remak morphology was low but it was newer observed in wt animals (1.66 ± 0.88 vs 0; 
p=0.06) (Fig. 10B; right panel). Besides previously mentioned examples of the aberrant 
Remak morphology, EM analysis showed no substantial morphological alteration in the 
majority of the Remak bundles in mutant animals. Remak bundles showed normal 
gross morphology comparable to the wt controls (Fig. 10C). Axons in the Remak 
bundles are properly compartmentalized by the nmSc cytoplasm (Fig. 10C; blow up 
lower panel). However while not quantified we have observed an increase in spacing 
between individual axons in mutant Remak bundles (Fig. 10C; arrowheads).  
4.9 Overexpression of the GIEF does not induce Schwann cell 
proliferation 
Besides its crucial role in myelination, NRG1 type III has also been trusted to control 
earlier stages of Sc development, including proliferation and survival of Sc precursors 
in peripheral nerves before the onset of myelination (Birchmeier and Nave, 2008; Dong 
et al., 1995; Garratt et al., 2000a) Therefore, we investigated if GIEF overexpression 
effects Sc proliferation. For that we determined the absolute number of Sc on the 
semithin sciatic nerve cross section (n=3) by counting nuclei of mSc and nmSc (Fig. 
11A). We did not identify a significant change in the number of mSc in GIEF mutants 
compared to the WT animals (126±14.93 vs 152.66±36.52; p=0.15) (Fig. 11B; upper 
panel). Moreover, there was also no difference in nmSc number observed between 
mutants and WT controls (75.±19.6 vs 58±8.71;p=0.11) (Fig. 11B; lower panel). We 
also evaluated the cell proliferation in sciatic nerves by counting DAPI positive nuclei 
on paraffin nerve cross section (n=3) at 4 months of age. No increase was observed as 
the number of nuclei per mm2 was unchanged in mutants compared to wt controls 






Fig. 11 Absence of Schwann cell proliferation upon overexpression of GIEF 
(A) The examples of mSc and nmSc on semithin cross section of sciatic nerve counted for analysis of 
proliferation.  
(B) The number of mSc per mm2 is not significantly different in GIEF mutants compared to a wt (n=3; 
average±STDEV; p=0.15) Quantified average number of nmSc in GIEF mutants was slightly increased 
compared to the wt animals without significant difference (n=3; average±STDEV; p=0.11) 
(C) Quantification of the DAPI positive nuclei per mm2 of sciatic nerve cross section (n=3) shows no 
significant change in mutants compared to the control animals (average±STDEV; p=0.1).  
(D) The Krox20 positive nuclei number per mm2 (n=3) was not significantly changed between mutants and 
wt (average ±STDEV; p=0.4). 
(E) Measurement of the sciatic nerve cross section area in mm2 (n=3). No difference between the 




To examine if GIEF overexpression recruits more Schwann cell precursors to myelinate 
axons we have also stained the sciatic nerve cross section for Krox20. Krox20 is a 
major transcriptional regulator the myelination program in Schwann cells (Topilko et al., 
1994). Quantification of the number of Krox 20 positive nuclei per mm2 of GIEF and wt 
sciatic nerve cross section showed unchanged numbers of Schwann cells engaged in 
myelination (79.98±19.78 vs 84.35±38.63;p=0.4) (Fig. 11D). From these results, we 
could conclude that GIEF overexpression does not induce proliferation of Sc or change 
in Sc profiles in the sciatic nerve. Correspondingly, there was no increase in overall 
section area size of sciatic nerve in the mutants compared to the wt (2±0.38 
vs1.95±0.69; p=0.4) (Fig. 11E).  
4.10 ErbB receptor stimulation by overexpression of GIEF induces 
mild tomacula formation. 
NRG1 signalling promotes myelination through activation of ErbB receptor and PI3-
kinase-Akt pathway, at least in vitro (Maurel and Salzer, 2000). Strong constitutive 
activation of the PI3K (pAkt-mTor) pathway by conditional PTEN (phosphatase and 
tensin homolog) inactivation induces hypermyelination and aberrant myelin swellings 
termed tomaculas (Göbbels et. al submitted). Tomacula structures can be grouped into 
different categories based on characteristic morphology formed by the aberrantly 
growing myelin membranes. We have asked if similar aberrant myelin growth is 
induced as a consequence of ErbB receptor stimulation and activation of PI3K pathway 
by strongly overexpressed GIEF variant. We have identified two different types of 
tomaculas in the transgenic nerves at two months of age. One type is defined by axon 
compression induced by the growing myelin membranes (Fig. 12A; left panel). The 
second one forms out folding of the myelin sheath and is termed as “myelin budding” 
(Fig. 12A; right panel).  Tomacula formation was quantified on semi thin cross sections 
of sciatic nerves in a setting of three animals per genotype. Compressed axon 
tomacula never occurred in wt animals, whereas mutants showed a modest incidence 
of this type of tomacula formation with average of 6 tomaculas per sciatic nerve 
(6±2.08 vs 0; *p< 0.05) (Fig. 12B; upper panel). Myelin budding occurred with a higher 
incidence (27±17 vs 1±0.58) and with high variability between transgenic animals, due 
to which the 27 fold increase in transgenics was not statistically significant compared to 
wt controls (p=0.1) (Fig. 12B; lower panel). Therefore, we will include more mice in 
future analysis. According to the mild tomacula phenotype, it is most likely that even 
substantial GIEF overexpression does not induce a strong upregulation of PI3K 






Fig. 12 GIEF overexpression induces mild tomacula formation 
(A) Electron micrograph (50nm) of sciatic nerves showing examples of tomacula morphology. Compressed 
axon tomacula (left panel). Myelin budding (right panel). Scale bar 1 µm.  
(B) Quantification of tomacula on sciatic nerve cross semithin (0.5µm) sections form wt (n=3), GIEF (n=3), 
and HANI (n=2) animals. Values are expressed as average±SEM. Number of compressed axons is 
significantly higher than in wt (*p< 0.05) where tomacula formation is not found. Difference between GIEF 
and HANI is not significant (p=0.18). Considerable increase in the number of myelin buddings 
(average±SEM) in GIEF mutants is not significant compared to wt (p=0.1). No significant difference can be 
observed between GIEF and HANI (p=0.46). 
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(C) Comparison of g-ratios between GIEF (n=3) and HANI (n=2). At least 100 axons per animal were 
measured on semithin sciatic nerve cross sections. HANI and GIEF transgenics display similar g-ratio 
values (average±STDEV p=0.39)  
 
4.11 GIEF and HANI lines show comparable potential in promoting 
myelination 
Overexpression of GIEF in neurons provides excess amounts of the mature NRG1 type 
III-β1 fragment with the EGF like signalling domain available to activate ErbB receptors 
in Schwann cells. According to the currently accepted concept (Falls, 2003), the full 
length NRG1 is processed in the stalk region by proteases, predominantly BACE1 
(Willem et al., 2006) or ADAMs (Horiuchi et al., 2005) before it binds to ErbB receptors. 
Therefore we have hypothesized that GIEF must be more potent in inducing 
phenotypes characteristic for NRG1 type III-β1 overexpression. To asses this we first 
compared the myelination promoting potential of HANI and GIEF overexpressing mice. 
Comparison of g-ratios (HANI n=2; GIEF n=4) showed no difference between these 
transgenic lines (0.58±0.08 vs 0.57±0.09; p=0.39) (Fig. 12C). We next examined if 
HANI mice show signs of tomacula formation similar to those in GIEF mice. Again, 
HANI compared to GIEF transgene has been equally potent in inducing tomacula 
formation. There was no significant difference in number of compressed axons 
between GIEF and HANI mice (6±2.08 vs 3±1; p=1.18) (Fig. 12B; upper panel). Finally 
the incidence of myelin budding was also without significant difference between GIEF 
and HANI mice (27±17 vs 24.5±14.5; p=0.46) (Fig. 12B; lower panel). Overexpression 
of BACE1 processed NRG1 type III-β1 phenocopied all the hallmarks of myelin 
morphology alterations seen after overexpression of the full length NRG1 type III-β1, 
showing that GIEF is not per se more potent than the full length NRG1. The similarity of 
the phenotype seen after overexpression of the full length and BACE1 activated NRG1 
variant also shows that C-terminus is not required for myelination promoting function of 
NRG1.  
4.12 Functional interaction between NRG1 myelination promoting 
function and BACE1 in vivo  
Neuronal overexpression of BACE1 in transgenic mice increases amyloidogenic 
processing of APP in the brain (Willem et al., 2004). We wanted to investigate if NRG1 
type III-β1 and activity is also increased upon BACE1 overexpression resulting in 
further stimulated myelination. After breeding BACE1 transgenic mice to HANI 
overexpressors, BACE1/HANI double transgenics, HANI transgenics and wt littermate 
controls were analyzed at three months of age. Sciatic nerves semithin cross sections 
were analyzed by light microscopy. Obtained sections were used for the quantification 
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of myelin thickness. Quantification of myelin thickness by g-ratio measurement of 
(n=100 axons/nerve) showed that NRG1 induced hypermyelination was not further 
promoted by BACE1 overexpression (0.535±0.005 vs 0.532±0.005; p=0.36) (Fig. 13D). 
Thus, BACE1 is not rate limiting for the myelination promoting function of the NRG1 in 
vivo. Endogenous amounts of BACE1 have the capacity to activate increased levels of 
NRG1 in HANI transgenic mice. Inactivation of BACE1 throughout development leads 
to the formation of extremely thin myelin sheath around PNS axons (Willem et al., 
2006) (Fig. 13A; BACE-/-). This phenotype is supposedly caused by abolished or 
decreased processing of NRG1 (Willem et al., 2006) as it phenocopies 
hypomyelination seen in NRG1 heterozygous mutants (Michailov et al., 2004). We 
therefore wanted to investigate if the absence of BACE1 would affect the myelination 
promoting function in HANI overexpressing mice. To achieve HANI overexpression in a 
BACE1 null background, HANI transgenics, which were heterozygous for mutant 
BACE1 allele, were bred to heterozygous BACE1 mutants.  Sciatic nerves were 
processed for semithin sections and analyzed. Light microscopy pictures showed 
increased myelin thickness in a sciatic nerve of the HANI, and BACE1-/-/HANI when 
compared to the wt animal (Fig. 13A; axons of the same diameter labeled with 
asterisk). We also observed significantly thinner myelin of BACE1-/- compared to wt 
(Fig. 13A) as previously described (Willem et al., 2006). To quantify these observations 
we measured g-ratios. Overexpression of NRG1 in the complete absence of BACE1 
still induced peripheral hypermyelination, but not to the same extent as observed in the 
presence of active BACE1 (0.580±0.005 in HANI vs 0.616±0.007 in BACE1-/-/HANI; 
***p< 0.001) (Fig. 13B; upper panel). Scatter plot depicting g-ratio as a function of axon 
diameter for HANI and BACE1-/-/HANI displays an equal shift in g-ratio values 
regardless of the axon diameter (Fig. 13C; upper panel). Thus, we could show a 
functional interaction of BACE1 and NRG1 during myelination in vivo. However, this 
result also suggests the existence of compensatory protease that (partially) activates 
NRG1 or the ability of NRG1 to mediate signalling without being previously 
proteolytically processed. Another interesting perspective is the finding that 
hypomyelination in BACE1-/- mutants is rescued by providing more NRG1 protein as 
seen in BACE1-/-/HANI (0.776±0.003 vs 0.616±0.007; ***p< 0.001) (Fig. 13B; lower 
panel). The corresponding scatter plot shows that smaller diameter axons of BACE1-/- 
are more potently rescued (Fig. 13C; lower panel). This is consistent with a 
proportionally lower NRG1 level required on small-diameter axons compared to large-






Fig. 13 NRG1 type III overexpression rescues hypomyelination in the PNS of BACE1 null 
mutants 
(A) Semithin sciatic nerve cross sections (0.5µm). Metyleneblue stained myelin in HANI, HANI/BACE1-/- , 
BACE1-/- and wt animals at 2 months of age. Asterisk labels axons of equal diameter. It is apparent that 
the myelin sheaths in sciatic nerves of HANI/BACE1-/- animals have a comparable thickness to HANI 
mutants, while they are hypermyelinated when compared to wt animals. BACE1-/- mutants show 
hypomyelination of SN axons. Scale bar 10 µm. 
(B) Analysis of myelin sheath thickness by g-ratio measurement performed on 2 animals per genotype and 
100 axons per sciatic nerve. NRG1 myelin promoting function partially depends on the presence of 
BACE1. g-ratio values (average±SEM) in HANI/BACE1-/- are significantly decreased compared to wt  
animals (
*
p< 0.05). g-ratio values of HANI/BACE1-/- are significantly increased compared to HANI mutants 
(***p< 0.001). BACE1-/- hypomyelination is rescued after overexpression of NRG1. BACE1-/- g-ratio 
values are increased compared to wt controls (***p< 0.001). Note the extreme decrease in g-ratio values of 
HANI/BACE1-/- mutants compared to BACE1-/- (***p< 0.001).  
(C) Individual g-ratio values plotted against axon diameter.  Shift in HANI/BACE1-/- g-ratio values 
compared to HANI is equal through out the axon diameter distribution range. Difference in g-ratio values 
between BACE1-/- and HANI/BACE1-/- mutants is higher for smaller diameter axons.  
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(D) BACE1 is not rate limiting for myelination promoting function of NRG1. G-ratio values (average±SEM) 
comparing HANI, HANI/BACE transgenic animals and wt animals at 3 months of age (n=2). G-ratio values 
are not significantly changed between HANI and HANI/BACEtg (p=0.36) 
 
4.13 HANI and GIEF protein are detected on the surface of the 
spinal cord motor neurons in vivo 
Neuregulin1 type III-β1 is produced as a proprotein harboring two TM-domains. It is 
believed that it is converted in to a mature signalling molecule by proteolytic processing 
in the stalk region after which “U” shaped NRG1 opens to expose the EGF like domain 
(Nave and Salzer, 2006; Wang et al., 2001). However, trafficking routes of newly 
synthesized NRG1, and sites as well as the order of processing are not well 
understood. The lack of functional NRG1 antibodies has made it difficult to specifically 
visualize the protein and address these questions. Only one antibody directed against 
C-terminus (sc-348 against ‘a’ type cytoplasmic tail of NRG1) yields satisfactory results 
as it detects elevated NRG1 protein in the tissue of transgenic overexpressors. By 
introducing the HA tag at the N-terminus of NRG1 in our transgenic animals (HANI and 
GIEF), we have enabled the detection of the N-terminal fragment of NRG1 type III in 
vivo. To investigate the cellular localization of NRG1 we performed immunostaining of 
the lumbar spinal cord that contains the somata of motor neurons that project axons 
into the sciatic nerve. Spinal cords of HANI, GIEF and wt animals (n=3 per genotype) 
at 12 days and 4 moths of age were processed for paraffin sections. NRG1 was 
detected by fluorescent immunostaining on spinal cord cross sections using HA and C-
terminus specific antibodies recognizing antibodies. Using the C-terminal antibody in wt 
control animals NRG1 was detected at both time points on the cell surface of the motor 
neurons where it displayed a patchy pattern of localization (red) (Fig. 14; wt 
arrowheads). As expected HA immunoreactivity (green) was absent in wt controls. We 
speculate that the patchy membrane domains could correspond to postsynaptic 
compartments on the motor neuron soma as we have data colocalizing HANI protein in 
CNS with PSD-95 (Gummert unpublished observation). This finding has to be 
addressed in more detail using antibodies directed against pre- and post-synaptic 
markers such as PSD-95, synapsin, VGLUT, and GAD65. Another possibility is that the 
patches represent lipid raft membrane microdomains. It has been previously reported 
that NRG1 is localized to lipid rafts in vivo (Frenzel and Falls, 2001). In HANI 
overexpressing mice at both time points, neuronal cell surface domains containing the 
N-termini of NRG1 were widened and immunoreactivity of the N- and C-terminal 
antibody completely overlapped (yellow) (Fig. 14; HANI arrowheads). It is not clear if 
full length NRG1 is first delivered to the membrane surface before being cut in the stalk 
region or the cut already occurs in the Golgi network. The GIEF variant was localized to 
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neuronal surface, but also detected in the intracellular compartments presumably ER 
and Golgi networks (Fig. 14; GIEF). The HA signal intensity in the GIEF overexpressor 
was stronger than in HANI mice presumably due to the stronger overexpression of the 
GIEF transgene. Interestingly, in GIEF mice membrane domains containing transgene 
detected by HA tag antibody (green) did not overlap with the domains containing 
endogenous NRG1 detected by C-terminal antibody (red) (Fig. 14; arrowheads; far low 
right panel). Thus, GIEF was transported into a domain different to endogenous NRG1. 
This finding is in line with a previous in vitro study (Frenzel and Falls, 2001) where 
authors showed that N-terminal fragment of NRG1 localized to a non lipid raft 
membrane compartment in contrast to full length NRG1 and the C-terminal fragment, 




Fig. 14 NRG1 type III is localized on the surface of spinal cord motor neurons of wt and 
NRG1 transgenic mice 
Paraffin spinal cord cross sections (5µm) of wt, HANI and GIEF mice at P12 and 4 months. 
Immunostaining was performed using anti HA (green) and sc-348 (red) antibodies. Nuclei are stained with 
DAPI (blue). Confocal images showing NRG1 signal on spinal cord motor neurons. Wt and transgenic 
NRG1 variants localize to neuronal surface (arrowheads). In GIEF mutants transgenic protein is 
additionally enriched in the intracellular compartment.  
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Far down right panel depicting an example of a motor neuron in GIEF mutants. wt -NRG1 (red) and GIEF 
transgenic proteins (green) are found in distinct membrane compartments (arrowheads). Scale bar 10 µm. 
 
4.14 Transport of the NRG1 fragments from neuronal soma in to the 
axonal compartment is limited 
According to the functional role of NRG1 in myelination (Michailov et al., 2004; 
Taveggia et al., 2005) NRG1 has to be transported from the neuronal cell body into the 
axonal compartment to stimulate signalling in Sc. After cleavage of the NRG1 type III-
β1 proprotein in the stalk region, C- and N- terminal fragments are separated (Falls, 
2003). The EGF-like signalling domain, responsible for ErbB receptor activation is 
located at the membrane anchored N-terminal fragment. To further address the 
mechanism of NRG1 action we have assessed the transport of NRG1 fragments in to 
the sciatic nerve. To detect NRG1 in vivo in axonal compartment we have performed 
immunostaining on paraffin sciatic nerve cross sections of wt, HANI and GIEF animals 
at P12 and 4 months of age in a setting of 3 animals per genotype. Nerves were 
immunolabeled for neurofilament (NF) to define the axonal compartment (red) and with 
HA antibody to detect NRG1 (green) (Fig. 15). As expected NRG1 staining of wt nerves 
with the HA antibody did only result in background signal and served as a negative 
control (Fig. 15A, B). In HANI transgenic NRG1 was localized to the axonal membrane 
forming a ring structure around the NF labeled axon at the P12 time point (Fig. 15A 
arrowhead and inset). However, the number of labeled axons was low (observation not 
quantified). NRG1 immunoreactivity at the axonal surface could not be detected in 
HANI sciatic nerves at 4 months of age probably due to the low amount of available 
NRG1 protein below the sensitivity threshold of the staining method (Fig. 15B). The fact 
that NRG1 was detected on neuronal cell somata, but not on the axons suggests 
limited transport of the protein into the axonal compartment. HA antibody staining 
detected the GIEF fragment on the axonal surface at both time points (Fig. 15A, B; 
arrowheads). The GIEF fragment was clearly localized to the axonal surface forming 
ring like structure around the axon (Fig. 15A, B inset). At the 4 months time point we, 
could also see vesicle like structures in the axonal lumen, potentially representing 










Paraffin embedded sciatic nerve cross sections (5µm) of wt, HANI and GIEF animals (P12) immunostained 
with antibodies against the N-terminal HA tag in HANI and GIEF transgenics are shown in green, 
neurofilament is shown in red.  
(A) At P12 in HANI and GIEF transgenics NRG1 protein can be detected on axons (arrowheads). It is 
apparent with higher magnification that the tg-derived protein localizes to the axonal membrane surface. 
Transport of NRG1 into the axonal compartment is limited. Scale bar 10µm. 
(B) At 4 months of age transgene derived protein is not detected in HANI sciatic nerve. GIEF transgenic 
protein is detected on the axonal surface (arrowheads; inset). The vesicular structures containing NRG1 
are apparent in the axonal lumen (inset). 
 
 
To asses the transport of the C-terminal fragment at P12 and 4 months, HANI sciatic 
nerves were stained with an antibody against tubulin (Tuj1, green) and an antibody 
directed against  NRG1 C-terminus (red) (Fig. 16) At both time points, the C-terminal 




Fig. 16 Immunohistological detection of the C-terminal fragment of NRG1 type III in 
sciatic nerve 
Paraffin embedded sciatic nerve cross sections (5µm) of HANI animals (P12 and 4 moths) immunostained 
with sc-348 antibody against NRG1 C-terminus (red) and tubulin (green). The sciatic nerves examined 
were devoid of NRG1 C-terminal fragment evidenced by the lack of fluorescent signal.  
 
 
To study the transport of NRG1 fragments into the sciatic nerve, we have performed 
the WB analysis of spinal cord and sciatic nerve protein lysates. HANI and GIEF 
mutants were sacrificed at 2 months of age and three animals per genotype were 
analyzed. Protein lysates containing 40 µg of protein were analyzed and tubulin was 
used as a loading control. Immunoblotting of the HANI spinal cord and sciatic nerve 
supported the limited transport theory. Western blotting of the spinal cord lysates using 
the HA antibody, revealed typical processing pattern consisting of 140kD full length 
protein and processed ~70kD and ~38kD N-terminal fragments (Fig. 17A; first three 
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lanes). Corresponding bands were absent from sciatic nerve lysates containing the 
same protein amount and only unspecific bands could be detected (Fig. 17A; second 
three lanes).  Protein lysates from wt spinal cord and sciatic nerve were used as 
controls (Fig. 17A; last two lanes). Immunodetection of the C-terminal fragment in the 
HANI and wt spinal cord and sciatic nerve protein lysates produced similar results. A 
140kD full length protein and a processed ~60kD C-terminal protein fragment were 
detected in the HANI spinal cord while corresponding bands in the wt were very weak 
(Fig. 17B). Corresponding bands could not be detected in sciatic nerve lysates of both 




Fig. 17 WB analysis supports limited transport of NRG1 from neuronal somata into 
axonal compartments 
(A) WB of the spinal cord and sciatic nerve lysates (40 µg) of HANI (n=3) and wt mice containing 40 µg of 
protein, performed with the anti HA antibody. The 140kD band corresponding to the full length HANI and a 
processed N-terminal ~70kD and ~38kD bands (arrows) are detected in spinal cord lysates. 
Corresponding bands are not visible in sciatic nerve lysates. Transgenic protein bands are absent in the wt 
lysates. β-tubulin was used as a loading control in all blots. 
(B) WB of the HANI and wt spinal cord and sciatic nerve lysates (n=2) containing 40 µg of protein 
performed with a sc-348 antibody to NRG1 C-terminus. The 140kD full length and 60kD processed C-
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terminal NRG1 band are detected (arrows) in the spinal cord, with obvious increase in the protein amounts 
in transgenic animals. Corresponding bands are not detected in sciatic nerve lysates.  
(C) WB showing GIEF transgenic protein bands detected in the spinal cord and sciatic nerve using anti HA 
antibody. The full length GIEF protein band ~70kD and a processed band of ~38kD are detected in spinal 
cord and sciatic nerve lysates (arrows). Reduced amount of the  protein in sciatic nerve is evident.  
(D) WB showing enrichment in Necl1 protein in sciatic nerve compared to spinal cord (n=4).Paraffin 
embedded sciatic nerve cross sections (5µm) of a HANI mouse stained for Necl1 (red) and tubulin (green). 
Necl1 appears to be localized to the axonal membrane. Scale bar 10 µm. 
 
 
Western blotting performed with GIEF protein lysates revealed the presence of the 
typical transgene protein bands of ~70kD and ~38kD in a sciatic nerve, which were 
strongly reduced, compared to spinal cord (Fig. 17C). Taken together western blot 
analysis agrees with theory of in vivo limited transport of NRG1 from the neuronal 
soma where protein is synthesized in to the axonal compartment, supporting data from 
immunostainings. To exclude technical reasons for the difficulties to detect NRG1 in 
sciatic nerves of HANI mutants we performed western blotting and immunostaining for 
Necl1 protein which is known to be localized at the axonal surface (Spiegel et al., 
2007). On WB, we could detect Necl1 protein in both spinal cord and sciatic nerve 
protein lysates with enrichment in the sciatic nerve (Fig. 17D). Immunostaining of 
sciatic nerve cross sections also revealed localization of Necl1 on the axonal surface 
forming ring-like structures (red) surrounding the tubulin labeled axon (green) (Fig. 
17D; lower panel).  
4.15 Inhibition of ADAMs proteases promotes in vitro myelination in 
DRG-Sc co-culture 
In our experiments with transgenic mice NRG1 stimulated myelination even in the 
absence of BACE1 protease. NRG1 activation was probably compensated for by other 
proteases, most likely belonging to the ADAMs family such as TACE (Horiuchi et al., 
2005). To asses the effect of ADAMs activity on myelination we took advantage of 
Dorsal root ganglion-Schwann cell (DRG-Sc) co-cultures in which myelination can be 
stimulated by addition of ascorbic acid. This in vitro myelination system proved to be 
compatible with our in vivo findings. HANI and GIEF constructs were cloned into 
lentiviral expression plasmid pLenti6/V5-DEST (Invitrogen) using gateway cloning. 
Expression was confirmed in vitro by immunostaining against HA tag after transfection 
of HEK 293T cells (Fig. 18A). In experiments made in collaboration with Dr. Carla 
Taveggia, similar to our transgenic mice, lentivirally overexpressed HANI and GIEF 
proteins in DRG neurons strongly promoted myelination by Sc after 7 days in 
myelinating conditions. HANI and GIEF infected cultures have a considerable increase 
in number of MBP positive myelin segments (red) compared to a non infected control 





Fig. 18 Lentiviral overexpression of GIEF promotes myelination in DRG-Sc co-cultures. 
(A) Functional assessment of viral expression plasmids pLenti6/V5-DEST containing HANI and GIEF 
expression constructs. Anti HA tag immunocytochemistry (red) was done to detect HANI and GIEF 
expression in HEK 293T cells 24h post transfection. 
(B) Extent of myelination in DRG-Sc co-culture detected by immunostaining for MBP myelin protein (shown 
in red). Sc were cultured for a week with in the presence of neurons that virally overexpressing HANI or 
GIEF. Controls represent non infected cultures. Myelination is strongly promoted in co-cultures 
overexpressing HANI and GIEF compared to controls, as evidenced by the increase in number of MBP 
positive myelin segments (not quantified). 
 
 
We therefore used this system for pharmacological treatment with protease inhibitors. 
Treatment with the BACE1 inhibitor (2µM β secretase inhibitor IV in DMSO) almost 
completely blocked myelination. Only few MBP positive myelin segments (green) were 
found after two weeks in myelinating condition (Fig. 19A, upper panel) representing 
3.12% of the average number of myelin segments counted in control DMSO treated 
cultures (Fig. 19A; lower panel). Inhibition of myelination in vitro by pharmacological 
BACE1 inactivation was thus in agreement with the hypomyelination phenotype of 
BACE1 null mouse mutants. To block ADAMs activity we used a broad spectrum 
ADAMs inhibitor GM6001 (1µM). After two weeks in myelinating conditions, cultures 
were stained for MBP and unexpectedly we observed a considerable increase in the  
number of MBP positive myelin segments (green) when compared to DMSO treated 
control cultures (Fig. 19A; upper panel) Quantification of MBP positive myelin 
segments was done on there independent cultures with 2 coverslips per culture. 
ADAMs inhibitor treatment significantly promoted myelination, such that the average 
number of myelin segments was increased by 1.9 fold compared to DMSO cultures 
(100% vs 190.13%±32.5; **p< 0.01) (Fig. 19A; lower panel). From these experiments 
we conclude that BACE1 and ADAMs have opposing effects on myelination, possibly 
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by differential processing of NRG1. Changed number of myelin segments after inhibitor 
treatment could result from changes in the number of Sc associated with axons. Thus 
we quantified the number of Sc aligning with axon bundles (Fig. 19B; upper panel). 
Two independent cultures treated with BACE1 and ADAMs inhibitors were analyzed 
after one week in myelinating conditions. DAPI-positive Sc nuclei aligning with axon 
bundles were counted on confocal images (3 coverslips/culture; 3 bundels/coverslip) 
and percentage average number of nuclei/µm/axon in treated culture relative to control 
was displayed as a result. BACE1-inhibitor treatment did not significantly change the 
number of Schwann cells in contact with the axon (Fig. 19B; lower panel). BACE1 
treated cultures had almost unchanged number compared to DMSO treated cultures 
(94%±5.1 vs 100%; p=0.17). In ADAMs inhibitor treated cultures, compared to controls, 
more Sc aligned with the axons (144%±23.24 vs 100%). However the increase in 
number was not statistically significant (p=0.09). This result strongly suggests that 
inhibition of BACE1 and ADAMs induces changes in myelination relevant signalling 
between axons and Sc rather than a change in the number of myelination competent 
Sc. We therefore preformed a WB to evaluate changes in the activation of PI3K and 
MAPK pathways upon inhibitor treatment. Protein lysates from DRG co-culture were 
immunobloted with the antibodies directed against phosphorylated PI3K and MAPK 
proteins. Unexpectedly the phosphorylated levels of PI3K and MAPK after inhibitor 
treatment were unchanged compared to control cultures (Fig. 19C). In a pilot 
experiment we asked if ADAMs inhibition has similar effects on myelination by 
oligodendrocytes. Co-cultures of cortical neurons and oligodendrocyte precursors cells 
(OPC) were treated with the ADAMs inhibitor (1µM) for four days and oligodendrocytes 
were analyzed. As previously described (Stevens et al., 2002) we could clearly identify 
in culture 5 stages of oligodendrocyte differentiation towards the mature myelinating 
stage (Fig. 20A). When we quantified the number of oligodendrocytes with morphology 
of the developmental stage V (Fig. 20A myelin stage), a 2.14 fold increase in the 
number of myelinating oligodendrocytes was observed in ADAMs inhibitor treated CNS 
co-cultures compared to the DMSO treated control cultures (1 vs 2.14±0.32 ;**p<0.01) 
(Fig. 20B). Further studies are required to address if the ADAMs inhibition promotes 
differentiation or proliferation of oligodendrocytes. Nevertheless, with these 
experiments we showed that ADAMs activity opposes BACE1 at least in vitro to affect 






Fig. 19 Inhibition of ADAMs activity promotes myelination in DRG-Sc co-cultures 
(A) Effects of ADAMs inhibitor (1 µM GM6001) and BACE1 inhibitor (2 µM β-secretase inhibitor IV) on 
myelination in DRG-Schwann cell co-culture. Extent of myelination is detected by immunostaining for MBP 
myelin protein (green) after 2 weeks in myelinating conditions. Treatment with ADAMs inhibitor treatment 
promoted myelination apparent by the increase in MBP positive myelin segments compared to control 
DMSO treated cultures. Almost no myelin can be detected in BACE1 inhibitor treated cultures. Scale bar 
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200µm Absolute number of myelin segments on the coverslips was counted. Quantified number of myelin 
segments (3 cultures; 2 coverslips/culture) is expressed in percentage relative to the wt ±SEM. Average 
increase in number of myelin segments is almost two fold after ADAMs inhibition compared to control 
culture (**p< 0.01). Decrease in number after BACE1 inhibition is significant (***p< 0.001) compared to the 
control. 
(B) Confocal images of the DRG-Schwann cell co-cultures (1 week in myelinating conditions) 
immunostained for tubulin (red) with DAPI stained nuclei (blue). Example of an axon bundle (boxed) is 
used for quantification of the Sc association with the axon. Scale bar 20 µm. Two independent cultures 
were quantified (3 coverslips; 3 bundles/coverslip). Numbers of nuclei/axon /µm are expressed in 
percentage±SEM relative to the DMSO treated controls. 40% increase after ADAMs inhibition compared to 
control was not significant (p=0.07). BACE1 inhibition induced 2% decrease compared to control (p=0.17) 
(C) WB was performed on DMSO and inhibitors treated DRG Schwann cell co-culture (7 days in 
myelinating conditions). 40µg of protein was used for WB. The WB was probed with antibodies against 
pAkt and pMAPK. No change in the amount of pAkt and pMAPK is detected upon inhibitor treatment. β-





Fig. 20 Inhibition of ADAMs activity promotes myelination in cortical neuron 
oligodendrocyte co-cultures 
(A) Different developmental oligodendrocyte stages with distinct morphology visualized by MBP staining 
(green) after 4 days co-culture with neurons. The myelinating stage is defined by formation of myelin 
segments (arrowheads). Scale bar 100µm. 
(B) Quantification of the number of myelinating oligodendrocytes in 3 independent cultures (2 
coverslips/culture) treated with ADAMs inhibitor (1µM GM6001) and DMSO treated controls. Numbers are 
expressed as an average percentage±SEM relative to DMSO treated cultures. Inhibition of ADAMs 




5.1 Transgenic overexpression of tagged NRG1 variants in 
transgenic mice - advantages and disadvantages of the 
approach. 
The goal of this study was to further explore the role of BACE1 in the NRG1 type III-β1 
mediated control of peripheral myelination, and to decipher the structure of the “active” 
form of NRG1 type III-β1 in vivo. Furthermore, we wanted to address the subcellular 
localization of NRG1 in spinal cord motor neurons. For the purpose of this study, we 
have generated a transgenic mouse line that harbors a Thy1-promoter (Caroni, 1997) 
driven cDNA encoding a BACE1 processed N-terminally tagged NRG1 type III-β1 
(GIEF).The “GIEF” construct represents an N-terminal fragment of full length NRG1 
type III-β1 tagged at the N-terminus (HANI), resulting after BACE1 cleavage in the stalk 
region (Fig. 3). We have decided to introduce an HA-tag at the N-terminus due to the 
lack of the appropriate NRG1 antibodies. This allowed us to detect and follow N-
terminal NRG1 fragment supposed to carry the EGF like signaling domain (Wang et al., 
2001). Previous studies which successfully analyzed processing of NRG1 proteins in 
vitro also relied on the indirect detection of NRG1 by introducing peptide tags (HA, 
myc, fluorescent) at different positions of the NRG1 protein (Hu et al., 2008; Shirakabe 
et al., 2001; Wang et al., 2001; Yokozeki et al., 2007). Alternatively, shedding of the 
NRG1 was indirectly measured by the level of enzymatic activity detected after release 
of alkaline phosphatase linked to the NRG1 ectodomain (Horiuchi et al., 2005; Willem 
et al., 2004). However, this has the disadvantage, that the cell culture system cannot 
provide the full complexity of the in vivo system, thus only allows basic protein 
characterization. The NRG1 processing pattern observed in cell culture does not 
necessarily correlate to the in vivo situation. In our approach, we went one step beyond 
the in vitro analysis of transfected cells, as we studied NRG1 processing in vivo. 
Transgenic overexpression of the tagged NRG1 variants, “HANI” (Gummert 
unpublished) and GIEF under the neuron specific Thy1-promoter (Caroni, 1997) 
allowed us to visualize products of NRG1 type III-β1 processing. This approach made 
stage for a more detailed analysis of the processing pattern of NRG1 type III-β1 in vivo 
especially with regard to the evaluation of the possible further processing of N-terminal 
protein fragments and the putative release of the EGF signalling domain (Fig. 1). These 
studies have not been possible previously, since the only reliable NRG1 antibody 
recognizes the C-terminus of NRG1. Additionally, overexpression of tagged NRG1 
variants in neurons creates the venue for answering question of neuronal localization of 
NRG1 fragments in vivo. The levels of the overexpressed proteins are likely to be 
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above the sensitivity threshold of applied staining methods and the HA-tag enabled us 
to detect the N-terminus which previously has not been visualized in vivo. As the 
Introduced HA-tag could have an impact on maturation and protein function and we 
wanted to asses the activity of the GIEF variant in myelination in vivo, it was important 
verify normal intracellular trafficking and targeting as well as preserved function in 
signalling. Therefore, the integrity and function of GIEF and HANI-variants were 
confirmed in a battery of in vitro experiments, which showed transmembrane 
localization of GIEF-variant  as well as unchanged activity in inducing ErbB receptor 
dimerization (Fig. 3). Importantly transgenic approaches carry several disadvantages 
that need to be taken under consideration before interpretation of phenotypes. One 
disadvantage is the virtual absence of control over the integrated transgene copy 
number and the transgene integration site. This random integration effect can induce 
different levels of transgene expression and it is hampering the comparison between 
two independent transgenic lines. Moreover, the onset of the transgene expression can 
vary depending on the transgene integration site. Our study addressing the role of 
NRG1 variants in myelination required that the transgene is expressed early postnatally 
at the onset of myelination. We have therefore analyzed the onset of transgene 
expression and expression levels in HANI and GIEF lines before making conclusive 
statements regarding the myelination phenotypes. Both Thy1 driven transgenes were 
expressed at P1 at the beginning of myelination similar to previously described Thy1 
driven mouse line overexpressing full length wt NRG1 type III-β1 (Michailov et al., 
2004) (Fig. 6). Transgenic overexpression in the GIEF-line was three fold higher when 
compared to HANI (Fig. 6) which was taken under consideration when phenotypes 
were compared.  Taken together, transgenic NRG1 mouse lines used and generated in 
our study have satisfied experimental criteria necessary to reveal if BACE1 processing 
activates NRG1 in vivo. Additionally, overexpression of tagged NRG1 variants in 
neurons created the opportunity to address the transport and localization of NRG1 in 
vivo. 
5.2 BACE1 activates NRG1 type III-β1 to promote myelination 
Myelin formation is controlled to provide optimal conduction properties of myelinated 
fibers, which are necessary for functional integration of the nervous system (Waxman, 
1997). Structural parameters, such as myelin sheath thickness and internodal length, 
are not randomly chosen but strictly defined relative to axon diameter to provide 
millisecond precision in neuronal signal transmission. The identity of one of the axonal 
signals that regulate myelin sheath thickness was revealed 50 years later after the 
question was asked (Rushton, 1951) with the identification of axonal membrane 
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derived growth factor NRG1 type III-β1 (Michailov et al., 2004). The amount of NRG1 
type III presented to the Sc was found to be a measure of axon diameter that signalls 
to the Sc how many myelin wraps to produce. To generate a mature signalling 
fragment, NRG1 type III-β1 is believed to be proteolytically cleaved. Recent work 
discovered a physiological role of BACE1 in myelination (Hu et al., 2006; Willem et al., 
2006). Lack of BACE1 in mouse mutants causes hypomyelination similar to the 
previously described phenotype of NRG1 type III heterozygous mice (Michailov et al., 
2004). The similarity of these phenotypes led to the conclusion that the phenotype 
observed in BACE1-/- mice is linked to impaired NRG1 processing. Even though the 
inactivation of BACE1 induces accumulation of full length NRG1 type III-β1 in the brain, 
it is not known if impaired processing of NRG1 also occurs in the PNS and thus 
whether a direct functional link exists between BACE1 and NRG1. Transgenic 
overexpression of the epitope-tagged GIEF construct, mimicking BACE1 processing of 
the tagged NRG1 type III-β1 (HANI), induces hypermyelination in the PNS (Fig. 9). Very 
similar to full length NRG1 type III-β1 (HANI). This is compatible with the hypothesis 
that BACE1 cleaves NRG1 type III-β1 in the stalk region to generate a protein fragment 
which is competent in promoting myelination in vivo. This is the first in vivo observation 
of a functional interaction between BACE1 and NRG1 type III-β1 in myelination. As the 
GIEF fragment alone is sufficient to induce hypermyelination in vivo, we conclude that 
back signalling to the nucleus by the cytoplasmic tail of NRG1 (Bao et al., 2004; Bao et 
al., 2003) does not play a role in myelination promotion by NRG1 type III-β1. The effect 
of the GIEF fragment on myelination seems to be specific for its primary structure 
rather than the paracrine signalling mode. Another type III isoform highly expressed in 
PNS neurons known as SMDF (Ho et al., 1995; Schroering and Carey, 1998) only 
differs from the GIEF-variant by the EGF-β3 domain. Neuronal overexpression of NRG1 
type III-β3 under control of the neuron specific enolase (NSE) promoter has no effect on 
myelination despite the incredible structural similarity to the GIEF-variant (Gomez-
Sanchez et al., 2009). Indeed, biochemical analysis of  NRG1 type III-β3 suggest a 
topological model in which its C-terminus interacts with the membrane and bends the 
extracellular part of the protein possibly creating different signalling by the EGF-β3 
domain (Cabedo et al., 2002). Thus, it is possible that processing by BACE1 is 
important to create a specific EGF domain environment, which is competent for 
myelination. Inactivation of all type III isoforms induces a 50% reduction in the number 
of spinal motor and sensory neurons (Wolpowitz et al., 2000). It has been speculated 
that the mechanism of NRG1 type III, which mediates neuronal survival involves back 
signalling by its C-terminus. Considering the fact that NRG1 type III-β3 does not contain 
a cytoplasmic tail, the type III-β1 isoform represents a mayor candidate for NRG1 type 
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III mediated neuron survival. Taken together, we propose that NRG1 type III-β1 evolved 
to serve two distinct independent functions in neuronal cells that are mediated by its N-
terminal and C-terminal domains. After proteolytic cleavage by BACE1 or/and  other 
proteases, the N-terminal fragment harboring EGF serves a myelination function by 
forward signalling, whereas the C-terminus ensures neuronal survival by back 
signalling. 
5.3 Ectopic myelination in mice overexpressing BACE1 cleaved 
NRG1 type III-β1 
NRG1 type III is an instructive signal for the binary choice between axon ensheathment 
and myelination (Taveggia et al., 2005). Small caliber axons (<1µm) expressing low 
dosage of NRG1 type III are not myelinated but ensheathed by a nmSc, which results 
in formation of Remak bundles. Proper formation of Remak bundles has been shown to 
be sensitive to the dosage of NRG1 type III (Taveggia et al., 2005). Mice 
haploinsuficient for the type III-isoform have aberrantly organized Remak bundles with 
axons unsegregated by the nmSc cytoplasm. Overexpression of the GIEF variant on 
small caliber axons induces ectopic myelination (Fig. 10). Thus, axons normally found 
in Remak bundles are sorted out and acquire a compacted myelin sheath. We also 
observed the formation of myelinated Remak bundles containing unsegregated axon 
fibers (Fig. 10). Otherwise, Remak bundles did not show major structural aberrations, 
as they display normal gross morphology with properly segregated axons (Fig. 10). 
Taken together, nmSc appear to be less sensitive to the increased doses of the GIEF 
variant than mSc. It is very interesting that in contrast to GIEF overexpression, NRG1 
type III-β3 overexpression in neurons induces major disturbances of Remak bundles 
(Gomez-Sanchez et al., 2009). Most of the Remak bundles have unsegregated axons 
and ~ 20% of the Remak bundles are myelinated. Even though we are comparing two 
different transgenic lines, it is tempting to speculate that after initial ensheathment 
versus myelination choice, which is defined by NRG1 type III-β1 correct structural 
organization of the Remak bundle depends more on type III-β3 isoform. In light of all 
these findings it is also possible that the Remak bundle phenotype observed in NRG1 
type III +/- mice (Taveggia et al., 2005) is caused manly by the loss of the β3 isoform 
but not by the β1 isoform. 
5.4 GIEF and HANI are equally potent in promoting myelination 
Activation of the PI3K-pAkt pathway was shown to be required for the initial events of 
myelination in vitro (Maurel and Salzer, 2000). Accordingly increasing PI3 kinase 
activity induces downstream pAkt and promotes myelination in DRG-Sc co-culture 
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(Ogata et al., 2004). PI3K-pAkt activation was shown to be mediated by axonal surface 
presented NRG1 type III-β1 in vitro (Taveggia et al., 2005). Although overexpression of 
NRG1 type III-β1 and hypermyelination are not clearly coupled to an upregulation of the 
PI3K-pAkt pathway in transgenic mice (Humml unpublished observation), constitutive 
activation of the PI3 kinase pathway by conditional inactivation of PTEN in Sc induces 
hypermyelination and tomacula formation (Göbbels et al., submitted). GIEF 
overexpression induced formation of tomacula, which are similar in structure to the 
tomacula observed in PTEN mutants (Fig. 12). Originally, we hypothesized that the 
GIEF variant represents a “ready to signal” NRG1 type III-β1 variant which might be 
more potent in activating Akt. However, quantification of tomacula revealed that the 
phenotype is very mild in comparison to PTEN mutants. Myelin in GIEF transgenic 
mice, aside from mild tomacula formation, has a normal ultrastructure and increased 
myelin thickness is a result of an additional myelin membrane wraps (Fig. 9). Moreover, 
analysis of HANI transgenic mice revealed the same potency to induce tomacula (Fig. 
12). This was unexpected considering the three-fold higher expression of the GIEF-
variant compared to HANI. Similarly, HANI and GIEF transgenic mice also displayed a 
comparable level of hypermyelination as g-ratios values are not significantly different 
(Fig. 12). This could be explained by a saturating effect of ErbB2/ErbB3 receptor 
heterodimers by increased levels of NRG1. The available amount of receptors for 
NRG1 ligand binding might be below the capacity to fully translate the increased NRG1 
signal into a corresponding increase in activity of the p-Akt signaling pathway. By 
PTEN inactivation p-Akt is activated downstream of the receptor level and the 
saturation effect is omitted resulting in a severe tomacula phenotype. It is also likely 
that the activation of alternative pathways downstream of p-Akt strongly depend on 
specific ligand-receptor complexes. Tomacula formation of the PTEN mutants is 
mediated through the m-Tor pathway (Göbbels et al., submitted) known for it 
implication in cell mass growth and tumorigenesis (Liu et al., 2009; Wullschleger et al., 
2006). As the exact mechanisms of myelin membrane growth are still not known, it is 
possible that HANI and GIEF overexpression activate alternative pathways that 
enhance myelin growth, which is distinct from the cell mass growth induced by the m-
TOR pathway. 
5.5 Absence of the Sc proliferation upon GIEF overexpression  
NRG1 induces proliferation of Sc in vitro (Dong et al., 1995; Lemke and Brockes, 1984; 
Levi et al., 1995). However, in most cases a recombinant EGF domain of NRG1 was 
used in these experiments. A role of NRG1 type III in Sc survival was also shown. 
Inactivation of NRG1 type III isoforms reduces the numbers of Sc precursors 
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(Wolpowitz et al., 2000). However, neuronal overexpression of the NRG1 type III-β1 in 
vivo does not effect the proliferation of Sc (Michailov et al., 2004). In a recent study, in 
vivo overexpression of NRG1 type III-β3 induced the proliferation of nmSc but not mSc 
(Gomez-Sanchez et al., 2009). Overexpression of GIEF, which is very similar in 
structure to type III-β3, did not effect the proliferation of both mSc and nmSc (Fig. 11). It 
has been shown previously that two major pathways activated in Sc upon NRG1 
signaling (MAP kinase and PI3 kinase) serve opposing function in the process of Sc 
differentiation (Ogata et al., 2004). Thus, it is possible that a difference in the primary 
structure of a NRG1 ligand can engage ErbB2/ErbB3 receptors differentially resulting in 
a different biological response of Sc. Moreover, NRG1 affects also differentiation of Sc. 
Stimulation by NRG1 in cell culture promotes differentiation of SCP (Dong et al., 1995). 
Viral overexpression of the HANI variant of NRG1 type III-β1 in DRG neurons promotes 
myelination in co-culture (Fig. 18). In addition, overexpression of GIEF in DRG-Sc co-
culture recruited more Sc to myelinate resulting in increased number of myelin 
segments in DRG-Sc co-culture. Overexpression of GIEF in vivo did not recruit more 
SCP to further differentiate towards myelinating phenotype showed by the unchanged 
number of Krox 20 positive Sc (Fig. 11). In vivo overexpression of GIEF affected 
apparently only myelinating Sc in the close contact with the axon, in the final phase of 
the myelination process. Mechanisms adjusting the number of Sc to the number of 
myelin segments during development (Grinspan et al., 1996; Syroid et al., 1996) are 
not affected by the GIEF overexpression similar to the overexpression of NRG1 type 
III-β1 (Michailov et al., 2004) 
5.6 NRG1 promotes myelination in the absence of BACE1: 
Implications for the existence of compensatory mechanism. 
BACE1 mutants and transgenic mice were generated to support the efforts in 
establishing therapeutic approaches in Alzheimer disease (AD) (Willem et al., 2009). 
Their analysis revealed that overexpression of BACE1 promotes production of amyloid 
β peptide, whereas inactivation of BACE1 completely abolished APP processing 
(Dominguez et al., 2005; Willem et al., 2004). However, inhibition of BACE1 as a 
therapy of Alzheimer disease was shaded after the discovery that inactivation of the 
BACE1 causes hypomyelination (Hu et al., 2006; Willem et al., 2006). NRG1 as a 
substrate of BACE1 was implied to be responsible for this effect. We here show for the 
first time in vivo, that BACE1 contributes to the activation of NRG1 during myelination. 
However, this contribution is surprisingly mild as NRG1 type III-β1 is still capable to 
induce hypermyelination in the absence of BACE1, albeit with reduced potency (Fig. 
13). Complete absence of NRG1 type III in vivo results in reduced numbers of Sc in 
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sciatic nerve (Wolpowitz et al., 2000). Cultured DRG neurons from type III -/- mice are 
not myelinated by Sc in vitro (Taveggia et al., 2005). It is therefore intriguing that even 
though thickness is greatly reduced, compact myelin still forms in the absence of 
BACE1 in vivo, similar to the NRG1 type III +/- mice. This suggests that some NRG1 
type III activity persists in the absence of BACE1 and/or that other molecules can 
signal a “baseline” myelination program in vivo. Surprisingly, overexpression of the 
HANI-variant with absence of BACE1, albeit at reduced levels induces 
hypermyelination (Fig. 13). This finding can be explained by compensatory processing 
by other proteases, such as ADAM17, ADAM19 or (partial) myelin-promoting 
competence of uncut NRG1 type III. Biochemical analysis of protein extracts from 
spinal cord and sciatic nerve of HANI-transgenic mice with absence of BACE1 will 
allow to address this question. It will be interesting to see if in the absence of BACE1, 
GIEF is more potent than HANI in promoting myelination. In that case, we could 
suggest the relevance of BACE1 over compensatory proteases in NRG1 activation for 
myelination. Taken together myelination by NRG1 type III-β1 only partially depends on 
BACE1. 
5.7 Does BACE1 cut twice to activate NRG1? 
The function of NRG1 in myelination is restricted to the type III NRG1 isoform as 
overexpression of the type I isoform does not induce hypermyelination (Michailov et al., 
2004). According to the current concept of NRG1 signalling, type I and II isoforms 
signal in a paracrine manner through a shedded EGF like domain and type III isoforms 
mediate paracrine signalling (Falls, 2003). Moreover, it has been shown that virally 
overexpressed NRG1 type III-β1 in DRG neuron presents its EGF domain bound to the 
membrane (Taveggia et al., 2005). Accordingly, it is thought that axonally presented 
NRG1 type III-β1 juxtacrine signal is essential for NRG1 function in myelination. 
Nevertheless recently, based on in vitro biochemical analysis recently, has been 
speculated that the EGF domain of type III is released once the first myelin wraps are 
formed to complete myelin maturation in a paracrine signaling manner (Birchmeier and 
Nave, 2008). The subsequent cleavage and release of NRG1 type III after ErbB 
receptor binding makes sense in terms of signaling promotion. It has been shown the 
NRG1 signalling in neurons by ErbB4 requires receptor internalization to activate PI3K 
and MAPK pathways. This occurs only with the soluble ligands (Liu et al., 2007). After 
initial receptor binding, the release of the membrane tethered ligand also could 
enhance receptor dimerization and downstream signaling by increasing diffusion of the 
receptor-ligand complex (Blobel, 2005). Both BACE1 and ADAMs proteases are 
candidates for the second cleavage releasing the EGF domain (Willem et al., 2009). 
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Analysis of the processing pattern of full length NRG1 type III-β1 and BACE1 processed 
GIEF, strongly suggests that the GIEF-variant results from BACE1-mediated 
processing of HANI. The ~70kD protein product resulting from BACE1 cleavage of 
HANI in vitro  exactly corresponds in size to the GIEF-isoform on a WB (Fig. 4). In 
addition, WB analysis of spinal cord lysates from HANI and GIEF overexpressors 
revealed that the GIEF-variant corresponds in size to the N-terminal product of HANI 
cleavage (Fig. 4). Moreover, the existence of two bands (~70kD and ~38kD) in cells 
transfected with GIEF construct and spinal cord lysates suggest further processing in 
the extracellular domain. At least in vitro, no evidence was obtained that this 
processing is BACE1 mediated (Fig. 4), as the processing pattern in the GIEF 
transfected cell lysates remained unchanged after cotransfection with BACE1 and 
application of the BACE1 inhibitor. Application of the broad spectrum ADAMs inhibitor 
also did not influence processing pattern of both HANI and GIEF proteins in vitro (Fig. 
4). Thus we can not exclude the presence of additional proteases different from BACE1 
and ADAMs in HEK239T cells such as nardilysin (Ohno et al., 2009) that cleaves 
NRG1 under baseline conditions and that the activity of this protease was not affected 
by our manipulations. After breeding our transgenic lines to BACE1 mutants, we will 
also test in vivo if a second cleavage by BACE1 occurs. Finding that overexpression of 
GIEF promotes myelination in vivo strongly indicates that NRG1 type III-β1 is cleaved 
by BACE1 in the stalk region to be activated for myelination function. Furthermore, 
analysis of the hypermyelination status of GIEF transgenics in a BACE1 null 
background will allow us to address whether BACE1 mediates a second processing 
step that is required for the myelination promoting function of GIEF. This will provide a 
more detailed picture of the structure of an NRG1 signaling complex responsible for 
myelination.  
5.8 Localization of NRG1 in neurons in vivo 
Studies of the trafficking and subcellular localization of NRG1 have been hampered by 
the lack of appropriate antibodies and sensitivity levels of the staining methods. Our 
transgenic mouse lines that overexpress HA-tagged NRG1-variants offer an 
opportunity to investigate the subcellular localization of NRG1 in neurons in vivo. By 
immunostaining with antibodies directed against the N- and C- terminus of NRG1, we 
were able to show that N- and C- terminal protein products colocalize at the cell 
surface of spinal cord motor neurons (Fig. 14). WB analysis of spinal cord protein 
lysates identified a ~70kD N-terminal fragment resulting after processing of the 140kD 
full length NRG1 (Fig. 17). We suggest that NRG1 is transported to the cell surface to 
be processed by BACE1. However, processing might already occur in the Golgi 
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compartment. Thus, even though N- and C-terminal fragments colocalize on the cell 
surface of transgenic mice that overexpress full length NRG1 type III-β1, it is possible 
that they are delivered to the membrane already separated by the cleavage in the stalk 
region. Available BACE1 antibodies did not produce conclusive information about the 
subcellular localization of BACE1. Therefore, to further elucidate the site of NRG1 
cleavage by BACE1 it will be necessary to perform WB analysis after subcellular 
fractionation, which will allow us to identify if NRG1 is already processed in the 
intracellular compartment. The GIEF variant is strongly enriched within the intracellular 
vesicular compartment, but also detected at the cell surface of spinal cord motor 
neurons (Fig. 14). Endogenous NRG1, detected by the C-terminal antibody is localized 
in patchy pattern on the neuronal surface which could correspond to lipid rafts micro 
domains. Interestingly, the endogenous C-terminal fragment occupies distinct 
membrane microdomains when compared to the GIEF variant. Thus, N- and C-terminal 
fragments are transported to a distinct membrane compartments. Accordingly, the 
GIEF variant would than localize to non lipid raft domains. These findings are in line 
with previously described biochemical assays which revealed that full length NRG1 and 
the C-terminal fragment harboring the transmembrane domain localize to the lipid raft 
membrane fraction in transfected cells (Frenzel and Falls, 2001). In contrast, the HA 
tagged N-terminal fragment was detected in a non lipid raft membrane fraction. In this 
study lipid raft localization was suggested to be significant for NRG1 signalling. This is 
in agreement with the proposed function of lipid rafts in the compartmentalization of 
signaling complexes and formation of platforms for proteolytic processing (Brown and 
London, 2000; Simons and Ikonen, 1997; Simons and Toomre, 2000). Indeed, in vitro 
studies showed that the processing of NRG1 by ADAM19 takes place within lipid raft 
microdomains (Wakatsuki et al., 2004). BACE1 is also compartmentalized to lipid rafts 
(Riddell et al., 2001) and it is possible that NRG1 type III-β1 processing by BACE1 
requires lipid raft colocalization. After processing of the full length NRG1 N-terminal 
fragment is probably released to the non lipid raft microdomain. We also found that the 
transport of NRG1 into the axonal compartment is limited. While wt and transgenic 
variants of NRG1 were prominently expressed in spinal cord motor neurons, sciatic 
nerve expression was very low or even undetectable (Fig. 14, Fig. 15, Fig. 16, Fig. 17). 
Strong overexpression in the GIEF transgenic line increased protein transport into the 
sciatic nerve above a level that allowed immunodetection. Immunostaining of sciatic 
nerve cross sections identified an HA-tagged N-terminal fragment on the axonal 
membrane. Moreover, vesicles containing the N-terminal fragment were present in the 
axonal lumen presumably transporting the N-terminal fragment from the neuronal cell 
body. It is still an open question to which extent the C-terminus is transported in to the 
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axon at all since it was not detected in sciatic nerve of NRG1 overexpressing mice (Fig. 
15, Fig. 16, Fig. 17,). In contrast to our findings authors of the study analyzing NRG1 
levels in sciatic nerve of wt and Erbin mutant mice detected by WB full length NRG1 
protein of 140kD and ~60kD processed C-terminal fragment (Tao et al., 2009). We 
assume that by increasing in protein levels in the homozygous HANI mice will allow us 
to resolve this question. Taken together, our findings suggest that the regulated 
transport of NRG1 into the axon serves as a mechanism to provide appropriate level of 
NRG1 on the axonal membrane for myelination control compatible with the finding that 
the amount of NRG1 rather than ErbB receptors appears to be rate limiting for myelin 
formation (Michailov et al., 2004). Therefore, the amount of NRG1 in the nerve must be 
tightly regulated to produce the appropriate amounts of  myelin. Indeed, our data show 
that only a fraction of the synthesized NRG1 is transported into the axonal 
compartment as we detect only small amounts of NRG1 in the sciatic nerve by WB and 
immunostaining. The identity of the mechanisms involved in regulation of axonal 
trafficking of NRG1 is currently unknown. We speculate that proteolytic cleavage could 
be one of the checkpoints. It is also possible that transport into the axon is regulated by 
the level of endosomal vesicle release. Taken together, we propose that NRG1 
accumulates in lipid rafts and it is transported to the neuronal surface to be 
proteolyticaly cleaved by BACE1. Subsequently, the N-terminal fragment diffuses into 
non-lipid raft compartments from where it is internalized and transported into the 
endosome. Vesicles containing NRG1 are subsequently transported from the recycling 
endosome into the axon and integrated into the axonal membrane. The C-terminal 
fragment most likely stays behind in the  neuronal soma to mediate neuronal survival 






Fig. 21 Model of NRG1 trafficking in neurons 
(1) Synthesized NRG1 and BACE1 transported in vesicles from trans-Golgi network (TGN) to the neuronal 
cell surface. After proteolytic processing (2) NRG1-N-terminal fragment (green) is localized to distinct 
membrane compartment (3) to NRG1-C-terminal fragment (red). N-terminal fragment is than internalized 
(4) and transported  to recycling endosome (RE) (5). From RE vesicles containing NRG1-N terminus are 
transported to the axon (6) and integrated into the membrane. N-terminus on axonal membrane is 
potentially further cleaved (labeled with question mark) to release the EGF-like domain. C-terminus most 
likely remains in the neuron soma to mediate back signalling to the nucleus (7).  
5.9 Inhibition of ADAMs proteases stimulates myelination in vitro u 
We have shown that BACE1 is required to fully activate the myelination promoting 
function of NRG1. However, the potential of overexpressed NRG1 to promote 
myelination remains, albeit at lover levels, even in the absence of BACE1. Therefore, 
we wanted to investigate possible processing of NRG1 by other proteases in the 
absence of BACE1. Members of the ADAMs family, ADAM17 and ADAM19, which 
have been shown to mediate NRG1 cleavage in vitro (Horiuchi et al., 2005; Shirakabe 
et al., 2001) and are attractive candidates. Unexpectedly, inhibition of ADAMs activity 
in DRG-Sc co-cultures by a broad spectrum inhibitor (GM6001) promoted myelination 
and increased the number of myelin segments by twofold in comparison to control 
culture (Fig. 19). We speculate that this effect might also be observed in vivo as DRG 
co-cultures replicate other in vivo effects. For instance, BACE1 inhibition almost 
completely abolished myelination, and viral overexpression of GIEF and HANI-variants 
in DRG neurons promoted myelination, very similar to finding in transgenic mice (Fig. 
18,Fig. 19). The molecular targets and mechanisms responsible for this effect are 
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currently not clear. However, we found that the association of Sc with the DRG axons 
is largely unchanged upon treatment with ADAMs and BACE1 inhibitors. This would 
suggest that proteolytic processing is not required for the initial stage of Sc-axon 
association but controls axo-glial signalling after an initial contact has been established 
(Fig. 19). Nevertheless, PI3K and MAPK activities were not significantly changed upon 
inhibitor treatment (Fig. 19). However, it is possible that other downstream signalling 
cascades involved in Sc differentiation are affected by the treatment such as 
calcineurin/NFAT, shown to be activated in Sc after addition of NRG1 in vitro (Kao et 
al., 2009). Even though the ADAMs inhibitor is not specific for ADAM17, it blocks 
ADAM17 activity in low-nanomolar concentrations (Moss and Rasmussen, 2007)  
Based on the importance of NRG1 signalling in PNS myelination (Michailov et al., 
2004), one obvious explanation is therefore that inhibition of ADAM17 activates NRG1 
to promote myelination. This hypothesis implicates that proteolytic processing can also 
negatively regulate NRG1 signalling, which is beyond the simple model of proteolysis 
mediated activation. APP can be cleaved by BACE1 and ADAM17 to produce two 
functionally different protein fragments (Turner et al., 2003). Therefore, it is possible 
that a similar scenario exists for NRG1 processing. While currently, no data directly 
connect ADAMs inhibition with NRG1 processing it will be interesting to study if the 
GM6001 inhibitor can promote myelination or remyelination after nerve crush in vivo. 
This would open and avenue for the therapy of peripheral neuropathies. Interestingly, 
we observed a similar effect of ADAMs inhibition in co-cultures of CNS neurons and 
oligodendrocytes. Here the number of myelinating oligodendrocytes was increased by 
twofold compared to control cultures (Fig. 20). It will be an important task for future 
experiments to determine if the effect is a consequence of induced oligodendrocytes 
proliferation at if ADAMs inhibition mainly affects post mitotic oligodendrocytes. It is 
tempting to speculate that treatment with ADAMs inhibitor could be used in future as a 
potential treatment to stimulate OPC differentiation in MS lesions and repair of 
damaged myelin sheaths.  
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6 SUMMARY AND CONCLUSIONS 
NRG1 type III-β1 is a master regulator of peripheral myelination (Michailov et al., 2004; 
Taveggia et al., 2005). It has been suggested that NRG1 isoforms undergo proteolytic 
cleavage to generate mature signalling ligands (Mei and Xiong, 2008). Although NRG1 
processing by the ADAMs family of metalloproteases has been widely studied, 
(Horiuchi et al., 2005) the identity of the protease activating NRG1 type III and the 
exact structure of signaling fragment that regulates myelination remained elusive. 
Recently studies of BACE1-/- mutants revealed hypomyelination of the PNS axons and 
described a physiological role of BACE1 in the PNS myelination (Willem et al., 2006). 
Even though processing of the type III NRG1 isoform by BACE1 has been shown in 
vitro (Hu et al., 2008) the importance of BACE1 processing for NRG1 type III-β1 
mediated myelination in vivo has not been directly demonstrated.  
 
Neuronal overexpression of a NRG1 variant mimicking BACE1 processed NRG1 type 
III-β1 in transgenic mice promotes myelination in the PNS similar to the full length 
NRG1 protein. This result strongly suggests that BACE1 processing occurs in vivo to 
activate NRG1 type III-β1 in myelination. Thereby we also showed that back signalling 
by cytoplasmic tail of NRG1 type III-β1 is not required for the myelination promoting 
function against previous speculations. Our finding also implies different signalling 
function of type III-β1 and type III-β3 NRG1 isoforms. 
 
We could show that BACE1 cleavage in the stalk region functionally activate NRG1. 
Analysis of the processing pattern of NRG1 type III-β1 in vivo and in vitro support this 
first opening cut. In vitro analysis shows no evidence that BACE1 further cuts NRG1 to 
release EGF domain, but our results strongly suggest cleavage by another protease.  
Analysis of the myelination as well as biochemical analysis of mice with GIEF 
overexpression in the absence of BACE1 will resolve whether second cleavage step by 
BACE1 occurs in vivo and whether it is necessary for the function in myelination.   
 
BACE1 overexpression does not further promotes myelination in NRG1 type III-β1 
overexpressing mice. In the absence of BACE1, overexpressed NRG1 type III-β1 
retains the potential to promote myelination, albeit to the less extent showing for the 
first time functional interaction between BACE1 and NRG1 in vivo. It remains to be 
elucidated if BACE1 activity is compensated by another protease or NRG1 function in 
myelination can be independent of processing mediated activation.  
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NRG1 protein fragments localize to the cell surface of spinal cord motor neurons and 
the transport into axonal compartment is limited. Proteolytic processing represents 
possible rate limiting step for the axonal transport.    
 
Inhibition of the ADAMs proteases promotes myelination in vitro. This finding presents 
potential approach to stimulate myelination in demyelinating diseases. Whether NRG1 
participates in the effect observed with ADAMs inhibitor is not clear, but could be 




Despite the fact that the following project was discontinued, I will briefly introduce and 
discus it in the following chapter. I have attempted to generate a NRG1-antibody fusion 
protein, as an experimental therapy in a mouse model of Multiple sclerosis (MS). This 
project, done in collaboration with Dr. Moses Rodriguez at Mayo clinic USA, led to the 
identification of an antibody that following intraperitoneal injection (i.p.) binds to axons 
in the spinal cord of Theiler’s murine encephalomyelitis virus (TMEV) mediated mouse 
model of MS. 
7.1 NRG1 as a potential therapy of MS 
Multiple sclerosis is a chronic progressive inflammatory demyelinating disease of the 
CNS. MS is the most common cause of neurological disability in the world population 
affecting more than 2.5 million individuals (Hauser and Oksenberg, 2006). Pathological 
hallmarks of the disease are focal plaques of demyelination characterized by 
inflammation, axonal loss and gliosis (Bruck, 2005). T-cell and antibody mediated 
inflammatory mechanisms and oligodendrogliopathies lead to the myelin damage in the 
lesions (Lassmann et al., 2001) impeding axonal saltatory conduction. Clinical 
manifestations in the early phase of the disease are believed to result form the 
inflammatory reactions due to the recurrent autoimmune attacks (Bruck, 2005). Later 
on, axonal injury in MS plaques (Ferguson et al., 1997; Trapp et al., 1998) further 
contributes to the loss of neuronal functional integrity and it is thought to be the main 
cause of neurological symptoms in the progressive phase of the disease (Trapp and 
Nave, 2008). Remyelination in MS plaques is a beneficial regenerative process that 
can restore the conduction velocity and appears to confer axonal protection (Irvine and 
Blakemore, 2008; Kornek et al., 2000). Unfortunately, the extent of remyelination in the 
course of MS is inefficient and inadequate, leaving the majority of lesions largely 
demyelinated (Franklin, 2002). During remyelination myelin sheaths are formed by 
newly differentiated oligodendrocytes from OPCs pool residing in the CNS (Blakemore 
and Keirstead, 1999; Gensert and Goldman, 1997). It is not clear why remyelination 
fails in MS. Critical points in the process of remyelination are recruitment of the OPCs 
into demyelinated regions, proliferation and subsequent differentiation resulting in 
formation of new myelin sheaths (Franklin and Ffrench-Constant, 2008). Therefore, 
stimulation of these processes could potentially increase the efficiency of 
remyelination. This in turn would lead to restored functional integrity of CNS axons and 
improvement clinical picture in MS patients.  
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NRG1, given its role in the oligodendrocyte development is one of the candidates for 
stimulation of OPCs differentiation in MS. Immature oligodentrocytes fail to develop in 
cultured spinal cord explants derived from NRG1 null mutants (Vartanian et al., 1999). 
Proliferation and survival of OPCs and oligodendrocytes in vitro is stimulated after 
addition of NRG1 (Canoll et al., 1996). Similarly increasing NRG1 levels in optic nerve 
in vivo also promotes survival of oligodendrocytes (Fernandez et al., 2000). Astrocytic 
NRG1 has been found to be decreased in MS lesions suggesting that altered levels of 
NRG1 contribute to the disturbed homeostasis in MS lesions (Viehover et al., 2001). 
Therapeutic attempts employing recombinant NRG1 to stimulate remyelination have 
previously been carried out. Systemic application of the recombinant NRG1 in mice 
with experimental autoimmune encephalomyelitis (EAE) improved the extent of 
remyelination in this model (Cannella et al., 1998; Marchionni et al., 1999). In a follow 
up study in which recombinant NRG1 was directly injected in to the gliotoxin-induced 
demyelinated CNS lesion, no improvement in remyelination was observed (Penderis et 
al., 2003). In light of the fact that the underlying pathology in EAE models is to a great 
extend caused by inflammatory immune system responses, the beneficial effect of 
NRG1 on remyelination in this model was probably due to modulation of immune 
responses as no improvement in myelination was found in gliotoxin model. The NRG1 
isoform used in previous experiments is the type II isoform differ from the type III 
shown to promote myelination in PNS (Michailov et al., 2004). It is believed that NRG1 
type III signals in a juxtacrine manner while the type II isoform signals in a paracrine 
fashion. It has been speculated that the failure of NRG1 to promote myelination in the 
gliotoxin model is due to the inadequately presented NRG1 signal. Previous studies 
underscore this hypothesis: Addition of recombinant NRG1 to oligodendrocytes in 
culture was shown to block differentiation and induce dedifferentiation of matured 
oligodendrocytes (Canoll et al., 1999; Canoll et al., 1996). A similar de-differentiation 
effect was observed in DRG neuron-Sc co-cultures (Zanazzi et al., 2001). Based on 
these findings by it was hypothesized that a possible way to promote myelination in the 
CNS could be achieved by elevating the levels of axonally presented NRG1 type III. 
Indeed, overexpression of NRG1 type III in neurons under transcriptional control of the 
Thy1 promoter induces early onset of myelination in optic nerve and hypermyelination 
in the corpus callossum of transgenic mice (Brinkmann et al., 2008). 
We therefore hypothesized that for NRG1 to be effective in remyelination NRG1 has to 
be delivered to the surface of demyelinated axons following systemic administration. To 
direct recombinant NRG1 to the surface of demyelinated axons, we thought to create a 
fusion protein composed of the NRG1 EGF-like domain coupled to the variable region 
of a single chain antibody recognizing axonal surface epitope. Theoretically, this would 
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allow NRG1-antibody fusion product to cross the disrupted blood brain barrier (BBB) in 
MS and to bind to the demyelinated axons increasing the levels of NRG1 on their 
surface. This in turn could potentially induce remyelination given that mere elevation of 
NRG1 protein levels on axonal surface is sufficient for oligodendrocytes to initiate the 
complete remyelination program.  
7.2 Characterization of the axon binding antibody from IgM auto 
antibody repertoire  
The first step towards generation of single chain antibody-NRG1 fusion protein is to 
identify an axon-specific antibody that will bind to CNS axons after i.p. injection in a 
mouse model of MS. We have tested a repertoire of human and mouse natural IgM 
and IgG autoantibodies for axon binding properties. These antibodies were obtained 
from the Mayo Clinic archive (Rochester, MN). Human derived antibodies originate 
from sera of patients suffering from Waldenström syndrome, multiple myeloma, 
monoclonal gammopathy (Rodriguez et al., 2009) and from human fetal cord blood B-
cell clone derived hybridoma (Warrington et al., 2004). Natural autoantibodies are 
polyreactive to self antigens and serve as effectors of rapid immune response to 
pathogens (Coutinho et al., 1995). These antibodies were of great interest for our re-
myelination approach, because of previous findings showing that sHIgM22 antibody 
from this repertoire enters the CNS after i.p. injection and binds to oligodendrocytes to 
stimulate remyelination in a TMEV mouse model of MS (Warrington et al., 2000). For 
preliminary characterization we have tested the binding properties of these antibodies 
on acute unfixed 225 µm thick spinal cord cross sections. The unfixed tissue was used 
to preserve native structure of the epitopes. A subset of antibodies which were found to 
bind in a preliminary analysis, were tested on acute unfixed longitudinal spinal cord 
sections of the TMEV infected mice (4 moths post infection). Floating sections were 
incubated with IgM antibodies and fluorescently labeled for microscopy. Imaging of the 
lateral column of spinal cord revealed that antibodies sHIgM42 showed axonal 
distribution pattern (Fig. 22; arrowheads). The sHIgM42 antibody has been previously 
shown to bind to cerebellar granule cells and promote neuronal outgrowth in culture 
(Warrington et al., 2004). The oligodendrocyte-binding rIgM22 antibody was localized 
to axonal tracts in the spinal cord. Two additional antibodies, mIgM79.08 and CB2bG8, 









Fig. 22 Characterization of IgM auto-antibodies for axon binding in the mouse spinal cord 
Characterization of IgM auto-antibodies for axon binding in the mouse spinal cord 
Acute floating longitudinal sections (225µm) of spinal cord labeled with HIgM antibodies rHIgM22, 
sHIgM42, mIgM79.08, CB2bG8. Fluorescent images of lateral column of spinal cord showing staining 
pattern of antibodies. Oligodendrocyte binding rHIgM22 antibody and neuron binding rHIgM42 show 
axonal staining pattern (arrowheads). The antibody mHIgM79 labels cells possibly astrocytes and CB2bG8 
displays staining of undefined structures in spinal cord different from axons.  
7.3 Antibody-mediated targeting of CNS axons following in vivo 
injection 
As a next step we injected sHIgM42 antibody into TMEV infected mice (4 months post 
infection) to assess in vivo binding to CNS axons. A small cohort of three mice was 
injected i.p. with 650µl PBS containing 500µg of sHIgM42 antibody. Control mice were 
injected with the same amount of sHIgM39 antibody, which previously showed no 
binding to cells within the CNS (Warrington et al., 2004). 24 hours post injection mice 
were perfused with 4% PFA and spinal cords were processed for cryosectioning. 
Longitudinal spinal cord cryosections (10-12 µm) were fluorescently labeled with anti 
human IgM secondary antibodies. Microscopic analysis revealed that sHIgM42 signal 
could be detected on the axons in discrete regions in the lateral columns of the spinal 
cord (Fig. 23A, arrow heads). The nuclear staining with DAPI showed massive immune 
cell infiltrates characteristic of lesions (asterisk). Similar signals were never found in 
spinal cords of mice injected with sHIgM39 (Fig. 23C). Spinal cords contained lesions 
where sHIgM42 antibody did not bind (Fig. 23B), probably due to the difference in the 
pathology of different demyelinated lesions concerning BBB opening, level of 
demyelination and axon preservation. This is corroborated by Gallyas staining on 
spinal cords of TMEV infected mouse showing lesions infiltrated by immune cells 
(asterisk) (Fig. 23D) with largely preserved myelin in contrast to heavily demyelinated 
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regions (Fig. 23D; boxed). To show that the sHIgM42 binds to demyelinated regions 
consecutive paraffin section of spinal cords was fluorescently co-labeled to detect 
sIgM42 and anti neurofilament antibodies. Demyelinated region in the spinal cord (Fig. 
23D; boxed) corresponded to the region in which axonal localization of IgM42 was 




Fig. 23 Human IgM42 binds to spinal cord axons after in vivo injection into a Theiler’s 
mouse model of MS. 
TMEV infected mice 4 months post infection were injected intreperitoneally with 500µg of sHIgM42 or 
sHIgM39 antibodies. Spinal cord tissue collected after 24 hours was processed for cryosectioning. 
Longitudinal spinal cord sections (10µm) were immunolabeled with FITC-anti human IgM antibody (green). 
(A) Image of a region in the lateral column of spinal cord region showing axons labeled with rHIgM42 
antibody (arrowheads). DAPI staining shows massive immune cell infiltrates (asterisk). (B) Region of the 
same spinal cord without labeled axons. Region is clearly overlaps with a lesion with infiltrated immune 
cells showed by DAPI staining. (C) Two different spinal cord regions of a mouse injected with a control 
sHIgM39 antibody. Staining similar to rHIgM42 could not be observed. 
(D) Gallyas myelin stain on a longitudinal spinal cord paraffin section (5µm) from a TMEV infected mouse 
injected with rHIgM42. Boxed demyelinated area corresponds to the region in depicted in (C). Not all 
lesioned regions infiltrated by immune cell are demyelinated (asterisk).  
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(E) Consecutive longitudinal spinal cord section, labeled with neurofilament antibody. Images of a lateral 
spinal cord showing overlap between rHIgM42 (green) signal and NF (red) (arrowheads). 
 
During the course of this project, data concerning the CNS myelination revealed that 
the contribution of NRG1 to CNS myelin formation and stimulation of remyelination is 
less essential (Brinkmann et al., 2008). In contrast to the PNS, NRG1 is dispensable 
for myelination in the CNS. Conditional mouse mutants lacking NRG1-β isoforms in the 
CNS show no disruption in myelin formation. Additionally, myelination appears to be 
unaffected in the absence of NRG1 receptors ErbB3 and ErbB4 expressed by 
oligodendrocytes. Importantly, CNS remyelination in mice overexpressing NRG1 type 
III in CNS neurons did not promote remyelination in the spinal cords of following 
lysolecithin-induced focal demyelination (Brinkmann et al., 2008). In the light of these 
results NRG1-based strategies for myelin regeneration in MS no longer appear to 
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